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ABSTRACT
Any compound which has the potential to disrupt cognitive and psychomotor 
performance will exacerbate the impairments which are a feature of depressive illness. 
The consequences of this include compromising the patient in terms of recovery from 
depression, reducing the quality of life and increasing the risk of accident. A critical 
review of the literature on the effects of antidepressants on performance in healthy 
volunteer and depressed patient populations showed that the older tricyclic 
antidepressants (TCAs) impaired cognitive and psychomotor performance, whereas 
the newer antidepressants appeared to have little or no effect. This review also 
revealed that there were tests which were sensitive to the effects of antidepressants on 
human information processing, but only when used in appropriately designed 
experiments. On the basis of these findings, seven experiments were carried out to 
investigate the effects of the second generation antidepressants moclobemide, 
brofaromine, paroxetine, litoxetine, fluvoxamine, citalopram and fengabine in healthy 
volunteers. These antidepressants either improved performance on the battery of tests 
or were no different to placebo, whereas the TCAs dothiepin and amitriptyline 
produced impairments throughout. The eighth experiment evaluated the effects of 
fluoxetine versus dothiepin in depressed patients treated in general practice. Although 
fluoxetine and dothiepin were equipotent in reducing clinical ratings of depression, 
the cognitive and psychomotor abilities of patients in the fluoxetine group were 
superior to those in the dothiepin group.
It is generally accepted that there is little to choose between antidepressants in terms 
of efficacy, however, the data presented in this thesis suggest that there are differences 
in the extent to which these drugs affect performance. These factors should be taken 
into consideration in the management of depression in ambulant outpatients.
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CHAPTER 1 - INTRODUCTION
1.0 Chapter Outline
This chapter discusses the context in which the present research was carried out and 
why it is important to study the effects of antidepressants on cognition and 
psychomotor function in human subjects. The concept of cognitive and psychomotor 
retardation associated with depression is discussed, and how an antidepressant can 
potentially affect these processes. A brief introduction to the history of antidepressants 
is given, then background information on the drugs investigated in this thesis follows. 
Finally, the content of this thesis is outlined.
Depression: a temporary mental state or chronic mental disorder characterised by
feelings o f sadness, loneliness, despair, low self-esteem and se lf reproach; 
accompanying signs include psychomotor retardation, or less frequently 
agitation, withdrawal from social contact, and vegetative states such as loss o f  
appetite and insomnia (from Stedman’s Medical Dictionary, 1995)
1.1 Introduction and Rationale
Depression is probably the most common mental disorder suffered in the community, 
and has been referred to as the common cold of mental illness (Miller and Seligman, 
1973). Although diagnosed depression has been described as the “tip of the iceberg” 
(Kelly, 1987), Hagnell et al (1982) estimate that every second woman and every 
fourth man will experience an episode of depression requiring treatment at least once 
in their lives. In order to prevent relapse or re-emergence of the symptoms of the 
illness, recent guidelines (Paykel and Priest, 1992; Cowen, 1996) recommend that 
depression should be treated for at least four to six months after recovery from the 
acute phase, and for longer in patients with recurrent depression. This means that the 
management of depression requires chronic therapy, and so the antidepressants
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prescribed must be well tolerated in long term use. As over 90% of depressed 
individuals are diagnosed and treated in primary care (Goldberg and Huxley, 1980; 
Lader, 1996), it follows that a large number^Sepressed patients are ambulant. It is 
essential that the antidepressants prescribed to them do not impair cognitive and 
psychomotor abilities, i.e., are not behaviourally toxic. Any compound which does 
interfere with these processes may exacerbate the retardation that underlies the 
disease, thereby further compromising the patient in terms of recovery from 
depression, quality of life and safety. This is particularly relevant to the treatment of 
depression in elderly patients who are more susceptible to side effects following 
psychoactive medication (Greenblatt and Allen, 1978), and many of whom may 
already be disadvantaged in terms of performance and so more prone to the risk of 
accidents and to suffer their consequences. It is therefore essential that a putative 
antidepressant is assessed not only in terms of its efficacy in alleviating depression, 
but is also profiled with respect to its effects on psychomotor and cognitive abilities.
1.2 Depression and Retardation
It is well established that depression is associated with changes in psychological 
processes, and that this has implications in cognitive and psychomotor performance. 
In fact, in addition to depressed mood, diagnostic criteria for major depression also 
includes changes in psychomotor performance, decreased energy, fatigue, difficulties 
in thinking, lack of concentration and problems with decision making (American 
Psychiatric Association, 1994). Traditionally, a fluctuation of mood or affect has been 
considered as the major defining feature of depression, and that a change in 
psychomotor activity is an expression or a by-product of the mood state. Miller (1975) 
and Cohen et al (1982) argue that impairments in tests of cognitive and psychomotor 
abilities are secondary to motivational deficits, however this viewpoint has been 
disputed by others who have shown that depressives exhibit lower performance levels 
in some tasks but responded normally in others (e.g. Davies et al, 1978; Weingarter et 
al, 1981), indicating that reduced motivation alone is not a sufficient explanation. 
Widlocher (1983) and Widlocher and Ghozlan (1989) argue that psychomotor 
retardation (expressed as a general slowing down of reactions, of speech and of
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movements) is a primary manifestation of depressive illness and is a symptom in 
itself, rather than an expression of psychological state. Whether this is the case 
remains to be clarified^ Jjfiwever. what is clear from subjective reports and objective 
evidence is that depressives do suffer from impairments in cognitive processing and 
psychomotor abilities.
1.2.1 Obj ective evidence
Quantitative aspects of retardation associated with depression are reflected in 
performance changes across a range of psychometric assessments. For example, 
Miller (1975) concluded from a review of the literature that depressives suffered from 
cognitive and psychomotor retardation across a range of tests. He also found that, 
although there were differences in the extent to which the depth of depression affected 
performance, similar deficits were observed across the different sub-types of 
depression. The latter observation was also reported by Siegfried et al (1984), where 
the level of performance on tasks of memory, cognition and reaction time in elderly 
depressed patients corresponded well to the severity of depression. Furthermore, the 
performance of elderly depressives was found to be worse than non-depressed 
matched controls (Davies et al, 1978), and, at the height of illness, exhibited 
reversible cognitive deficits which were similar to those seen in late life dements. In 
addition to the deterioration of task performance, Szabadi et al (1976) demonstrated 
that depressives paused longer during speech than healthy controls (as measured by 
speech rate polygraphy). Evidence suggests that the decrements in abilities to perform 
tasks correlate with Hamilton Depression Rating Scale scores (Austin et al, 1992) and 
that these deficits are reversed following successful treatment of the depression 
(Szabadi et al, 1976; Davies et al, 1978; Siegfried et al, 1984; Austin et al, 1992).
There are debates as to whether the degree of impairment associated with depression 
will vary with the degree of sustained information processing effort required for a 
specific task. In the opinion of Wiengarter and Silberman (1982) and Cohen et al 
(1982), memory deficits in depression reflect impairments in the ability to allocate 
cognitive effort to increasingly demanding tests, rather than a specific memory deficit,
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whereas Golinkoff and Sweeney (1989) have demonstrated that depression-induced 
memory impairment is independent of general cognitive inefficiency.
In addition to the assessment of depressed individuals on the performance of tests at 
particular time points, actigraphs (activity monitors) have been used to monitor motor 
activity over long periods of time. In a review of the use of actigraphy in psychiatry, 
Teicher (1995) found that bipolar depressives had reduced motor activity levels 
compared to matched controls and to agitated unipolar depressives of comparable 
severity. The percentage of low levels of activity correlated with the severity of 
depression (Teicher, 1995) and with scores on Widlocher’s Retardation Scale 
(Royant-Parola et al, 1986).
1.2.2 Subjective reports
In addition to the changes in behaviour seen in depressives, qualitative aspects are 
also affected, i.e. how the individuals rate themselves and their experiences, and some 
theorists describe negative thinking as the most prominent feature of depression. Beck 
(1976) for example, proposed the concept of a negative cognitive triad, where 
“depression itself is a result o f a negative cognitive set, a negative view o f the se lf the 
world and the future, which is maintained by typical information processing errors”, 
hypothesising that depressed mood and the behavioural deficits observed in 
depression follow on from these negatively biased patterns of thought. This has been 
illustrated in a group of depressed patients whose mood states showed diurnal 
variation. When asked to respond to neutral cue words, memories related to unhappy 
experiences were retrieved more during the more depressed occasions than when 
patients felt less depressed (Clark and Teasdale, 1982). Inability to concentrate is 
frequently reported by depressed patients, and so Watts and Sharrock (1985) carried 
out a detailed study of subjective complaints of concentration to further investigate 
this problem. Their findings show that patients complained of concentration problems, 
particularly when reading or watching television, and that these subjective reports 
correlated well with scores on an objective memory task and severity of depression. 
The authors suggest that these concentration deficits are due to “mind-wandering”. 
Depressed subjects also have the tendency to underestimate their level of performance
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on laboratory tasks (e.g. Wener and Rehm, 1975; Nelson and Craighead, 1977). 
Despite the impairments evidenced by the objective measurements and subjective 
reports outlined above, there are no differences in intellectual performance between 
depressed patients and normal controls (Blackburn, 1988). It must be noted, however, 
that subjective expectations and communication of the symptoms of depression vary 
across cultures (American Psychiatric Association, 1994). Bhugra (1996) reviewed 
these cross-cultural differences and criticised the practice of relying on subjective 
complaints alone for the diagnosis of depression, therefore the effects of depressive 
disorder on objective measures of cognitive and psychomotor function must be 
accepted as persistent features of the illness.
1.3 The relationship between antidepressants and performance
Several authors (see above) have shown that the degree of cognitive and psychomotor 
retardation corresponds to the severity of depression, and that these impairments 
reverse as the depression ameliorates. In light of this relationship it follows that an 
antidepressant can influence performance by alleviating the depression, thereby 
enhancing performance indirectly1 (Figure 1.1). However, an antidepressant may also 
affect the information processing system directly, so compromising the efficiency of 
the system.
Figure 1.1 Direct and indirect effects of antidepressants on performance
Antidepressant
direct indirect
Depressed
mood
Information processing
Performance
Although the main effect o f an antidepressant is to reduce depression, this thesis is concerned 
primarily with its effects on performance.
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For example, if a drug is known to be an efficacious antidepressant, but has a negative 
effect on performance in non-depressed subjects, the hypothesis is that the same 
antidepressant is more likely to impair performance in depressed individuals - the 
extent to which will depend on the relative strengths of its direct and indirect effects.
Likewise, if an antidepressant does not impair performance in non-depressed subjects 
then it will only act to alleviate the depression in patients, affecting performance 
indirectly.
1.3.1 Consequences of antidepressants and performance
If an antidepressant impairs performance in ambulant patients, then this will have an 
negative impact on the tasks that the patient performs, ranging from skilled activities 
to the simpler procedures carried out in everyday life. The consequences to the patient 
are threefold. Firstly, these iatrogenic impairments may reduce the quality of life and 
be counter-therapeutic. Secondly, if these behavioural impairments are perceived by 
the patient, then drug compliance may be affected, thereby mitigating against reliable
therapy. Thirdly, such drugs will place the patient, and anyone who comes into
hcw<2- | n
contact with that patient, at increased risk of accident. Epidemiological data -has 
shown that tricyclic antidepressants (TCAs) are associated with an increased risk of 
hip fractures in the elderly through falls (Ray et al, 1991) and that these drugs increase 
the risk of being involved in accidents on the road (Ray et al, 1992; Currie et al,
1995), at work, and during domestic or leisure pursuits (Currie et al, 1995).
1.4 Drugs used in the treatment of depression: past and present
The first substances to be developed specifically as antidepressants were the 
monoamine oxidase inhibitors (MAOIs) (Crane, 1957). These early antidepressants 
have an interesting and serendipitous history. After the Second World War excess 
stocks of the explosive rocket fuel hydrazine became available at low cost to drug 
companies as a "starting" material. All new pharmaceutical compounds at that time 
were tested against tubercle bacillus in the hope of finding an effective treatment for 
tuberculosis (Sandler, 1990). The hydrazine derivatives isoniazid and iproniazid, as 
well as being anti-tuberculous, appeared to have a euphoriant effect (Robitzek et al,
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1952), producing feelings of well being and elation. The beneficial action of 
iproniazid as an antidepressant was first identified by Loonier and his colleagues in 
1958. These discoveries led to the development of the first drugs for the treatment of 
depression.
Although these original MAOIs proved to be valuable in the treatment of depression 
and other psychiatric disorders, they also produced numerous adverse effects, 
including hepatotoxicity and interaction with certain foodstuffs rich in tyramine 
leading to hypertensive episodes. These MAOIs were superseded by the TCAs; the 
first being imipramine, which became the prototype for others such as amitriptyline 
and dothiepin. Even though they are more consistently clinically efficacious than the 
MAOIs, and are the most widely prescribed drugs for the treatment of depression 
(Donoghue and Tylee, 1996), the TCAs are far from being the ideal therapy as they 
produce a plethora of adverse effects and are toxic in overdose.
Dissatisfaction with the numerous problems associated with these drugs, including 
adverse events, toxicity, risk of accident and suicide and reduced patient compliance, 
all resulting in reduced cost effectiveness (Fairweather and Hindmarch, 1995a), has 
highlighted the need for research into alternative compounds.
1.4.1 Second generation antidepressants
Improvements in pharmacological technology and increases in the number of 
identifiable receptor sites over the years has allowed the development of a range of 
original molecules with various clinical activity profiles. These second generation 
antidepressants are more neuro-specific in their mechanism of action, and appear to 
have a more favourable side effect profile. Examples of the various types of second 
generation antidepressants, following the nomenclature adopted by Leonard (1994), 
are presented in Table 1.1.
There are several different mechanisms of action listed in Table 1.1, however all act to 
increase the availability of central monoamines. Considerable interest has been shown
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in the reversible inhibitors of monoamine oxidase-A (RIMAs) and the (selective
serotonin reuptake inhibitors (SSRIs) in recent years. Several of these have been 
investigated in terms of their effects on performance in the experiments presented in 
this thesis (see Chapter 4), i.e. moclobemide, brofaromine, citalopram, fluoxetine, 
fluvoxamine, litoxetine and paroxetine. The role of fengabine, a GABA-mimetic 
agent, has also been investigated.
Table 1.1 Examples of second generation antidepressants (classification from 
Leonard, 1994)
Drugs Pharmacological classification
brofarominea, cimoxatone, 
moclobemide3, toloxatone
reversible inhibitors of monoamine 
oxidase-A (RIMAs)
citalopram3, fluoxetine3, 
fluvoxamine3, litoxetine3, 
paroxetine3, sertraline
selective serotonin (5-HT) reuptake 
inhibitors (SSRIs)
fengabine3, progabide y-aminobutyric acid (GABA) - 
mimetics
idazoxan, mianserin a 2-adrenoreceptor antagonists
levoprotiline, nomifensine, 
oxaprotiline
noradrenaline reuptake inhibitors
tianeptine serotonin reuptake enhancers
buspirone, gepirone, 
ipsapirone
5-HT1A partial agonists
lofepramine, reboxetine novel tricyclic antidepressants
a drugs studied in this thesis
1.4.1.1 Reversible inhibitors o f monoamine oxidase A (RIMAs)
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The discovery that there are two distinct subtypes (A and B) of MAO by Johnston 
(1968), and the subsequent development of reversible inhibitors of MAO-A (RIMAs), 
led to renewed interest in the concept of inhibiting MAO in the treatment of 
depression. The advantage of the RIMAs is that they selectively and reversibly inhibit 
the breakdown of serotonin and noradrenaline while MAO-B is unaffected, thus 
allowing the deamination of sufficient quantities of dietary tyramine and reducing the 
risk of hypertensive episodes seen with non-selective MAOIs (the so-called “cheese 
reaction”).
Moclobemide
Moclobemide was the first member of the RIMAs and has been shown to be effective 
as an antidepressant in many trials. In doses up to 600mg daily, moclobemide was 
superior to placebo and comparable to other antidepressants, for example 
tranylcypromine (Rossel and Moll, 1990), amitriptyline (Beckers et al, 1990), 
clomipramine (Lecrubier and Guelfi, 1990) and imipramine (Versiani et al, 1989) in 
relieving depression. The most common side effects are insomnia, anxiety, 
restlessness and nausea, however moclobemide is largely devoid of anticholinergic 
effects and is better tolerated than the TCAs (Versiani et al, 1990; Hilton et al, 1995). 
There are also significantly less problems with moclobemide than with other MAOIs 
in terms of hepatic toxicity, interaction with tyramine and adverse reactions to the co­
administration of TCAs (Burgess and Mellsop, 1989; Da Prada et al, 1990; 
Warrington et al, 1991; Dingemanse et al, 1995). Pharmacokinetic studies show that 
moclobemide is rapidly absorbed and has a short half life of 1-2 hours.
Brofaromine
Brofaromine, being pharmacologically and structurally distinct from other MAOIs 
e.g. phenelzine and tranylcypromine, was developed as a RIMA for the treatment of 
depression. The development of this drug has since been terminated and so there 4S- 
very little data available. Nevertheless, research has shown that brofaromine 25- 
150mg daily was as effective as imipramine in alleviating depression and superior in 
terms of tolerability in depressed outpatients (Moller and Volz, 1992), elderly 
outpatients (Moller and Volz, 1993) and severely depressed inpatients (Volz and
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Moller, 1994). The most common side effects include sleep disturbance, nausea, 
nervousness/agitation, dry mouth and headache, and, like moclobemide, there appears 
to be less anticholinergic effects than with the TCAs (Volz et al, 1995) and 
significantly fewer problems in terms of hepatotoxicity and interaction with tyramine 
than the older MAOIs. As with moclobemide, brofaromine is rapidly absorbed but has 
a longer half life (9-14 hours).
1.4.1.2 Selective serotonin reuptake inhibitors (SSRIs)
Increased appreciation of the role of serotonin in depression has led to the 
development of highly selective inhibitors of 5-HT re-uptake which have little 
influence on noradrenaline or dopamine systems. By enhancing serotonergic 
transmission without interacting with other neurotransmitter receptors (Fuller and 
Wong, 1987) and inducing down-regulation of adrenergic receptors, these drugs 
provide effective antidepressant activity without the sedating, anticholinergic, or 
cardiotoxic reactions seen with the older antidepressant drugs. As a class the SSRIs 
are now established as an important treatment for depression. They have the 
advantage of being well tolerated, and there is good evidence of their efficacy 
compared to placebo and the earlier antidepressants.
Fluoxetine
Fluoxetine was one of the first of the SSRIs and has been extensively investigated in 
studies which have compared fluoxetine with placebo and standard TCAs. In reviews 
of clinical trials assessing its efficacy, the trends were that fluoxetine had similar 
efficacy to TCAs such as imipramine, amitriptyline and dothiepin, and was superior to 
placebo (Boyer and Feighner, 1991a; Kasper et al, 1992; Song et al, 1993). 
Moclobemide and fluoxetine were shown to reduce depression by similar extents in 
outpatients and inpatients, and to increase the quality of life (Lonnqvist et al, 1994). 
The main side effects associated with fluoxetine are gastro-intestinal in nature (e.g. 
nausea, constipation, diarrhoea) but others including insomnia and headache are also 
common (Boyer and Feighner, 1991b; Keegan et al, 1991). The half life of fluoxetine 
is approximately 1-3 days, however its active metabolite norfluoxetine has a long half 
life of 7-15 days.
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Fluvoxamine
In clinical trials the overall antidepressant efficacy of fluvoxamine up to 300mg daily 
is superior to placebo and similar to or better than that of imipramine in depressed 
inpatients (Amore et al, 1989) and outpatients (March et al, 1990; Mendlewicz, 1992). 
This pattern was also revealed in comparisons to amitriptyline, clomipramine, 
desipramine and dothiepin (Wilde et al, 1993) and the time to onset of therapeutic 
effects appears to be similar to that of other antidepressants. The effectiveness and 
tolerability of fluvoxamine in the elderly is similar to that observed in younger 
populations. The results of a post marketing surveillance study show that the most 
common adverse events were nausea, somnolence and asthenia, and that there were 
less anticholinergic effects than with imipramine (Wagner et al, 1992). The 
elimination half life of fluvoxamine is 14-22 hours and this is independent of the dose 
(Palmer and Benfield, 1994).
Citalopram
Citalopram is a potent and highly selective SSRI and has virtually no effect on 
noradrenaline reuptake nor on dopamine, muscarinic, or a 2 receptors (Hyttel, 
1984). This selectivity would suggest that citalopram has potentially fewer side 
effects than older treatments and this has been evidenced in clinical studies (e.g. 
Baldwin & Johnson, 1995). In clinical trials citalopram has been shown to be as 
effective as amitriptyline in reducing depression (Bech and Cialdella, 1992) and is 
efficacious in doses as low as 20mg (Montgomery et al, 1994a). The most common 
side effects reported so far (although the difference from those reported with placebo 
was always less than 10%) are increased sweating, tremor, somnolence, dry mouth 
and nausea (Lader, 1996), however citalopram is associated with fewer 
discontinuation rates for side-effects than the TCAs (Montgomery et al, 1994b). This 
drug has a long elimination half life of 35 hours.
Litoxetine
Litoxetine, as well as selectively inhibiting serotonin reuptake, also possesses 5-HT3 
antagonistic properties, giving this compound an original profile in that it may, unlike
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other SSRIs, be devoid of emetic effects (Angel et al, 1993). Preliminary human 
clinical pharmacology studies showed that litoxetine was well tolerated up to lOOmg 
and that the side effects (sedation, headache and nausea) were mild in nature (Angel et 
al, 1993). Litoxetine exhibits linear pharmacokinetics and its half life is approximately 
7-9 hours (Patat et al, 1994; Fairweather et al, 1995a). The development of this drug 
has recently ceased and so no clinical efficacy data-k available.
Paroxetine
Clinical studies have shown paroxetine to be superior to placebo in reducing 
depression (Claghom, 1988; Rickels et al, 1989) and equipotent to TCAs such as 
imipramine (Cohn et al, 1990), amitriptyline (Lund Laursen et al, 1985) and 
clomipramine (Guillibert et al, 1989), but with fewer unwanted side effects. Research 
suggests that paroxetine is well tolerated and that the side effects are similar to those 
reported for other SSRIs, i.e. nausea, headache, somnolence and insomnia (Boyer and 
Blumhardt, 1992). Two meta-analyses of clinical trials concluded that in outpatients 
there were no differences in efficacy between paroxetine and TCAs (Song et al, 1993; 
Anderson and Tomenson, 1994) and that cessation of treatment due to adverse effects 
was more frequent in the TCA group. Anderson and Tomenson’s (1994) analysis, 
however, revealed that paroxetine was less effective than TCAs in severely depressed 
inpatients. The elimination half life is approximately 16-30 hours (Dechant and 
Clissold, 1991).
1.4.1.3 y-aminobutyric acid (GABA) - mimetics
Since it was demonstrated that GABA-ergic stimulation was beneficial in the 
treatment of depression (Lloyd et al, 1986; Scatton et al, 1986), and that the GABA 
agonist progabide was well tolerated (Sanger et al, 1986), research into the 
involvement of this neurotransmitter system in depression was initiated.
Fengabine
Fengabine is novel benzylidene compound with a unique pharmacological profile of 
action. Its mechanism of action appears to be via the GABA system, although the 
precise mechanism is unclear. Fengabine shares some similar actions to traditional
rJJc O
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antidepressants, in that it increases noradrenaline turnover and down-regulates p- 
adrenoreceptor mediated responses, however it does not affect noradrenaline uptake 
and has no effects on serotonin or MAO activity (Zivkovic et al, 1986). The initial 
clinical studies revealed that fengabine reduced depression and was well tolerated in 
depressed inpatients (Chabannes et al, 1986) and outpatients (Mendlewicz et al, 1986; 
Musch and Garreau, 1986). Neilsen et al (1990) reported that, in depressed 
outpatients, fengabine was of similar clinical efficacy to clomipramine and appeared 
to have a faster onset of action. Fengabine also had significantly fewer side effects 
than clomipramine. Preliminary pharmacokinetic studies have demonstrated that the 
elimination half life of fengabine ranges from 10-20 hours (Musch, 1986), however 
there is-no further data as the clinical development of this GABA-mimetic has been 
terminated.
1.5 Outline of thesis
Evidence suggests that the second generation antidepressants described above are as 
effective in alleviating depression as reference compounds such as the TCAs, and also 
appear to possess favourable side effect profiles. As depression is often accompanied 
by cognitive and psychomotor retardation (manifest in objective tests and subjective 
ratings), it is important that a given drug does not have the potential to exacerbate 
these impairments. The aim of this thesis is to evaluate the effects of second 
generation antidepressants on psychomotor performance and cognitive function, and 
to assess whether these newer compounds are advantageous in this respect.
Chapter 2 presents a review of the literature on the effects of antidepressants on 
performance in healthy volunteers and depressed patients. Based on this evidence, 
Chapter 3 details the measures and methods chosen for the experimental work, and the 
results of these experiments are detailed in Chapter 4. The final chapter (Chapter 5) 
discusses the relevance of the findings and the impact that these have in the treatment 
of depression.
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CHAPTER 2: A REVIEW OF THE LITERATURE
2.0 Chapter Outline
The preceding chapter highlighted the necessity for assessing the effects of 
antidepressants on cognitive and psychomotor functioning. This chapter presents a 
critical review of previous research on the effects of antidepressants on measures of 
cognitive and psychomotor performance in both healthy volunteers and depressed 
patients. Firstly a model of information processing is presented and, as there is great 
variability in the assessments used across studies, the tests are grouped according to 
which aspect of information processing they are assumed to measure. The studies 
reviewed are presented in two sections: healthy volunteers and depressed patients. 
These are presented separately in terms of the model of information processing then 
discussed together at the end of the chapter.
2.1 Introduction
Chapter 1 discussed the cognitive and psychomotor retardation that accompanies 
depressive disorders and presented examples of performance deterioration in 
depressed individuals. If an antidepressant has the potential to induce performance 
deficits, then it also has the potential to increase the behavioural impairments that 
accompany depression and make the illness more severe. Furthermore, drug induced 
behavioural impairment will not only decrease patient compliance with the treatment 
regimen, but also may mask clinically relevant indices of changes in the severity of 
the illness. In order to understand the effects that a given antidepressant has on these 
processes it is essential that a well-defined model of information processing is first 
established.
2.1.1 Information processing
“The major assumption o f the psychopharmacologist is that the effect o f  a drug can 
be ultimately judged in behavioural terms” (Hindmarch, 1980). If this is so, then in 
order to obtain meaningful data, it is important that a coherent, consistent and concise
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model be used when assessing the effects of antidepressants on human behaviour. The 
model chosen must also utilise “appropriate techniques and the theoretical 
framework o f behavioural science” (Michon 1973).
Many complicated relationships exist between a given stimulus and a behavioural 
response, and the range of models which map these processes vary greatly in their 
degree of complexity. However, Hindmarch (1980) designed a simple model in which 
the major components of psychological activity which lead to a behavioural response 
were compartmentalised. This information processing model consists of three stages 
which mediate between a stimulus and a response, i.e. 1 - sensory information 
processing, 2 - central integration and processing and 3 - motor response organisation 
and output. Wesnes et al (1987) defined four aspects of human performance which are 
relevant to the activities of daily behaviour, these being attention, cognition, memory 
and behavioural response. A simplified version of Hindmarch’s model, incorporating 
Wesnes’ definitions, has been constructed and is presented in Figure 2.1. A 
psychoactive compound has the potential to affect all of these variables, either directly 
or indirectly.
The sections in this model, however, should not be perceived as discrete entities, but 
rather as a chain of events which are intrinsically linked through adaptive feedback 
systems. The stages are not necessarily hierarchical; it is thought that information 
flows from “sensory” through “central” and “memory” to output mechanisms via 
“motor” effectors. The level of processing of one stage may affect performance at 
another stage, that is, if the sensory processes are disturbed or if information is not 
attended to then it cannot be processed or remembered. For instance, a psychomotor 
response relies on sensory, cognitive and motor processes and if any of these states^are 
altered psychomotor performance will be affected.
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It must be noted that the effects of drugs on the above mentioned categories cannot be 
measured directly, and thus only inferences can be made as to which, and to what 
degree, particular processes have been involved. After reviewing the literature on the 
effects that psychoactive drugs had on particular performance tasks, Hindmarch 
(1980) suggested which psychological variables may have been affected and grouped 
the tests accordingly, i.e. those which assess sensory processes, cognition, 
psychomotor performance, motor activity and sensorimotor performance.
For the purpose of the present literature review, this classification of tests 
(Hindmarch, 1980) and the model presented in Figure 2.1 have been adopted and 
expanded upon to provide an up-to-date version of which tests are thought to measure 
specific aspects of information processing (Table 2.1 and Figure 2.2). Several tests 
measure more than one aspect of performance, and so have been placed according to 
which category is deemed to be most relevant! In addition to obtaining objective data 
on drug effects, it is important that subjective views are also recorded. Although this 
does not fit directly into the model of information processing, it could be argued that 
there is a cognitive aspect where the subject is required to interpret and answer the 
question. These divisions may vary according to particular theoretical viewpoints, 
however, the differences between experimenters in the usage of particular tests and 
methodologies are reduced by the consistent use of the categorisations derived from 
the model.
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Table 2.1: Tests of information processing
Cognitive Tests
Angles Test (AG) Pauli Test (PT)
Arithmetic Test (AT) Rapid Information Processing (RIP)
Baddeley Reasoning Test (BR) Rapid Visual Information Processing (RVIP)
Critical Flicker Fusion (CFF) Semantic Facilitation (SF)
Cognitive Flexibility (CgF) Semantic Polarity (SP)
Concept Identification Task (CIT) Sentence Verification (SVT)
Decision Making (DM) Stroop Test (STR)
Digit Symbol Substitution Test (DSST) Time Estimation (TE)
Grammatical Reasoning (GR) Visual Integration (VI)
Letter Matching (LtM) WAIS Vocabulary (WAIS)
Letter/Digit Differentiation (LDD) Word Fluency (WF)
Non Verbal Inductive Reasoning (NVIR)
Memory Tests
Benton Visual Retention Test (BVRT) Numerical Memory (NM)
Buschke Recognition Task (BRgT) Paired Associate Learning (PAL)
Buschke Selective Reminding Test Paired Words Associate Test (PW)
(BSRT)
Card Recognition (CRg) Peterson Memory Task (PM)
Corsi Blocks (CB) Pictures Test (PcT)
Digit Span (DS) Recognition Memory (REG)
Dual Coding (DC) Rey Test (REY)
Free Recall (FR) Semantic Retrieval (SRt)
Global Memory (GM) Short Term Memory (STM)
Guild Memory Scale (GMS) Signal Detection Recognition Memory (SDR)
Ideational Recall (IR) Sternberg Memory Test (SMT)
Interpersonal Learning Task (ILT) Symbol Digit Modalities Task (SDMT)
Learning Memory Task (LMT) Verbal Encoding (VE)
Logical Memory (LM) Verbal Learning (VL)
Matching To Sample (MTS) Verbal Memory (VM)
Memory Scanning (MS) Visual Working Memory (VWM)
Memory for Faces (MF) Who’s Who (WW)
Memory Questionnaire (MQ) Word Completion (WC)
Name-Face Memory (NF) Word Recall ( W R l ^ j
News Recall (NR) Word Recognitio,rf(Wfe J
Non Verbal Incidental Learning (NVIL)
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Table 2.1: Tests of information processing (continued)
Motor Tasks
Blink Rate (BLR) Motor Reflex (MRx)
Body Sway (BS) Pegboard (PB)
Hand Eye Co-ordination (HEC) Tapping Rate (TAP)
Manual Dexterity )MD)
Psychomotor Tests
Car Following (CAR) On The Road Driving (OTR)
Card Sorting (CS) Proprioceptive Test (PPT)
Choice Reaction Time (CRT) Simulated Driving Task (SDT)
Complex Reaction Time (CxRT) Weaving Test (WT)
Gap Acceptance Task (GA) Weiner Determinationsgerat (WD)
Grunberger Psychomotor Test (GPS)
Sensorimotor Tests
Auditory Reaction Time (ART) Reaction Time - Tone (RTT)
Brake Reaction Time (BRT) Steering Accuracy (SA)
Co-ordination (COD) Sustained Night Driving Task (SNDT)
Continuous Performance Task (CPT) Tracking (TRK)
Divided Attention (DA) Trail Making (TM)
Gibson Spiral Maze (GSM) Weiner Reaktionsgerat (WRK)
Pursuit Rotor (PR) Wiener Koordinationsgerat (WK)
Reaction Time (RT) Wire Maze Tracing (WMT)
Reaction Time - Light (RTL)
Sensory Tests
Alphabetical Cross Out (AC) Letter Cancellation (LC)
Alphabetical Reaction Test (ALR) Line Following Test (LFT)
Attention Task (ATT) Perceptual Speed (PS)
Auditory Vigilance (AV) Proof Reading (PfR)
Clock Attention Task (CA) Spiral After Effect (SPA)
Continuous Attention Task (CAT) Sustained Attention (S A)
D2 (cancellation) Test (D2) Symbol Copying (SC)
Digit Cancellation (DIC) Vigilance (VG)
Global Attention Task (GAT) Visual Perception (VP)
Grunberger AD (GAD)
Subjective Ratings
Aggression Questionnaire (AQ) Profile Of Moods Scale (POMS)
Asberg Rating Scale (ARS) Self Rating Memory Complaints (SRMC)
Basle Mood Scale (BMS) Self Report Questionnaire (SRQ)
Leeds Sleep Evaluation Questionnaire Subjective Ratings (SR)
(LSEQ)
Mental Status Questionnaire (MSQ) Visual Analogue Rating Scales (VAS)
Mood Adjective Checklist (MACL) Von Zerssen Score (VZS)
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2.2 Literature review methods
The material for this literature review was obtained using computer assisted searches 
(i.e. Medline) to identify studies which reported the effects of antidepressants on 
cognitive function and psychomotor performance up to mid 1996. Published papers 
were also obtained from other sources, including manual library searches. The 
keywords used in the literature selection were: antidepressants, psychometrics, 
cognition, psychomotor and performance. Conference abstracts were deemed 
insufficient for the purpose of this review due to lack of descriptive data. All papers 
analysed have been tabulated according to which aspects of performance have been 
measured i.e. sensory (where the stimulus is perceived), central (the manipulation and 
processing of information), memory (the storage and retrieval of information) and 
motor (the response mechanism). Tests which include both central and motor features 
are regarded as psychomotor:; and those which assess sensory and motor responses are 
deemed sensorimotor. Subjective ratings have also been included in this model.
M o s t
Studies are then discussed in these specific sections. Thesnra^ife=a£ studies employ 
more than one behavioural measure, and therefore appear in(one or more jabltffi.
i P ' I aCXM. ! crvuG.
A drug effect was documented if the authors reported a significant difference of 
p<0.05 compared to placebo and/or baseline treatment conditions. Non-significant 
trends were not included. In order to avoid repetition, results from the volunteer and 
patient studies are documented separately, then discussed together at the end of this 
section. A total of 111 studies were analysed; 83 of these were investigations in 
healthy volunteers and 28 were in patient populations.
2.3 The effects of antidepressants in healthy volunteers - a literature review
Eighty three studies which assessed the cognitive and psychomotor effects of 
antidepressants in healthy volunteers were identified by the review methods outlined 
above.
Study designs
P
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Seventy three of these studies followed a double blind, randomised, placebo 
controlled, cross-over design. Double blind placebo controlled parallel groups were" 
employed in five investigations, two were non-placebo controlled cross-over 
experiments, one followed an open design and one was a single blind (blind to 
subjects) placebo controlled cross-over experiment. The final study was a placebo 
controlled cross-over design, however the authors did not state if the study was blind.
Categorisation o f tests
All studies performed in healthy volunteer subjects are listed in Table 2.2. This list 
also indicates which authors have evaluated which aspects of performance. For 
example Allen et al (1991) investigated five of the seven categories whereas only two 
were examined by Bayliss and Duncan (1974). Of the 83 studies, 71 included tests of 
central processing or integration, 41 looked at memory, 49 assessed psychomotor 
performance, 47 evaluated sensorimotor performance, 34 measured motor ability and 
27 examined sensory skills. In addition, subjective ratings were collected by 65 
groups.
Fifty seven studies utilised tests from four or more of the seven categories of 
performance measures. Only one experiment included all seven components.
Effects o f  alcohol
Several authors measured the effects of co-administration of antidepressants and 
alcohol. In this review, the effects of the combination of antidepressants with alcohol 
were only documented if the combination potentiated the effect of either substance 
when given alone. For example, Hindmarch and Kerr (1994) reported that both 
amitriptyline and alcohol impaired critical flicker fusion thresholds and that 
amitriptyline and placebo given concomitantly exacerbated each of the individual 
effects. On the other hand, although Stromberg et al (1988) found that alcohol 
impaired performance on critical flicker fusion and the digit symbol substitution test, 
no additive effect was observed in the presence of nomifensine or maprotiline.
38
Ta
bl
e 
2.
2:
 
St
ud
ie
s 
wh
ich
 
ha
ve
 
as
se
ss
ed
 
th
e 
ef
fe
ct
s 
of 
an
tid
ep
re
ss
an
ts
 
on 
as
pe
ct
s 
of 
in
fo
rm
at
io
n 
pr
oc
es
sin
g 
in 
he
al
th
y 
vo
lu
nt
ee
rs
Su
bj
ec
tiv
e
X X X X X X X X X X X X X X X X X X X
Se
ns
or
y
X X X X X X X X X X
M
ot
or
X X X X X X X X X X X
Se
ns
or
im
ot
or
X X X X X X X X X X X X X
P
sy
ch
om
ot
or
X X X X X X X X X X X X X X
M
em
or
y
X X X X X X X X X X X X X
C
en
tr
al
X X X X X X X X X X X X X X X X X X X X X X X X
R
ef
er
en
ce
| 
Al
len
 
et
al
, 
19
91
| A
lle
n 
et 
al,
 1
99
3
| A
na
nd
 
an
d 
W
es
ne
s, 
19
90
| 
Ba
rb
ha
iy
a 
et 
al,
 1
99
6
| 
Ba
yl
iss
 
an
d 
D
un
ca
n,
 1
97
4
| 
Be
rli
n 
et
al
, 
19
90
a
j 
Be
rli
n 
et
al
, 
19
90
b
j 
Br
an
co
nn
ie
r 
et 
al,
 1
98
2
| 
By
e 
et 
al,
 
19
78
| 
Cl
ay
to
n 
et
al
, 
19
77
| 
C
ul
ig
et
al
, 
19
83
| 
Cu
rr
an
 
an
d 
La
de
r, 
19
86
| 
Cu
rr
an
 
et
al
, 
19
88
1 
Da
l 
Po
zz
o 
et 
al,
 1
99
6
| 
D
in
ge
m
an
se
 
et 
al,
 1
99
2
| 
Fa
ga
n 
et 
al,
 1
98
4
| 
Fa
ir
w
ea
th
er
 
et 
al,
 1
99
3a
| 
Fe
rr
is 
et 
al,
 1
98
0
1 
Fr
ew
er
 
an
d 
La
de
r, 
19
93
| 
G
ho
se
 
an
d 
Se
dm
an
, 
19
87
1 
H
am
ilt
on
 
et 
al,
 1
98
3
| 
H
er
be
rg
, 
19
82
j 
H
er
rm
an
n 
an
d 
M
cD
on
al
d,
 1
97
8
| 
H
in
dm
ar
ch
 
an
d 
Bh
at
ti,
 1
98
8
| 
H
in
dm
ar
ch
 
an
d 
H
ar
ri
so
n,
 1
98
8
| 
H
in
dm
ar
ch
 
an
d 
K
er
r, 
19
94
39
Ta
bl
e 
2.
2:
 
St
ud
ie
s 
wh
ich
 
ha
ve
 
as
se
ss
ed
 
the
 
ef
fe
ct
s 
of 
an
tid
ep
re
ss
an
ts
 
on 
as
pe
ct
s 
of 
in
fo
rm
at
io
n 
pr
oc
es
sin
g 
in 
he
al
th
y 
vo
lu
nt
ee
rs
 
(c
on
tin
ue
d)
Su
bj
ec
ti
ve
X X X X X X X X X X X X X X X X X X X X X X
Se
ns
or
y
X X X X
M
ot
or
X X X X X X X X X
Se
ns
or
im
ot
or
X X X X X X X X X X X X X X X
P
sy
ch
om
ot
or
X X X X X X X X X X X X
M
em
or
y
X X X X X X X X X X X X X X
C
en
tr
al
X X X X X X X X X X X X X X X X X X X X X X X
R
ef
er
en
ce
| 
H
in
dm
ar
ch
 
an
d 
Pa
rr
ot
t, 
19
77
| 
H
in
dm
ar
ch
 
an
d 
Su
bh
an
, 
19
86
| 
H
in
dm
ar
ch
 
et 
al,
 1
98
0
| 
H
in
dm
ar
ch
 
et 
al,
 1
98
3
| H
in
dm
ar
ch
 
et 
al,
 1
98
8
| H
in
dm
ar
ch
, 
19
77
a
| H
in
dm
ar
ch
, 
19
87
| 
Id
est
ro
m 
an
d 
C
ad
en
iu
s, 
19
64
| 
Id
zi
ko
w
sk
i 
et 
al,
 1
98
7
| 
Ke
rr
 
et 
al,
 1
99
6
| K
in
iro
ns
 
et 
al,
 1
99
3
| 
Ki
rb
y 
an
d 
Tu
rn
er
, 
19
74
| 
Li
lje
qu
ist
 e
t 
al,
 1
97
8
| L
in
no
ila
 
et 
al,
 1
98
3
| 
Li
nn
oi
la
 
et 
al,
 1
99
3
| 
Lo
ng
m
or
e 
et 
al,
 1
98
8
| 
Lo
uw
er
en
s 
et 
al,
 1
98
6
| M
at
til
a 
et 
al,
 1
98
8
| 
M
at
til
a 
et
al
, 
19
89
| M
cC
le
lla
nd
 
et 
al,
 1
98
7
| 
M
cE
w
en
et
al
, 
19
84
j M
os
ko
w
itz
 
an
d 
Bu
m
s, 
19
88
| 
O
gu
ra
et
al
, 
19
83
a
| 
O
gu
ra
et
al
, 
19
83
b
| 
Og
ur
a 
et 
al,
 1
98
7
J P
ar
ro
tt 
et
al
, 
19
82
J P
at
at
et
al
, 
19
88
Pa
ta
te
ta
l, 
19
95
40
Ta
bl
e 
2.2
: 
St
ud
ies
 w
hi
ch
 
ha
ve
 
as
se
ss
ed
 
the
 
ef
fe
ct
s 
of 
an
tid
ep
re
ss
an
ts
 
on 
as
pe
ct
s 
of 
in
fo
rm
at
io
n 
pr
oc
es
sin
g 
in 
he
al
th
y 
vo
lu
nt
ee
rs
 (
co
nt
in
ue
d)
Su
bj
ec
tiv
e
X X X X X X X X X X X X X X X X X X X X X
Se
ns
or
y
X X X X X X X X X X X X X
M
ot
or
X X X X X X X X X X X X X
Se
ns
or
im
ot
or
X X X X X X X X X X X X X X X X X X
Ps
yc
ho
m
ot
or
X X X X X X X X X X X X X X X X X X X X
M
em
or
y
X X X X X X X X X X
C
en
tr
al
X X X X X X X X X X X X X X X X X X X X
R
ef
er
en
ce
| 
Pe
ck
 
et 
al,
 1
97
9
j P
oir
ier
 
et
al
, 
19
93
j R
ae
m
ak
er
s 
et 
al,
 1
99
2
| 
R
am
ae
ke
rs
 
et
al
, 
19
95
| R
an
dh
aw
a 
et 
al,
 1
98
8
| 
Sa
ku
lsr
ip
on
g 
et 
al,
 1
99
1
| 
Sa
let
u 
an
d 
G
ru
nb
er
ge
r, 
19
85
a
| 
Sa
let
u 
an
d 
G
ru
nb
er
ge
r, 
19
85
b
| 
Sa
let
u 
et 
al,
 1
98
0
| 
Sa
let
u 
et 
al,
 1
98
3
| 
Sa
let
u 
et 
al,
 1
98
6a
| 
Sa
let
u 
et
al
, 
19
86
b
| 
Sa
let
u 
et 
al,
 1
99
2
| 
Se
m
lit
sc
h 
et 
al,
 1
99
3
J S
ep
pa
la
et
al
, 
19
77
1 
Se
pp
al
ae
ta
l, 
19
84
| 
Se
pp
al
a,
 1
97
7
| 
Sh
aw
 
et
al
, 
19
89
j S
to
ni
er
 
et
al
, 
19
82
| 
St
ro
m
be
rg
 
et 
al,
 1
98
8
| 
St
ro
m
be
rg
 
et 
al,
 1
99
1
| 
Ta
eu
be
r 
et 
al,
 1
97
9
| 
T
he
of
ilo
po
ul
os
 
et
al
, 
19
89
| 
Ti
lle
r, 
19
90
j v
an
 
Ha
rte
n 
et 
al,
 1
99
2
41
Ta
bl
e 
2.
2:
 
St
ud
ie
s 
wh
ich
 
ha
ve
 
as
se
ss
ed
 
the
 
ef
fe
ct
s 
of 
an
tid
ep
re
ss
an
ts
 
on 
as
pe
ct
s 
of 
in
fo
rm
at
io
n 
pr
oc
es
sin
g 
in 
he
al
th
y 
vo
lu
nt
ee
rs
 
(c
on
tin
ue
d)
Su
bj
ec
tiv
e
X X X ’■'SNC
Se
ns
or
y
t<N
M
ot
or
X
Se
ns
or
im
ot
or
X i -
Ps
yc
ho
m
ot
or
X X X Os
M
em
or
y
X X X X >■'
C
en
tr
al
X X X X tv
R
ef
er
en
ce
| 
van
 
La
ar
 
et 
al,
 1
99
5
| 
vo
n 
Fr
en
ck
el
l 
et 
al,
 1
99
0
1 
W
ar
ot
 e
t 
al,
 1
98
9
I 
W
ar
rin
gt
on
 
et 
al,
 
19
86
1 
TO
TA
L.
42
2.3.1 Cognitive aspects of performance
Seventy one of the studies in healthy volunteers included tests of “central” or 
cognitive aspects of performance (Table 2.3). The most widely used test was that of 
critical flicker fusion threshold (CFF); this was cited in 61 studies. The effects of 
amitriptyline were assessed in 31 studies, where it was mainly included as a verum. 
As 30 studies included both amitriptyline and critical flicker fusion, this subgroup 
warrants separate discussion.
Amitriptyline and critical flicker fusion
The effects of amitriptyline varied across experiments, although a majority (26) found 
that amitriptyline induced a decrement in the performance of CFF (Table 2.3a).
Table 2.3a: The effects of amitriptyline on critical flicker fusion (CFF) in
healthy volunteers
Impaired CFF:
Curran et al (1988); Fairweather et al (1993a); Ghose and Sedman (1987); Hindmarch (1987); 
Hindmarch and Harrison (1988); Hindmarch and Kerr (1994); Hindmarch and Subhan (1986); 
Hindmarch et al (1980); Hindmarch et al (1983) Hindmarch et al (1988); Kerr et al (1996); Kinirons et 
al (1993); Liljequist et al (1978); Longmore et al (1988); Mattila et al (1989); Ogura et al (1983a); 
Ogura et al (1983b); Patat et al (1988); Randhawa et al (1988); Sakulsripong et al (1991); Seppala et al 
(1984); Seppala (1977); Stonier et al (1982); Theofilopoulos et al (1989); Tiller (1990); Warrington et 
al (1986)
No effect on CFF:
Culig et al (1983); Herrmann and McDonald (1978); Mattila et al (1988); Stromberg et al (1991)
Although Mattila et al (1988) reported no effects of amitriptyline 50mg on critical 
flicker fusion, performance on the digit symbol substitution task was impaired. In 
another study where amitriptyline 50mg had no effect on critical flicker fusion, it 
impaired digit symbol substitution only when given in combination with alcohol 
(Stromberg et al, 1991). Hermann and McDonald (1978) found that amitriptyline 
disrupted the Pauli test, but did not affect critical flicker fusion. This is surprising, 
considering that a 75mg dose was administered here, and that amitriptyline has been
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shown to produce noticeable impairments with doses as low as 25mg (Hindmarch and 
Subhan, 1986; Kinirons et al, 1993; Kerr et al, 1996).
In several studies, alcohol was found to potentiate the effects of amitriptyline on 
critical flicker fusion (Hindmarch and Subhan, 1986; Hindmarch and Harrison, 1988; 
Hindmarch and Kerr, 1994; Seppala, 1977; Seppala et al, 1984; Kerr et al, 1996). On 
the other hand, no additive effects were observed by Warrington et al (1986) or 
Hindmarch (1987). Similar doses of amitriptyline and alcohol were given in all 
studies, and although specific study designs varied this did not differentiate the “no 
effects with alcohol” group. One suggestion (Warrington et al, 1986) was that the 
impairments caused by amitriptyline were so profound that any addition effect of 
alcohol could not be detected. A more likely explanation is that the number of 
subjects used (six in Warrington’s group) was not sufficient to show this impairment. 
The discrepancies in critical flicker fusion thresholds with the same drugs may also be 
due to differences in the apparatus and techniques used to measure this variable 
(Bobon et al, 1982).
Hindmarch et al (1980) and Stonier et al (1982) investigated the effects of a 
combination of amitriptyline and chlordiazepoxide (Ami/Chd). This was shown to 
impair performance on critical flicker fusion and an arithmetic test compared to 
placebo. Ogura et al (1983a) and (1983b) revealed that amitriptyline 25mg decreased 
critical flicker fusion when compared to dothiepin 25mg although as there was no 
placebo condition in this study, little credence can be given to the result.
Of the 31 amitriptyline studies, only one did not include critical flicker fusion in its 
battery of tests (Bye et al, 1978). However, in this study amitriptyline in doses as low 
as 12.5mg impaired scores on other tests of central processing (digit symbol 
substitution and arithmetic tasks).
The earliest study reviewed (Idestrom and Cadenius, 1964) showed that imipramine 
25mg and 50mg impaired critical flicker fusion after two weeks administration but 
Bayliss and Duncan (1974) failed to show any effects with this drug (50mg), although
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viloxazine lOOmg was shown to impair critical flicker fusion at one test point. 
Conversely, Clayton et al (1977) found no impairment with viloxazine 150mg on 
grammatical reasoning, but revealed that imipramine 75mg was detrimental. 
Imipramine 75mg also impaired scores on tests of semantic polarity and time 
estimation (Saletu et al, 1980; 1983) and lOOmg impaired letter matching (van Laar et 
al, 1995), but a range of doses (50mg - lOOmg) could not be distinguished from 
placebo on critical flicker fusion (Hindmarch and Parrott, 1977; Saletu et al, 1980; 
1983; Frewer and Lader, 1993) or digit symbol substitution (Frewer and Lader, 1993).
In addition to the above, the effects of several other drugs encountered in this review 
have varied from study to study. In studies performed by Allen et al (1993) and 
Ramaekers et al, (1995) dothiepin was reported to impair critical flicker fusion (in 
doses of 50mg and 75mg-150mg respectively). However, dothiepin 50mg was no 
different from placebo in a study by Hindmarch (1987), and 25mg could not be 
differentiated from amitriptyline in studies performed by Ogura et al (1983a; 1983b). 
In the two latter studies, the doses of dothiepin were very low in terms of therapeutic 
efficacy and may have been sub-threshold as regards the sensitivity of the tests. 
However, there exists the possibility that dothiepin may have affected performance, 
but to a lesser extent than the impairments observed with amitriptyline. As no placebo 
condition was included in these studies, no firm conclusions can be made. Hindmarch 
(1987) and Allen et al (1993) gave different results although they both used 50mg 
(these researchers employed different versions of the same test). The greatest 
impairment was observed with the higher doses of 75mg and 150mg (Ramaekers et al, 
1995). Furthermore, in a dose ranging study, Dal Pozzo et al (1996) reported 
impairment in critical flicker fusion with dothiepin 75mg, but not 25mg or 50mg. The 
authors also reported that, on closer inspection of the data, several subjects scored 
lower (but not significantly lower) than the mean value with 25mg and 50mg and 
suggest that these subjects were more sensitive to the effects of dothiepin. Although 
there were non-significant trends for the two lower doses of dothiepin to reduce 
critical flicker fusion thresholds, and two of the 16 subjects appeared to have a greater 
sensitivity to the effects of dothiepin 25mg and 50mg, the number of subjects scoring 
below the mean was similar in the placebo group. The TOAtrazodone (50mg-lOOmg),
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has been shown to impair critical flicker fusion thresholds (e.g. Hindmarch and 
Harrison, 1988; Sakulsripong et al, 1991) but other researchers have reported no 
effects (Longmore et al, 1988). One study which investigated the effects of the TpA^ ( 
reboxetine, found that it had no effect on critical flicker fusion and did not interact 
with alcohol (Kerr et al, 1996).
So far, the antidepressants reviewed have either had no effect on performance or have 
produced an impairment. Other antidepressants have been shown to improve 
performance, although again, there exists variability in the results. For example, 
nomifensine 75mg improved critical flicker fusion scores in three experiments 
(Hindmarch and Parrott, 1977; Hindmarch, 1980; Culig et al, 1983) but doses of 
50mg-lOOmg could not be distinguished from placebo in a further five (Taeuber et al,
1979; Parrott et al, 1982; McEwen et al, 1984; Hindmarch et al, 1988; Stromberg et 
al, 1988;). When nomifensine and alcohol were taken concomitantly, the impairing 
effects of alcohol on critical flicker fusion and the digit symbol substitution test were 
not further affected by nomifensine (Stromberg et al, 1988). A combination of 
nomifensine and clobazam (HOE 8476) produced differential effects on assessments 
of central activity. HOE 8476 increased critical flicker fusion thresholds but reduced 
scores on arithmetic and concept identification tests (Hindmarch et al, 1980). Taeuber 
et al (1979) demonstrated that nomifensine lOOmg improved arithmetic scores but had 
no effect on critical flicker fusion.
A general pattern of improvement was seen with the SSRIs zimeldine 200mg, 
(Hindmarch et al, 1983), sertraline 25mg-400mg (Saletu et al, 1986b; Hindmarch and 
Bhatti, 1988), paroxetine 30mg (Hindmarch and Harrison, 1988; Hindmarch and Kerr,
1994) and fluvoxamine 75mg (Saletu et al, 1980; 1983). However a few studies 
reported no differences from placebo (Herberg, 1982; Curran and Lader, 1986; 
McClelland et al, 1987; Mattila et al, 1988; Linnoila et al, 1993). Although Saletu et 
al (1980; 1983) reported an improved critical flicker fusion, fluvoxamine 75mg was 
also associated with a decrement in time estimation.
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Of the three experiments which evaluated fluoxetine, two were single dose studies. 
The first found that an acute dose of 30mg fluoxetine (Saletu and Grunberger, 1985a) 
impaired performance, whereas the second reported that a single dose of 40mg had no 
effect (Hindmarch, 1987). The third study revealed an impairment with fluoxetine 
20mg given for a period of 22 days (Ramaekers et al, 1995). The results reported by 
Hindmarch’s group are of interest, especially considering that the dose of fluoxetine 
here was twice that given by Ramaekers’ group. Furthermore, fluoxetine in 
combination with alcohol showed no additive effects in the study carried out by 
Hindmarch et al (1987). Alcohol consumption did not appear to affect performance 
enhancements seen with paroxetine (Hindmarch and Harrison, 1988) and zimeldine 
did not further impair the effects of alcohol (Seppala et al, 1984).
Moclobemide, a RIMA, was found to be no different from placebo on the critical 
flicker fusion test (Berlin et al, 1990a; Dingemanse et al, 1992; Ramaekers et al, 1992) 
and the digit symbol substitution test (Berlin et al, 1990a) but by increasing the daily 
dose from 450mg to 600mg (both t.i.d.) an improvement was detected in critical 
flicker fusion (Berlin et al, 1990b). The results of the latter must be treated with 
caution, as placebo was only given during the run-in phase, and was not included in 
the treatment phase. Any comparisons to placebo, therefore, may be due to practice 
effects, although the authors did state that subjects were trained on the tests prior to 
the study. Fairweather et al (1993a) reported that moclobemide 400mg impaired 
critical flicker fusion at two test points in elderly volunteers but was no different from 
placebo at the remaining eight test points. Anand and Wesnes (1990) utilised a model 
whereby cognitive impairment could be induced by scopolamine in healthy 
volunteers. These decrements are thought to mimic the cognitive disturbances 
associated with the dementias, and possibly the impairments which have been 
described in the previous chapter to accompany depression. Using this model, the 
researchers suggested that it was possible to investigate whether or not putative 
antidepressants had the potential to exacerbate or reverse the impairments seen in 
depressed individuals. However, the antidepressant moclobemide 400mg did not 
further affect the impairments induced by scopolamine on a task of central processing 
(rapid visual information processing). Neither toloxatone lOOOmg per day
47
(Dingemanse et al, 1992) nor befloxatone 5mg-10mg (Patat et al, 1995) exerted any 
effect on critical flicker fusion, however there is very little information on these drugs 
as yet.
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2.3.2 Memory
Forty one of the studies examined included tests which assessed memory or memory 
components of performance (Table 2.4). In these 41 studies, 31 different tests of 
memory function were cited. As with the cognitive tests, amitriptyline was the most 
widely assessed compound on memory, being cited in 18 studies. Memory 
impairment was recorded in 13 of these studies (Table 2.4a).
Table 2.4a: The effects of amitriptyline on memory in healthy volunteers
Impaired memory:
Branconnier et al (1982); Curran et al (1988); Fairweather et al (1993a); Hindmarch and 
Subhan (1986); Kerr et al (1996); Kinirons et al (1993); Liljequist et al (1978); Linnoila et al 
(1983); Moskowitz and Bums (1988); Peck et al (1979); Sakulsripong et al (1991); Shaw et al 
(1989); Warrington et al (1986)
No effect on memory:
Bye et al (1978); Ghose and Sedman (1987); Hindmarch et al (1980); Mattila et al (1989); Patat 
et al (1988)
Although only used in 11 experiments, digit span was the most frequently used test. 
Curran et al (1988), Liljequist et al (1978); Peck et al (1979); Warrington et al (1986); 
Ghose and Sedman (1987) and Mattila et al (1989) were the only researchers who 
assessed amitriptyline on digit span. Decrements were found in the first four studies 
where the doses ranged from 25mg -75mg, but the latter two studies found that 
amitriptyline 50mg was no different to placebo. In addition to digit span, Mattila et al
(1989) found no significant differences in paired associate learning scores, and 
likewise with a pictures memory test as reported by Ghose and Sedman (1987).
The same doses of amitriptyline (50mg) were used by Warrington’s, Ghose’s and 
Mattila’s groups but with different effects (i.e. impairment in the former but no effect 
in the two latter studies). Furthermore, lower doses of 25mg did induce impairment on 
digit span (Peck et al, 1979) and the Sternberg memory task (Hindmarch and Subhan, 
1986; Kerr et al, 1996). Amitriptyline did not appear to exacerbate the effects of
54
alcohol on digit span (Warrington et al, 1986; Liljequist et al, 1978) but did on paired 
associate learning (Liljequist et al, 1978) and on the Sternberg memory test 
(Hindmarch and Subhan, 1986; Kerr et al, 1996).
Branconnier et al (1982) reported that amitriptyline 50mg impaired performance on 
the Buschke selective reminding task and verbal encoding, but not on Sperling’s 
perceptual trace, non-verbal incidental learning, the Buschke recognition task or the 
Sternberg memory. Amitriptyline also impaired performance on all memory tests (free 
recall, Corsi blocks, digit span, semantic retrieval, news recall and who’s who) 
employed by Curran et al (1988). Only one non-specified memory test was used by 
Bye et al (1978) and Hindmarch et al (1980) and both groups found no effects of 
amitriptyline. Imipramine potentiated the impairing effects of alcohol on free recall 
(Frewer and Lader, 1993). Dothiepin was shown to be free from impairment in doses 
ranging from 25mg - 75mg (Dal Pozzo et al, 1996) whereas another study 
demonstrated impaired free recall with dothiepin 50mg (Allen et al, 1993).
Newer antidepressants seemed to have little or no effect on memory, and in some 
cases improvements were observed. For example, it was demonstrated that neither 
moclobemide 450mg nor toloxatone lOOOmg had any effects on recall or recognition 
memory for paired words after eight days of treatment (Berlin et al, 1990a; 
Dingemanse et al, 1992). Increasing the daily dose of moclobemide to 600mg did not 
affect memory performance, but in one test attenuated the effects of alcohol (Berlin et 
al, 1990b). In Anand and Wesnes’ model of scopolamine-induced deficit, 
moclobemide 400mg reversed the impairment in both memory tests (memory 
scanning and the Buschke selective reminding task). This finding may suggest that 
moclobemide has a role to play in individuals suffering from memory impairments.
In the tests of central processing (see section 2.3.1) the pattern observed with the 
SSRIs was of general improvement. Memory tests however, revealed that only 
zimeldine lOOmg enhanced memory, although this was only reported in one study 
(Saletu et al, 1986b). Even though Linnoila et al (1983) used a higher dose (200mg) of 
zimeldine, they found that it had no effect, although it did antagonise the effects of
55
alcohol to a certain extent. A ran^e of doses of fluvoxamine, fluoxetine, sertraline and 
paroxetine were no different/to Jplacebo in any of the memory tests (Linnoila et al, 
1993; Moskowitz and Bums, 1988; Saletu et al, 1986b; McClelland et al, 1987). 
Furthermore, fluoxetine and fluvoxamine did not significantly alter alcohol-induced 
impairment (Shaw et al, 1989; van Harten et al, 1992). Shaw et al (1989) included 
amitriptyline 50mg as a vemm, but this failed to have any effect on the tasks of 
memory (verbal memory and word recall) and did not potentiate the effects of alcohol. 
Venlafaxine given in doses of 50mg improved numerical memory, whereas lower 
doses of 12.5mg and 25mg were no different from placebo (Saletu et al, 1992).
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2.3.3 Psychomotor function
Forty nine of the studies examined in the literature review included tests which 
assessed the psychomotor aspects of performance (Table 2.5). The most widely used 
test was that of choice reaction time (cited in 36 studies). The effects of amitriptyline 
(usually included as a verum) were assessed in 21 studies, 19 of which used choice 
reaction time tests.
Amitriptyline and choice reaction time
As with central and memory tests, different effects of amitriptyline appeared across 
experiments. Thirteen studies revealed that amitriptyline impaired choice reaction 
time, and six reported that amitriptyline was no different from placebo (Table 2.5a).
Table 2.5a: The effects of amitriptyline on choice reaction time (CRT) in
healthy volunteers
Impaired CRT:
Culig et al (1983); Curran et al (1988); Ghose and Sedman (1987); Hindmarch (1987); Hindmarch et 
al (1980); Hindmarch et al (1983) Hindmarch et al (1988); Kerr et al (1996); Randhawa et al (1988); 
Sakulsripong et al (1991); Seppala (1977); Stonier et al (1982); Tiller (1990)
No effect on CRT:
Fairweather et al (1993a); Hindmarch and Harrison (1988); Hindmarch and Subhan (1986); Seppala et 
al (1984); Stromberg et al (1991); Warrington et al (1986)
Although five of the six studies which have no effect on choice reaction time all used 
amitriptyline 50mg, this was also the dose given in the majority of studies where 
amitriptyline impaired performance. In fact, impairment of choice reaction time was 
detected with doses as low as 37.5mg (Sakulsripong et al, 1991) and even 25mg (Kerr 
et al, 1996). The combination of amitriptyline and chlordiazepoxide (Ami/Chd) was 
evaluated in two studies; in the first Ami/Chd impaired choice reaction time 
(Hindmarch et al, 1980) whereas it had no effect in the second (Stonier et al, 1982), 
although here it did impair card sorting and on-the-road driving.
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Of the studies which assessed amitriptyline, only two did not include CRT in if f  
battery of tests (Louwerens et al, 1986; Mattila et al, 1989). Instead, Mattila et al
(1989) measured abilities on a simulated driving task, in which similar abilities to 
those utilised in the choice reaction time test are required. They found that 
amitriptyline 50mg impaired the skills required for this task. Louwerens et al (1986) 
found that amitriptyline 75mg impaired performance in an assessment of driving 
ability which also contains a reaction time component.
The same dose (75mg) of imipramine had varied effects in that it impaired scores on a 
gap acceptance test and a weaving task (Clayton et al, 1977) but did not affect choice 
reaction time (Hindmarch and Parrott, 1977) or Grtinberger’s psychomotor test (Saletu 
et al, 1983). Dothiepin 75mg-150mg did not alter driving performance (assessed by 
on-the-road driving and car following) (Ramaekers et al, 1995), and 50mg had no 
effect on choice reaction time nor simulated driving (Hindmarch, 1987). Dal Pozzo et 
al (1996) found no significant effect with 25mg or 50mg dothiepin whereas 75mg 
significantly impaired choice reaction time.
Similarly to the tests classified into “central” performance, there is a pattern to suggest 
that the newer antidepressants may improve psychomotor abilities. It must be noted, 
however, that inconsistencies do exist. It has already been stated that moclobemide 
reversed memory deficits induced by scopolamine (Anand and Wesnes, 1990). The 
same group of researchers also demonstrated that moclobemide 400mg ameliorated 
the psychomotor impairments induced by scopolamine. Furthermore, moclobemide 
(450mg and 600mg) improved choice reaction time in non-impaired subjects in two 
separate studies (Berlin et al, 1990a; 1990b). However, Tiller (1990) found no 
differences with doses of lOOmg and 300mg. The most obvious discrepancy here may 
be due to dosage regimens, that is, whilst Berlin et al (1990a; 1990b) measured the 
effects of the drugs after eight and seven days administration respectively, Tiller
(1990) evaluated performance after a single dose. However, Anand and Wesnes
(1990) found the improvement of scopolamine-induced impairment after only one day 
of moclobemide administration. Contrary to the above, moclobemide 400mg was 
found to impair the recognition component of the choice reaction time task following
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seven days dosing, albeit at only one test point (Fairweather et al, 1993a) in elderly 
volunteers.
Contrasting effects of sertraline on psychomotor performance have been reported. 
Saletu et al (1986b) found that although sertraline lOOmg and 200mg improved 
Griinberger’s psychomotor test scores, 400mg impaired this task and 200mg and 
400mg impaired the Weiner Determinationsgerat. Conversely, lower doses of 75mg 
and lOOmg sertraline significantly improved choice reaction time (Hindmarch and 
Bhatti, 1988). Although zimeldine has been shown to improve central and memory 
components (see earlier), the evidence suggests that it has no effect on choice reaction 
time (Fagan et al, 1984; Hindmarch et al, 1993; Seppala et al, 1984) or the Weiner 
Determinationsgerat (Herberg, 1982). In one study zimeldine lOOmg impaired 
performance on Griinberger’s psychomotor test (Saletu et al 1986b). Both fluoxetine 
20-40mg (Hindmarch, 1987; Ramaekers et al, 1995; Saletu and Grunberger, 1985a) 
and fluvoxamine 50mg-75mg (Saletu et al, 1980; 1983; van Harten et al, 1992) had no 
effects on psychomotor performance.
Similarly, nomifensine improved performance in some studies (Hindmarch et al, 
1980; 1988) but was no different from placebo in others over similar dose ranges 
(50mg-100mg) (Hindmarch and Parrott, 1977; Parrott et al, 1982; McEwen et al, 
1984; Stromberg et al, 1988). Also of note is the fact that lofepramine 70mg impaired 
choice reaction time (Hindmarch et al, 1988) whereas lofepramine 140mg improved 
scores. Again, no obvious differences in study design can explain the varied results.
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2.3.4 Sensorimotor performance
Forty seven of the studies examined included tests which assessed antidepressants and 
the sensorimotor aspects of performance (Table 2.6). The most common variable 
measured was speed of reaction to a given stimulus, which was assessed in 35 studies. 
The researchers who measured reaction time used the following tests: auditory 
reaction time, reaction time to light, reaction time to tone, brake reaction time, 
continuous performance task, the Weiner Reaktionsgerat and other reaction time tests. 
The latter includes simple reaction time tests (according to the authors) and other 
reaction time tests not specified by the authors. As the major component in the above 
measurements is reaction time, they will be dealt with together as “reaction time”. 
(Other tests in which reaction time is a contributory rather than a major factor will be 
dealt with separately e.g. tests of tracking ability or divided attention.)
The effects of amitriptyline were assessed in 20 studies, where it was usually included 
as a verum. Twelve studies evaluated the effects of amitriptyline on “reaction time”.
Amitriptyline and reaction Time
Following the pattern of results in central, memory and psychomotor tests, different 
effects appeared across studies with amitriptyline. Six studies reported that 
amitriptyline impaired reaction time, and six found amitriptyline to be no different 
from placebo. These findings are presented in Table 2.6a.
Table 2.6a: The effects of amitriptyline on reaction time (RT) in healthy
volunteers
Impaired RT:
Bye et al (1978) ; Hindmarch (1987); Hindmarch et al (1983); Linnoila et al (1993); Patat et al (1988); 
Peck et al (1979)
No effect on RT:
Hermann and McDonald (1978); Hindmarch and Harrison (1988); Hindmarch and Subhan (1986); 
Mattila et al (1988); Seppala et al (1984); Stromberg et al (1991)
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In the six studies where amitriptyline was reported to have no effect on reaction time, 
the doses ranged from 25mg - lOOmg. However, other researchers (Hindmarch, 1987; 
Hindmarch et al, 1983; Linnoila et al, 1993) found that doses at the lower end of this 
range (50mg) impaired performance. In addition, amitriptyline disrupted performance 
with doses as low as 25mg (Peck et al, 1979) and 12.5mg (Bye et al, 1978).
Inconsistencies in results were also found in other tasks of sensorimotor function. 
Amitriptyline impaired tracking in six studies (Hindmarch and Subhan, 1986; 
Hindmarch and Harrison, 1988; Hindmarch et al, 1983, 1988; Fairweather et al, 
1993a; Kerr et al, 1996) but was no different from placebo in two studies (Hindmarch, 
1987; Shaw et al, 1989). Impairment was observed when amitriptyline 50mg and 
alcohol were administered concomitantly (Hindmarch, 1987), and there was a 
potentiation of effects of 25mg in two studies (Hindmarch and Subhan, 1986; Kerr et 
al, 1996) however no measurable interaction was reported with amitriptyline 50mg by 
Shaw et al (1989). Theofilopoulos et al (1989) and Herrmann and McDonald (1978) 
found no effects of amitriptyline 50mg-75mg on wire maze tracking and the pursuit 
rotor respectively, whereas the Weiner Koordinationsgerat was impaired in two 
studies (Seppala, 1977; Seppala et al, 1984) with doses ranging from 20-lOOmg.
Results with drugs other than amitriptyline also differed across studies. Imipramine 
25mg-150mg had no effect on reaction time (Bayliss and Duncan, 1974; Ferris et al, 
1980; Idestrom and Cadenius, 1964), or on the Gibson spiral maze, pursuit rotor or 
auditory reaction time (Frewer and Lader, 1993), but 75mg impaired the Weiner 
Koordinationsgerat in two studies (Saletu et al, 1980; 1983). A similar pattern was 
seen with dothiepin where it slowed auditory reaction time (50mg) (Allen et al, 1993) 
and impaired tracking ability (25mg) (Dal Pozzo et al, 1996) but did not affect brake 
reaction time, sustained attention or tracking when given alone, although dothiepin 
50mg did induce decrements when given with alcohol (Hindmarch, 1987).
Enhancement of sensorimotor skills was observed in several studies, though again the 
pattern is not consistent. Lofepramine 70mg improved abilities on the pursuit rotor 
tests (Allen et al, 1993) but the same dose did not affect tracking (Hindmarch et al,
67
1988). Nomifensine lOOmg but not 50mg improved simulated night driving 
(Hindmarch, 1977a), but did not alter reaction time (Stromberg et al, 1988). Sertraline 
lOOmg improved reaction time but higher doses could not be distinguished from 
placebo (Saletu et al, 1986b). Seppala et al (1984) demonstrated that zimeldine 200mg 
slowed reaction times, but no discernible differences were detected by Hindmarch et 
al (1983) or Saletu et al (1986b). Moreover, disparity was seen within studies, for 
example nefazodone 200mg improved performance on Gibson’s spiral maze but 
impaired pursuit rotor skills (Frewer and Lader, 1993). In the same study nefazodone 
400mg improved performance on an auditory reaction time test and the pursuit rotor.
Although moclobemide 400mg reversed scopolamine-induced decrements in memory 
and psychomotor tasks, it had no effect on sensorimotor ability (Anand and Wesnes, 
1990; Ramaekers et al, 1992; Fairweather et al, 1993a). Befloxatone (Patat et al, 
1995), fluvoxamine (Saletu et al, 1980; 1983; van Harten et al, 1992; Linnoila et al, 
1993) and fluoxetine (Saletu and Griinberger, 1985; Hindmarch, 1987; Moskowitz 
and Bums, 1988; Shaw et al, 1989) had no effect on sensorimotor abilities and these 
findings were consistent across studies.
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2.3.5 Motor ability
Thirty four of the studies examined included evaluations of motor activity (Table 2.7). 
Over these studies, only six different tests were cited (numbers in parentheses refer to 
how many studies the test was performed in): tapping task (20); body sway (12); 
manual dexterity (2); peg-board (3); blink rate (1); hand-eye co-ordination (1). The 
effects of amitriptyline were assessed in 16 studies. Due to the relatively small 
number of studies in this category, the effects of amitriptyline on motor activity as a 
whole are listed below in Table 2.7a.
Table 2.7a: The effects of amitriptyline on motor ability in healthy volunteers
Impaired motor ability:
Bye et al (1978); Herrmann and McDonald (1978); Mattila et al (1989); Patat et al (1988); Peck et al 
(1979); Randhawa et al (1988); Sakulsripong et al (1991); Warrington et al (1986)
No effect on motor ability:
Kinirons et al (1993); Mattila et al (1989); Ogura et al (1983b); Seppala et al (1984); Shaw et al 
(1989); Stonier et al (1982); Stromberg et al (1991); Theofilopoulos et al (1989)
The majority of studies reported only one test of motor activity, however, Mattila et al 
(1989) and Patat et al (1988) included both body sway and tapping rate. Amitriptyline 
20mg-lOOmg had no effect on body sway and this finding was consistent across all 
studies (Kinirons et al, 1993; Mattila et al, 1989; Seppala et al, 1984; Shaw et al, 
1989; Stromberg et al, 1991) except one (Patat et al, 1988). Here, amitriptyline 75mg 
also exacerbated the decrement found with diazepam. Manual dexterity, however, was 
impaired by amitriptyline 50mg in both studies where it was included (Randhawa et 
al, 1988; Warrington et al, 1986). Different findings were presented with amitriptyline 
on tapping rate and peg-board performance. A combination of amitriptyline and 
chlordiazepoxide (Ami/Chd) did not affect the peg-board test (Stonier et al, 1982) but 
amitriptyline 75mg alone impaired performance (Herrman and McDonald, 1978).
Amitriptyline 12.5mg, 25mg (Bye et al, 1978) and 37.5mg (Sakulsripong et al, 1991) 
slowed the tapping rate. Amitriptyline 50mg was also shown to impair this motor test
72
in one study (Mattila et al, 1989) whereas no significant differences were found in 
another (Theofilopoulos et al, 1989). Ogura et al (1983b) reported that amitriptyline 
25mg and dothiepin 25mg were not significantly different from each other on tapping 
rate; however no placebo condition was included in this study. The conclusion by 
Ogura et al (1983b) must be treated with caution, as it is possible that amitriptyline 
and dothiepin both impaired this task to a similar extent.
Frewer and Lader (1993) assessed the effects of a range of doses of nefazodone 
(50mg-400mg) on tapping rate, both with and without alcohol. They concluded that 
nefazodone at any of these doses did not affect motor skills. In another study 
(Barbhaiya et al, 1996) nefazodone 200mg did not impair tapping rate, but did impair 
performance on the peg-board task.
buprcpibrv
Lofepramine (Allen et al, 1993), -buproprion (Hamilton et al, 1983), trazodone 
(Longmore et al, 1988), fengabine (Theofilopoulos et al, 1989), moclobemide (Berlin 
et al, 1990b), zimeldine (Fagan et al, 1984; Ferris et al, 1980), fluoxetine (Saletu and 
Griinberger, 1985; Shaw et al, 1989), fluvoxamine (Curran and Lader, 1986; Saletu et 
al, 1980; 1983), venlafaxine (Semlitsch et al, 1993) and paroxetine (McClelland et al,
1987) were no different from placebo on tests of motor activity.
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2.3.6 Sensory skills
Twenty seven studies from this literature review included evaluations of 
antidepressants on sensory skills (Table 2.8). Amitriptyline was assessed in nine of 
these studies. Due to the relatively small number of experiments in this category, the 
effects of amitriptyline on sensory skills as a whole are presented in Table 2.8a.
Table 2.8a: The effects of amitriptyline on sensory skills in healthy volunteers
Impaired sensory skills:
Bye et al (1978); Curran et al (1988); Kinirons et al (1993); Longmore et al (1988); Moskowitz and 
Bums (1988), Peck et al (1979); Sakulsripong et al (1991); Theofilopoulos et al (1989)
No effect on sensory skills:
Ghose and Sedman (1987); Curran et al (1988); Longmore et al (1988)
Six researchers included only one test of sensory skills in their protocol (Bye et al; 
1978; Kinirons et al, 1993; Moskowitz and Bums, 1988; Peck et al, 1979; 
Sakulsripong et al, 1991; Theofilopoulos et al, 1989). Amitriptyline up to 75mg was 
evaluated on two tests of sensory skills by two groups. Impairments were detected on 
letter cancellation (Curran et al, 1988) and digit cancellation (Longmore et al, 1988) 
but both groups found no significant differences on symbol copying. Ghose and 
Sedman (1987) reported no effects with amitriptyline 50mg, although impairments 
were seen with doses comparable to this or less with the other authors. Fluoxetine 
impaired sustained attention (Ramaekers et al, 1995) and Grunberger’s AD test 
(Saletu and Griinberger, 1985a) but had no effect on vigilance (Moskowitz and Bums,
1988).
Several dmgs were shown to improve sensory skills, although results varied across 
studies. For example, clovoxamine 75mg improved the spiral after effect whereas 
125mg impaired this task (Saletu et al, 1980). Although sertraline 200mg and 400mg 
impaired both Grunberger’s AD test and the spiral after effect, improvement was seen 
on an alphabetical reasoning task (Saletu et al, 1986b). Also, performance was better 
with venlafaxine 25mg and 50mg than with lower doses (Saletu et al, 1992). Scores
76
on the letter cancellation tests were improved with lofepramine 140mg than with 
placebo or lofepramine 70mg (Ghose and Sedman, 1987), whereas both zimeldine 
(Herberg, 1982) and tianeptine (Poirier et al, 1993) had no effect on the same task.
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2.3.7 Subjective ratings
Subjective ratings of the effects of antidepressants were recorded in 65 volunteer 
studies (Table 2.9). By far the most common approach for collecting this data was by 
means of non-specific visual analogue scales. This method was adopted in 52 studies, 
where the most frequently measured parameter was sedation.
Amitriptyline was investigated in 29 studies, all of which contained visual analogue 
scales (Table 2.9a). Twenty six of these studies concluded that amitriptyline had 
negative effects; in 25 studies amitriptyline increased subjective feelings of sedation 
or drowsiness, one other study revealed that amitriptyline reduced subjects ratings of 
driving ability (Louwerens et al, 1986).
Table 2.9a: The effects of amitriptyline on subjective ratings of sedation in
healthy volunteers
Increased feelings of sedation / drowsiness:
Bye et al (1978); Culig et al (1983); Curran et al (1988); Fairweather et al (1993a) Ghose and Sedman
(1987); Herrmann and McDonald (1978); Hindmarch (1987); Hindmarch and Subhan (1986); 
Hindmarch and Harrison (1988); Hindmarch et al (1980); Hindmarch et al (1983); Hindmarch et al
(1988); Longmore et al (1988); Louwerens et al (1986); Mattila et al (1988); Mattila et al (1989); Peck 
et al (1979); Patat et al (1988); Randhawa et al (1988); Sakulsripong et al (1991); Seppala et al (1984); 
Shaw et al (1989); Stonier et al (1982); Stromberg et al (1991); Theofilopoulos et al (1989), 
Warrington et al (1989)
No effect on feelings of sedation /  drowsiness:
Ogura et al (1983a); Ogura et al (1983b); Kerr et al (1996)
The exceptions to this pattern were three investigations (Ogura et al, 1983a; 1983b; 
Kerr et al, 1996) where amitriptyline 25mg produced no feelings of sedation. It must 
be noted, however, that the first two studies were the only two that did not employ a 
placebo condition; instead amitriptyline was compared to dothiepin 25mg. As 
amitriptyline and dothiepin are pharmacologically similar they are likely to induce 
similar levels of sedation, and given the consistent pattern of sedation with 
amitriptyline in the other 26 investigations, it is very likely here that amitriptyline and
80
dothiepin have induced similar levels of sedation. Furthermore, dothiepin has also 
been shown to increase drowsiness (Allen et al, 1993; Ramaekers et al, 1995) and 
sedation (Dal Pozzo et al, 1996; Hindmarch, 1987) in all studies in which it was 
assessed.
In Anand and Wesnes’ (1990) model of scopolamine-induced decrement, 
moclobemide 400mg ameliorated the memory impairment, but at the same time 
delayed recovery of subjective feelings of alertness compared to placebo. No 
differences, however, were observed between moclobemide 400mg-450mg and 
placebo on subjective ratings of sedation (Berlin et al, 1990a; Dingemanse et al, 1992; 
Ramaekers et al, 1992; Fairweather et al, 1993a) and moclobemide 600mg in 
combination with alcohol had no effect on subjective ratings of tiredness (Berlin et al, 
1990b). Venlafaxine reduced feelings of sedation and increased well-being (Saletu et 
al, 1992). Generally, zimeldine 100mg-200mg produced no feelings of sedation 
(Fagan et al, 1984; Ferris et al, 1980; Hindmarch et al, 1983), although Seppala et al 
(1984) reported an increase in subjective drowsiness following 200mg of the drug.
On the other hand, fluvoxamine (Linnoila et al, 1993), sertraline (Mattila et al, 1988), 
fluoxetine (Shaw et al, 1989) and nomifensine (Hindmarch et al, 1988; McEwen et al, 
1984, Parrott et al, 1982) did not differ from placebo on subjective rating scales in any 
of the reports analysed. No sedation was experienced with paroxetine (Hindmarch and 
Harrison, 1988, McClelland et al, 1987) although an increase in clumsiness compared 
to placebo was reported by the latter.
Eleven studies included the Leeds Sleep Evaluation Questionnaire (LSEQ), a specific 
visual analogue rating scale which measures subjective ratings of sleep. The factors 
are: ease of getting to sleep (GTS); quality of sleep (QOS); feelings on awakening 
from sleep (AFS) and integrity of behaviour following wakening (BFW). 
Amitriptyline 50mg was shown to improve ease of getting to sleep in two studies 
(Hindmarch and Harrison, 1988; Hindmarch et al, 1988) but was no different to 
placebo in a third (Fairweather et al, 1993a). A lower dose of 25mg did not affect 
subjective parameters of sleep as reported by Kerr et al (1996). The combination drug,
81
Ami/Chd, also improved getting to sleep and quality of sleep (Hindmarch et al, 1980; 
Stonier et al, 1982) but impaired feelings the following morning (AFS and BFW) 
(Hindmarch et al, 1980). Quality of sleep^fietter with nomifensine (Hindmarch et al, 
1980; Hindmarch and Parrott, 1977) as was integrity of behaviour following wakening 
(Hindmarch and Parrott, 1977). Tianeptine (Poirier et al, 1993) and mianserin 
(Hindmarch and Harrison, 1988) eased getting to sleep, whereas imipramine 
(Hindmarch and Parrott, 1977), dothiepin and fluoxetine (Ramaekers et al, 1995) 
impaired feelings on awakening. Lofepramine (Hindmarch et al, 1988), reboxetine 
(Kerr et al, 1996), moclobemide (Fairweather et al, 1993a) and befloxatone (Patat et 
al, 1995) had no effect on the LSEQ.
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2.4 The effects of antidepressants in depressed patients - a literature review
A total of twenty eight studies of the effects of antidepressants on behaviour or 
performance of depressed patients were reviewed.
Study designs
The designs of the studies of patient populations were more varied than those used in 
healthy volunteers. Only one study adopted a cross-over design whereas the others 
used parallel groups. Of these, nine used a double blind, randomised, parallel group 
design, and another two were double blind parallel studies, although it is unclear 
whether these were also randomised. Treatments were allocated in a single blind 
fashion (two studies) and a placebo condition was introduced in four studies, which 
were also double blind. Eight authors employed an open design where no attempt was 
made to blind the treatment regimens. The remaining two studies used parallel groups, 
but no further information on the specific design was provided by the authors.
Categorisation o f  tests
Table 2.10 lists the patient studies reviewed and also indicates which authors have 
evaluated certain aspects of performance. For example Georgotas et al (1983) have 
investigated five of the seven categories whereas only one has been examined by 
Fudge et al (1990). Of the 28 studies, 17 tested central integration or processing, 14 
memory, 12 psychomotor performance, 11 sensorimotor performance, five motor 
ability and five sensory skills. In addition, subjective feelings recorded by a variety of 
rating scales were collected in nine trials.
Eight studies utilised tests from four or more of the seven categories of performance 
measures. No study assessed more than five.
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2.4.1 Cognitive aspects of performance
Table 2.11 lists the 17 studies in which tests of central processing and integration 
were included. As with volunteer studies, amitriptyline was the most frequently 
examined drug, even though it was assessed in only five studies. A further two 
experiments included amitriptyline but the effects of this drug were not given alone; 
the effects of amitriptyline and other TCAs were presented as a whole.
Two of the five researchers found that amitriptyline 75mg-150mg had no effect on 
central variables i.e. critical flicker fusion (Beaini et al, 1980) and digit symbol 
substitution (McNair et al, 1984). Spring et al (1992) reported that, although 
amitriptyline 50mg-350mg could not be distinguished from clovoxamine 50mg- 
350mg or placebo, digit symbol substitution scores were improved relative to baseline 
values. Hanks (1984) demonstrated that amitriptyline 25mg impaired critical flicker 
fusion for up to seven weeks when compared to placebo, and Fairweather et al 
(1993b) found that patients receiving amitriptyline 75mg performed significantly 
worse on this test than those receiving fluoxetine 25mg when tested weekly for 6 
weeks. Hale and Pinninti (1995) compared two groups of antidepressants in patients 
who had been on a stable antidepressant medication for at least three months and who 
were in clinical remission. Those patients on TCAs (amitriptyline, dothiepin, 
clomipramine, imipramine, trimipramine) had significantly lower critical flicker 
fusion scores than matched (for sex and age) healthy non-drug controls. Scores 
following SSRI treatment (fluoxetine and sertraline) were significantly higher than 
controls, suggestive of improved cognition.
Neumann and colleagues (1993) investigated the concept of visual integration in 
depressed patients. Patients who had just started antidepressant treatment (DET) and 
those who were mid treatment (DMT) (these are the authors’ definitions) were 
compared to a group of matched healthy non-depressed controls. Patients were either 
receiving TCAs or SSRIs and the distribution of the two types of antidepressants was 
comparable across groups. Interestingly, the DMT group produced better scores than 
healthy non-depressed controls. The authors suggest that this may be a function of 
antidepressant drugs, but as this phenomenon has not been investigated in studies of
90
healthy volunteers, no firm conclusions can be made. Furthermore, as there were only 
ten patients in each group, it is more likely that the observed differences between the 
groups was the result of an experimental artefact or a Type I error.
Several studies have shown that antidepressants improve performance over time when 
compared to pre-treatment scores. For example, moclobemide (Allain et al, 1992), 
fluoxetine (Fairweather et al, 1993b), paroxetine (Hindmarch and Kerr, 1994), 
trazodone (Moon and Davey, 1988), mianserin (Moon and Davey, 1988; Siegfried and 
O’Connolly, 1986), nomifensine (Siegfried and O’Connolly, 1986) and maprotiline 
(Siegfried and O’Connolly, 1986) improved critical flicker fusion following two to six 
weeks treatment. Digit symbol substitution scores were improved from baseline 
following amitriptyline and clovoxamine, but there was no difference between drug 
and placebo scores (Spring et al, 1992). On the other hand, amoxapine impaired digit 
symbol substitution test and amitriptyline had no effects when compared to placebo 
(McNair et al, 1984). Mianserin reduced critical flicker fusion to a level lower than 
baseline scores (Khan et al, 1984). In comparison to L-tryptophan, doxepin and 
chlorimipramine reduced critical flicker fusion scores (Seppala et al, 1978).
No significant differences from baseline on the critical flicker fusion task were 
reported with imipramine (Beaini et al, 1980), phenelzine (Georgotas et al, 1983; 
Georgotas et al, 1989), nortriptyline (Georgotas et al, 1989) or sertraline (Ravindran et 
al, 1995) in depressed patients.
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2.4.2 Memory
Fourteen authors assessed the effects of antidepressants on tests of memory (see Table 
2.12). The influence of amitriptyline on memory processes was evaluated in five of 
these studies. Improvement was observed with amitriptyline 50mg-243mg on signal 
detection recognition memory and the Benton visual retention test (Lamping et al, 
1984) and memory for paired words, pictures and faces with doses ranging from 
150mg-350mg (Sternberg and Jarvik, 1976) when compared to baseline. Short term 
memory scores were significantly better with amitriptyline 116mg (mean dose) than 
with placebo (McNair et al, 1984). In Gillis and Moran (1980), the scores achieved in 
the amitriptyline 50mg-150mg group were no different to a non-medicated group or 
those taking imipramine 75mg-200mg. The fifth study revealed that performance on 
the Benton visual retention test and recognition memory were significantly worse with 
amitriptyline 50mg-350mg than with placebo after four weeks of administration 
(Spring et al, 1992).
The pattern for another TCA, imipramine 75mg-250mg, was that it was no different 
on memory tasks from baseline scores (Amin et al, 1980), placebo (Henry et al, 1973) 
or non-medicated patients (Gillis and Moran, 1980). However, one group indicated 
that imipramine 150mg-350mg improved scores in comparison to baseline levels 
(Sternberg and Jarvik, 1976).
Performance in memory tasks improved following treatment with moclobemide 
(Allain et al, 1992), viloxazine (Amin et al, 1980), fluoxetine and trazodone (Fudge et 
al, 1990), clovoxamine (Lamping et al, 1984) and nomifensine, mianserin and 
maprotiline (Siegfried and O’Connolly, 1986) with respect to baseline scores. The 
main drawback here is that these were the only studies performed with these drugs 
encountered in this review, and so before firm conclusions can be made these results 
must be shown to be reproducible.
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2.4.3 Psychomotor function
Twelve studies in this review evaluated psychomotor performance in depressed 
patients treated with antidepressants (Table 2.13). Choice reaction time was the most 
frequently used test, being employed in all 12 studies. Only three of these 
investigations included amitriptyline. Beaini et al (1980) reported that amitriptyline 
75mg-150mg improved choice reaction time relative to baseline, whereas in another 
study, scores from patients on amitriptyline (dose not given by authors) were shown to 
be lower than a group of healthy controls (Gerhard and Hobi, 1984). In/the third study 
(Fairweather et al, 1993b), there was a trend for fluoxetine(z5mg'|and amitriptyline 
75mg to improve reaction times, although after one week oPlreatment, fluoxetine 
patients had quicker reaction times than those on amitriptyline.
In an open study, patients taking maprotiline 150mg and dibenzepin 720mg scored no 
different to healthy controls on choice reaction time but scores were significantly 
better following treatment compared to baseline values (Hobi et al, 1982). This pattern 
was also revealed in an open study where patients’ scores improved from baseline 
values following treatment with antidepressants (but not neuroleptics), although these
fvUlfVt
changes were no different to changes in healthy controls (Hobi et al, 1981).
A comparison of TCAs and SSRIs in patients who had been on fixed medication for at 
least 3 months (Hale and Pinninti, 1995) found, similar to the effects seen with central 
processing, that those patients being treated with TCAs had significantly worse CRT 
scores than matched healthy non-drug controls. On the other hand, patients treated 
with SSRIs performed significantly better than those on TCAs.
In the only study that included a placebo condition (Ravindran et al, 1995), patients 
who had been treated for eight weeks with either sertraline 50mg-225mg, desipramine 
50mg-225mg or placebo, could not be differentiated from each other or baseline in 
terms of choice reaction time scores. On the other hand, these scores improved from 
baseline following mianserin 30mg-60mg (Khan et al, 1984; Siegfried and 
O’Connolly, 1986; Moon and Davey, 1988), trazodone 150mg (Moon and Davey, 
1988), nomifensine lOOmg- 150mg (Khan et al, 1984; Siegfried and O’Connolly,
1986) and maprotiline lOOmg (Siegfried and O’Connolly, 1986). Allain and 
colleagues (1992), however, reported that scores following maprotiline 150mg
(Turn
treatment were not different to pre-treatment scores, and likewise with moclobemide 
450mg and viloxazine 300mg.
Seppala et al (1978) demonstrated that patients taking doxepin or chlorimipramine 
were significantly faster than those taking L-tryptophan on choice reaction time tests, 
although the doxepin group scored worse on a proprioceptive test.
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2.4.4 Sensorimotor performance
Sensorimotor skills were assessed by ten authors (Table 2.14). Five of these included 
tests which have reaction time as a major component (Amin et al, 1980; McNair et al, 
1984, Allain et al, 1992; Spring et al, 1992; Ravindran et al, 1995). The remaining 
studies included other sensorimotor tests, e.g. tracking ability and divided attention.
In evaluations of reaction time, amitriptyline 116mg (mean dose) was found to be 
better than placebo (McNair et al, 1984), although amitriptyline 50mg-350mg was no 
different to placebo or clovoxamine 50mg-350mg in a study where patients had 
significantly faster reaction times following all three treatments when compared to 
baseline (Spring et al, 1992). Allain et al (1992) reported that moclobemide 450mg 
and maprotiline 150mg, but not viloxazine 300mg, improved performance relative to 
pre-treatment scores whereas Amin et al (1980) found that viloxazine 150mg-450mg 
and imipramine 75mg-225mg impaired reaction times. Performance on reaction time 
tasks was better with sertraline 50mg-225mg than with placebo (Ravindran et al, 
1995).
Performance in a group of patients with major depression treated with amitriptyline on 
divided attention could not be differentiated from that of healthy controls (Gerhard 
and Hobi, 1984). Impairment of tracking skills was reported with doxepin (Seppala et 
al, 1978) when compared to L-tryptophan. Improvement with viloxazine 150mg- 
450mg on reaction time was demonstrated compared to imipramine (Amin et al, 
1980) and the SSRI sertraline 50mg-225mg produced faster responses than placebo 
(Ravindran et al, 1995). Gerhard and Hobi (1984) and Hobi et al (1981; 1982) used a 
sample of healthy controls as their comparator group. In the former, (Gerhard and 
Hobi, 1984) patients taking amitriptyline were no different on a sensorimotor divided 
attention task from the control group, whereas the anti-psychotic drugs haloperidol 
and thioridazine impaired performance. Hobi et al (1981) found that patients taking 
antidepressants scored no different control group, but demonstrated that
performance improved from baseline levels. Furthermore, Hobi et al (1982) reported 
similar findings, where patients scored better than baseline following maprotiline, 
dibenzepin and lithium but could not be distinguished from the control group.
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2.4.5 Motor ability
Very few studies evaluated the effects of antidepressants on the motor abilities of 
patient populations (Table 2.15). Of the five studies reviewed, four employed tapping 
rate and one measured peg-board skills. No significant differences from baseline were 
revealed following treatment with phenelzine 15mg-50mg (Georgotas et al, 1983; 
Georgotas et al, 1989), nortriptyline (Georgotas et al, 1989) or imipramine 75mg- 
225mg (Amin et al, 1980) on tapping rate. Amitriptyline and clovoxamine (both 
50mg-350mg) were no different from placebo on this task, but all groups (including 
placebo) were significantly better than baseline (Spring et al, 1992). Amin et al (1980) 
found no changes from baseline tap scores and motor reflex with either viloxazine 
150mg-450mg or imipramine 75mg-225mg, but further analysis revealed that both 
scores were significantly better with viloxazine compared to imipramine. No changes 
were observed with nortriptyline 50mg-100mg on the peg-board task (Hoff et al, 
1990).
2.4.6 Sensory skills
Five studies investigated the relationship between antidepressants and sensory skills 
(Table 2.16). There was no consistency over the five studies regarding which specific 
tests were used. As with sensorimotor and psychomotor performance, Hobi et al 
(1982) found no difference in patients treated with maprotiline 150mg, dibenzepin 
720mg or lithium on the D2 cancellation test or attention tests compared to a group of 
healthy control subjects, although antidepressant treatment improved scores from 
baseline levels. Doxepin 75mg, however, induced significant performance 
impairments compared to L-tryptophan 1.5g (Seppala et al, 1978). When compared to 
baseline, no significant differences were observed with phenelzine 15mg-50mg on 
perceptual speed (Georgotas et al, 1983), and with nomifensine lOOmg, maprotiline 
lOOmg and mianserin 40mg on digit cancellation (Siegfried and O’Connolly, 1986), 
although in the latter study, nomifensine was significantly better than the other two 
drugs.
Contrasting results were observed with viloxazine 150mg-450mg and imipramine 
75mg-225mg in the same study (Amin et al, 1980). When compared to pre-treatment
100
conditions, both viloxazine and imipramine improved proof reading ability but at the 
same time impaired letter cancellation. This suggests that both viloxazine and 
imipramine only affect certain aspects of sensory abilities.
2.4.7 Subjective Ratings
Subjective ratings of patients’ feelings were collected in nine studies (Table 2.17). No 
significant differences were found with either nortriptyline (Georgotas et al, 1989) or 
phenelzine 15mg-50mg (Georgotas et al, 1989; Georgotas et al, 1983) on perception 
of mental status. Plotkin et al (1985) compared patients on TCAs with those 
undertaking psychotherapy. Both treatments improved self rated memory when 
compared to baseline scores, but no differences were detected between treatments. 
Conversely, patients on TCAs felt more sedated than those being treated with SSRIs 
(Hale and Pinninti, 1995), with this trend persisting after a minimum three months of 
treatment. Fairweather et al (1993b) demonstrated that fluoxetine 25mg decreased 
subjective drowsiness when compared to amitriptyline 75mg, and that amitriptyline 
was significantly better in improving the ease of getting to sleep, although both drugs 
improved ratings on the Leeds Sleep Evaluation Questionnaire (LSEQ) relative to 
baseline. Both trazodone 150mg and mianserin 30mg-60mg increased ratings on the 
LSEQ, i.e. improved ease of getting to sleep, quality of sleep and feelings on 
awakening (Moon and Davey, 1988) over time. Although the two treatments were not 
significantly different from each other, improvement in the LSEQ occurred sooner 
with trazodone. Patients being treated with mianserin 60mg or nomifensine 150mg for 
up to four weeks reported increased alertness and better quality of sleep compared to 
baseline ratings (Khan et al, 1984). Self ratings of depression improved with 
maprotiline 150mg, dibenzepin 720mg and lithium over time, but did not differ from 
those reported by healthy controls (Hobi et al, 1982).
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2.5 Summary of the effects of antidepressants in volunteer and patient 
populations
The evidence from a review of the literature shows that the effects of antidepressants 
on aspects of information processing are complex and diverse. Several-of the drugs 
have been reported to produce different effects in both the healthy volunteer and 
depressed patient populations, e.g. antidepressants which were no different from 
placebo according to some researchers, but were reported to impair or improve 
performance by others, included amitriptyline, clovoxamine, fluvoxamine, 
lofepramine and zimeldine. A summary of the drug - placebo effects (Table 2.18) 
shows that, despite the differences between individual studies, a general trend emerges 
when all of the results are pooled together. That is, the TCAs (particularly 
amitriptyline) appear to impair performance, whereas the RIMAs have very little 
effect. The SSRIs and SNRIs (^erotonin and noradrenaline reuptake inhibitors) tend 
either to improve performance or be no different fc^placebo.
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2.6 Discussion of literature review 1
On reviewing studies published during the period 1966-1996 it is evident that the 
effects of antidepressants on performance variables iafrbeTen considered. However, it 
is also apparent that the-reports-efr drug effects vary across the studies and so this 
section critically discusses the findings of the literature review.
2.6.1 Assessments
As suggested earlier in this chapter it is essential that, in order to obtain information as 
to how drugs affect behaviour, appropriate techniques must be adopted (Michon, 
1973; Hindmarch, 1980). Furthermore, the chosen techniques must be used 
consistently so that comparisons can be made across studies. A cursory glance at the 
literature review^ however, shows that many different methodologies have been 
adopted. In particular, the choice of assessments varies greatly from study to study. 
Even though the tests were categorised according to a model of information 
processing, each section of that model contains a diverse range of tests (Figure 2.2). 
For example, in healthy volunteer studies, 31 different memory tasks were utilised by 
41 authors, and the most frequently used memory test was cited in only 12 studies. 
Furthermore, many of the tests used appear to lack history and again this is 
particularly evident in the assessment of memory. Different researchers also had 
different viewpoints as to how specific tests should be performed? an example of this 
is seen with critical flicker fusion measurements where apparatus and specifications 
varied. In addition, although 68.7% of volunteer studies assessed four or more of the 
seven categories of the information processing model, only 1.2% of investigations 
evaluated all seven (Table 2.2). In patients, no studies assessed more than five aspects 
of behaviour, and only 30.8% measured four or more categories (Table 2.10).
2.6.2 Designs
In addition to the differences in assessments, specific study designs varied across 
studies, especially in patient populations where it is more difficult to perform 
controlled experiments. The optimum design for volunteer studies should be at least 
double blind, randomised, cross-over and placebo controlled. Blindness is essential to
108
this type of study so that neither subject nor experimenter bias can be introduced. 
Also, if subjects are randomised to treatment in a cross-over manner then any effects 
due to the order in which the drugs were administered will be cancelled. The greatest 
advantage of a cross-over study is that subjects act as their own controls, especially in 
tests where volunteers may perform better on the second experimental day as they are 
less apprehensive and more familiar with the study procedures, even though this 
should be controlled for during the training sessions prior to the study. Placebo 
conditions are beneficial in that performance can also be assessed in the absence of an 
active compound. In addition to an inactive control (i.e. placebo), it is often advisable 
to include an active control, or verum, that is known to have an effect on the test 
battery. This extra treatment increases the power of the experimental design and so 
strengthens the argument of the presence / absence of a drug effect, particularly if the 
tests have not previously been shown to be valid and reliable indicators of drug action. 
That is, if a particular drug was no different from placebo on a battery of tests, then 
the ability or sensitivity of the tests would be questioned. The presence of a verum, 
therefore, would show that the tests were sensitive indicators of drug action at that 
particular time.
The evidence from this review revealed that the majority (88%) of the volunteer 
studies employed a double blind, randomised, placebo controlled, cross-over design. 
Although these studies were consistent in their design, the range of tests were varied, 
as were the time points at which testing took place. A further 2.4% studies were non­
placebo controlled cross-over experiments, and 6% of studies did contain placebo but 
followed a parallel group design. Of the other experiments, one was an open design, 
one was a single blind (blind to subjects) placebo controlled cross-over experiment 
and one was a placebo controlled cross-over design, but the authors did not state if the 
study was blind.
In patient populations, the design of studies in which to assess performance is not so 
straightforward. As the patients are suffering from depression, many ethical questions 
arise and must be considered when designing a study. For example, it is acceptable to 
give healthy volunteers a placebo condition, but not to patients who are severely
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depressed, where pharmacological intervention will thus be denied. Furthermore, if 
the study follows a cross-over design, then treatments are stopped and patients are 
then allocated the next treatment. Apart from ethical considerations, the use of a 
placebo controlled cross-over design also has methodological implications. As 
described in Chapter 1, impairments in information processing are evident in 
depressed individuals. As the depression is alleviated by an antidepressant, the 
performance impairments due to the illness may also be reduced. However, if patients 
are given placebo then there is no pharmacological interaction with the depression and 
so no valid comparisons can be made between the effects of placebo and active drug 
on tests of information processing. If treatments are administered in a cross-over 
manner, a washout period must be included and this may have a negative impact on 
the patient, which will vary from individual to individual. Administration of the 
second compound will therefore be given at different stages of the recovery curve 
which then complicates any comparisons.
Of the patient studies reviewed, only one experiment adopted a cross-over design 
whereas the remaining 27 used parallel groups. Placebo conditions were present in 
four studies.
2.6.3 General discussion of studies in volunteers and patients
Several studies encountered in the literature review warrant further discussion in order
to illustrate the above points
2.6.3.1 Volunteer Studies
Of note are two studies reported by Ogura and colleagues (1983a; 1983b) where the 
effects of amitriptyline 25mg and dothiepin 25mg were compared in young and 
elderly healthy volunteers (mean ages 22.7 and 70.6 years respectively). The first 
study (Ogura et al, 1983a) concluded that amitriptyline impaired critical flicker fusion 
scores when compared to dothiepin and that this difference was greater in the elderly 
subjects. Similar results were reported in the second study (Ogura et al, 1983b). Due 
to the similarity of the designs, particularly the mean ages of the volunteers, it is 
possible that both of these reports stem from one investigation. The authors do not
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state that this is the case, and in addition to critical flicker fusion, digit symbol 
substitution test and tapping rate were assessed in the second study (although the 
drugs could not be differentiated on the latter two tests), and so the-^studies are taken 
as separate investigations.
Although the treatments were given in a double blind cross-over fashion, no placebo 
condition existed in either of these studies. This presents difficulties when judging 
drug action as there is no indication of how subjects’ performance would vary across 
the day in the absence of active treatment. Although performance was assessed pre­
drug, any changes from baseline may be due to circadian influences (as seen with 
placebo in other studies). It appears initially that dothiepin has no effect on critical 
flicker fusion in these studies, however, it cannot be ignored that this drug may too 
impair critical flicker fusion, but to a lesser extent than the amitriptyline-induced 
impairments. There is no doubt that amitriptyline impairs critical flicker fusion in 
these two studies in comparison to dothiepin, but in the absence of placebo, no firm 
statements about dothiepin can be made on the basis of these results alone.
In a study which did include a placebo condition (Dal Pozzo et al, 1996), dothiepin 
25mg and 50mg were not significantly different from placebo on central (critical 
flicker fusion), memory (Sternberg memory task) or psychomotor (choice reaction 
time test) aspects of performance but 25mg did impair sensorimotor (tracking) skills. 
A higher dose of 75mg impaired performance on the critical flicker fusion and choice 
reaction time tests. There were non-significant trends for the lower doses of dothiepin
i.e. 25mg and 50mg to impair critical flicker fusion, and the authors of this study 
report that several subjects scored lower (but not significantly lower) than the mean 
value for each of these treatments. The authors suggest that these subjects were more 
sensitive to the effects of dothiepin, however the number of subjects scoring below the 
mean was similar in the placebo group. Two subjects appeared to be particularly 
sensitive to the effects of 25mg and 50mg dothiepin, and given this variation in 
subject sensitivity, it would be useful to increase subject numbers in experiments 
which are designed to assess the effects of such low doses of drugs. Critical flicker 
fusion was also impaired by dothiepin (75mg and 150mg) in another placebo
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controlled study but had no effects on psychomotor performance (Ramaekers et al, 
1995). Allen et al (1993) and Hindmarch (1987) both investigated the effects of 
dothiepin 50mg in healthy volunteers in well designed studies (i.e. double blind, 
placebo controlled, cross-over designs). Allen et al (1993) found that dothiepin 
impaired several responses whereas the other test compound lofepramine appeared to 
possess a placebo-like profile. Conversely, Hindmarch (1987) reported that dothiepin 
50mg was not significantly different from placebo on any objective tests, and that 
amitriptyline 50mg tended to disrupt performance. The only obvious difference in the 
methodology of these two studies lies within the choice of tests. Discrepancies in 
these results may be largely due to differences in the methods of measuring critical 
flicker fusion (Bobon et al, 1982), however if certain criteria are met, then this test can 
provide a reliable measure of central processing capacity. It must also be noted that 
the pattern for dothiepin 50mg as reported by Dal Pozzo et al (1996) reflected that 
found by Hindmarch (1987), and incidentally, these researchers employed identical 
tests, so highlighting the need for consistently applied measures.
The reversible MAO inhibitor moclobemide has an interesting profile. Berlin et al 
(1990a) administered moclobemide 450mg per day, toloxatone lOOOmg per day and 
placebo to 12 healthy volunteers in a double blind cross-over study. Assessments were 
performed on the 8th day of treatment, where both moclobemide and toloxatone were 
shown to possess similar behavioural profiles to placebo, although there was one 
exception where moclobemide resulted in a faster recognition reaction time. In a 
second study (Berlin et al, 1990b) higher doses of moclobemide (600mg per day) 
were compared to clomipramine and placebo in 24 volunteers. The design of this 
study however, used parallel groups and 12 subjects received moclobemide and 12 
clomipramine for five days following a placebo run-in phase. Alcohol was given 
during both placebo and active drug phases. The authors report that, compared to 
placebo, both moclobemide and clomipramine improved critical flicker fusion. In 
addition, moclobemide improved choice reaction time. Alcohol impaired performance 
during the placebo phase, and on some occasions, the alcohol-induced impairments 
were attenuated by the active drugs. The design of this study may be criticised as 
placebo was given during the run-in phase only. Any comparisons to placebo may be
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influenced by environmental factors and although the authors state that subjects were 
trained prior to the study, the influence of a practice effect cannot be eliminated. Tiller 
(1990) demonstrated that neither moclobemide lOOmg nor 300mg had any effect on 
critical flicker fusion and choice reaction time whereas amitriptyline impaired both 
variables.
Anand and Wesnes (1990) investigated the action of moclobemide in a model of 
pharmacologically-induced cognitive impairment. Scopolamine was given to 28 
healthy volunteers in order to produce impairments which are thought to mimic the 
cognitive disturbances associated with the dementias, and possibly the impairments 
which have been described in the previous chapter to accompany depression. Using 
this model, the researchers suggested that it was possible to investigate whether or not 
putative antidepressants have the potential to exacerbate or reverse the impairments 
seen with these disorders. Once the impairment was established, subjects were 
randomised to receive either moclobemide 400mg or placebo in a double blind 
manner. Moclobemide was shown to reverse the impairments observed on tests of 
memory and psychomotor performance, but scores on central and sensorimotor tests 
were similar to those of placebo. Analysis revealed that recovery from the 
scopolamine-induced decrements was quicker in the moclobemide group, however 
moclobemide appeared to slow recovery of subjective ratings of alertness. The 
evidence from these studies suggests that moclobemide may have an advantageous 
role to play in the treatment of depression and dementia, where impairments of 
behaviour are profound. However, it is possible that the impairments induced by 
scopolamine were in fact due to a general sedative effect rather than specific cognitive 
deficits, and in order to substantiate the findings of this study, further research is 
required in studies of longer duration, at least to steady pharmacokinetic state, rather 
than acute studies.
2.6.3.2 Studies in Patients
The concept of study design in patient populations is discussed above, and it is clear 
that many complexities must be considered when evaluating effects of antidepressants 
on cognitive and psychomotor abilities in depressed patients. Where volunteer studies
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can be strictly controlled in a laboratory, research with patients is often confounded by 
extraneous variables such as lifestyle, concomitant illness and the pharmacological 
agents used for its treatment. For example, in a study by Nair et al (1993), the fact 
that, in addition to the test compounds, chloral hydrate was given to several patients 
for insomnia, adds another variable for consideration.
Although the designs of the studies carried out in patients differed, 27 investigations 
employed parallel groups. The one exception was that reported by McNair et al 
(1984). Here, patients were assigned to one of two drug groups: amoxapine and 
amitriptyline, in a form of cross-over pattern where they also received placebo either 
prior to or following active drug. Drugs were administered to patients for three weeks 
each and assessments were made at weekly intervals. The authors’ objective was to 
investigate effects on cognition under different degrees of depression. Both 
antidepressants appeared to influence aspects of performance, with amitriptyline 
exerting a greater effect. However, the pattern of results was complex, in that the 
changes in performance occurred in two directions. In comparison to the weeks on 
placebo, amitriptyline facilitated short term memory scanning but impaired long term 
memory. Sensorimotor reactions were quicker but less accurate with amitriptyline. 
Although patients were rated on the Hamilton Depression Rating Scale (HAM-D), the 
authors give no indication as to changes in the severity of depression over the study, 
and so it is difficult to make any assumptions on the cognitive data.
As can be seen in the volunteer studies, amitriptyline impairs performance on various 
aspects of information processing. This is not necessarily the case in depressed 
populations, however. Theoretically, if a test drug is efficacious in alleviating 
depression, then performance decrements which are associated with the illness should 
also improve with treatment. Nevertheless, it is possible that a given drug may mask 
these improvements or even exacerbate existing disturbances. Amitriptyline was 
reported to have no effect in two studies on central variables i.e. critical flicker fusion 
(Beaini et al, 1980) and digit symbol substitution test (McNair et al, 1984), even 
though scores for depression improved. Choice reaction time scores improved with 
amitriptyline but not imipramine when compared to baseline, however there were no
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differences between treatments (Beaini et al, 1980), and as already stated, different 
effects on memory were recorded by McNair et al (1984). In a third study (Spring et 
al, 1992) patients received either amitriptyline, clovoxamine or placebo and were 
assessed after 28 days of treatment. Clinical improvement (assessed by HAM-D) 
occurred in all three groups, though the treatments were statistically indistinguishable 
from each other. Furthermore, psychomotor performance improved relative to 
baseline with all treatments, with the exception that memory was worse following 
amitriptyline. In a six week study, critical flicker fusion thresholds and choice reaction 
time scores were significantly worse for those patients treated with amitriptyline than 
fluoxetine for the duration of the study (Fairweather et al, 1993b). Similar findings 
were reported with amitriptyline over five weeks by Hanks (1984).
The majority of the studies compared test scores following treatment to pre-drug 
baseline performance. Although these comparisons give an indication of how a patient 
performs following pharmacotherapy it is arguable that any changes can be the result 
of extraneous factors, particularly in longer term projects. It must also be taken into 
account that learning can occur during the study, i.e. due to familiarisation and 
repeated exposure to the tests, patients may respond better irrespective of their 
treatment, although this varies from test to test. In addition, all of the studies except 
one (Hale and Pinninti, 1995), monitored patients for only a few weeks following 
onset of treatment.
Hale and Pinninti (1995) studied the effects of antidepressants in depressed patients 
who were in clinical remission and whose treatment had been stable for three months 
or more. Patients were split into two groups, i.e. those taking SSRIs (fluoxetine and 
sertraline) and those taking TCAs (amitriptyline, clomipramine, dothiepin, 
imipramine and trimipramine). Also included in the study were a group of healthy 
controls who were matched by age and sex to the TCA group. All other studies in this 
review assessed patients after the first days or weeks of therapy, whereas the aim of 
Hale and Pinninti’s (1995) research was to investigate whether any detectable 
differences were apparent in stabilised patients. Their results demonstrated clear 
differences between the three groups. Critical flicker fusion measurements revealed
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that those patients in the SSRI group performed significantly better than the TCA 
group and the control sample. Furthermore, patients in the TCA group produced 
significantly impaired scores when compared to the controls. When these groups were 
broken down to reveal individual drug effects, it is clear that the impairments were 
induced by amitriptyline, dothiepin and trimipramine. Worthy of note is the 
observation that the scores in the control group were widespread, and that the range 
was larger than with the TCA and SSRI groups. The two drug conditions appear to 
polarise these effects, nevertheless it would be of interest to increase the number of 
healthy control subjects to match all patients rather than a sub-group, and to monitor 
any changes in the mean value. A similar pattern to that seen in the critical flicker 
fusion scores was evident in the choice reaction time task, where in addition to having 
faster reactions than TCA-treated patients, the SSRI group were also faster than 
controls. Subjective ratings (visual analogue rating scales) correlated well with 
objective findings in that patients felt more sedated on TCAs. No breakdown of 
individual drug effects was available for choice reaction time or subjective ratings.
As the objective of the study by Hale and Pinninti (1995) was to compare two drug 
groups in clinically stabilised patients no pre-study baseline data were available. This 
study represents a step forward in the assessment of antidepressants on cognitive and 
psychomotor function, however, it would be of interest to combine this design with 
one where patients were evaluated prior to treatment then followed up after therapy.
Neumann and colleagues (1993) also included a group of healthy non-depressed 
people in their study. They compared visual pattern integration in the control group to 
performance in two categories of depressed patients 1- patients who had just entered 
treatment (DET) and 2- those who were mid treatment (DMT). The patients had been 
prescribed either TCAs or SSRIs, and the numbers of patients receiving either of these 
two were comparable across groups. As expected, at the first test point, those patients 
who had just entered treatment performed significantly worse than the control group 
and interestingly, the mid treatment patients had significantly better scores that the 
controls. The second test point five weeks later revealed that performance had 
improved in the DET patients, where scores were now better than the control group.
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The superiority of the DMT over the DET group was maintained at this test point. 
Thi^clata^uggest/ that depressed individuals have impaired visual integration, and 
that antidepressants reverse this decrement to such an extent that patients perform 
better than matched healthy controls. Hale and Pinninti (1995) reported that patients 
treated with SSRIs had superior cognitive and psychomotor skills in comparison to a 
non-drug healthy control group, however they also found that TCAs impaired 
performance. From this, it can tentatively be suggested that SSRIs but not TCAs 
increase abilities. So, in light of Hale and Pinninti’s work, Neumann et al’s suggestion 
that antidepressant drugs improve visual pattern integration does not stand, especially 
considering that more patients had been prescribed TCAs than SSRIs in both DET and 
DMT groups. The major drawbacks with this research are threefold. Firstly, only ten 
patients were enrolled into each group. Given the complexities associated with patient 
studies (described above), these numbers are insufficient. Secondly, no analyses were 
carried out to differentiate the effects of TCAs versus SSRIs (the numbers of patients 
on each individual drug were probably too small anyway). The third factor is that 
Neumann and colleagues have no data on the effects of antidepressants on visual 
pattern integration in non-depressed volunteers.
2.7 Conclusions
The studies discussed in this literature review show that many researchers have 
attempted to evaluate the effects of antidepressants on performance in healthy 
volunteers and depressed patients. However, there is variation between studies, mainly 
due to inconsistent methodologies and inadequate study designs which introduce 
complications when attempting to compare and contrast the effects of antidepressants 
across studies. Despite these differences, however, trends were apparent when all of 
the findings were pooled together, suggesting that some of the tests were sensitive to 
the effects of antidepressants on human information processing when used in 
appropriately designed experiments.
Reasons for the need to evaluate the potential “behavioural toxicity” of 
antidepressants have been argued in Chapter 1. Many of the older antidepressarits
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have been assessed, but the findings from this review show that there is little work so 
far on newer compounds. In an attempt to take a closer view of the effects that these 
compounds have on information processing, tests from the information processing 
model (Figure 2.2) have been chosen and incorporated into the experiments presented 
in this thesis, which all use similar designs, populations and methods, thereby 
allowing between-study comparisons of drug effects.
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CHAPTER 3: MEASURES AND METHODS USED TO INVESTIGATE THE 
EFFECTS OF ANTIDEPRESSANTS ON PERFORMANCE 
3.0 Chapter outline
The preceding chapter presented a review of the effects of antidepressants on 
behaviour, and criticised the lack of consistency in the methodology used across the 
studies encountered. With this in mind, this chapter discusses the general methods and 
measures employed in each of the present experiments. Descriptions of selected tests 
are given, along with evidence of their validity and reliability. The common 
procedures adopted are outlined, including subject selection, study conduct, 
experimental design and statistical management. The study specific procedures are 
described in Chapter 4.
3.1 Introduction
The conclusions from Chapter 2 show that, although several researchers have studied 
the effects of antidepressants on performance, and that general patterns of effects were 
apparent when all of the studies were pooled together, discrepancies exist between the 
findings of individual investigations. These are mainly due to the differences in 
methodologies, and in particular the diverse range of tests adopted by different 
research groups. Many of the techniques and designs were complex, non-standardised 
and differed from researcher to researcher.
As discussed in Chapter 2, an appropriate model of information processing should be 
adopted in order to truly- assess the effects of antidepressants on psychological aspects 
of human behaviour. In addition, assessments should be carefully selected so that they -j ( 
do not merely detect a global sedative effect but allow differentiation between types of ' ‘
impairment on the various cognitive and psychomotor aspects of behaviour. However, 
there are so many aspects to a behavioural response (as shown in the information 
processing model in the previous chapter) and thus theoretical viewpoints differ as to 
which testing strategies should be employed. This has led to the use and abuse of a
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plethora of psychometric tests, which often lack history and validity. That is, several 
researchers construct their own testing measures which do not necessarily correctly 
assess the parameters they have been designed to measure, and are often complex and 
difficult to replicate. This was evident in many of the studies encountered in the 
literature review, particularly in tests of memory, where 31 different memory tests 
were employed in only 41 studies. In a review of performance tests Parrott (1991a) 
criticised this practice and aptly stated that many tests “owe more to the, often 
whimsical, ingenuity o f  their progenitors than to any serious attempt to provide a 
proper psychometric
Even where a particular measure has been a popular choice, the specific techniques for 
performing the task vary. For example several different methods of measuring critical 
flicker fusion have been documented (e.g. Liljequist et al, 1978; Hindmarch, 1987; 
Frewer and Lader, 1993; Hale and Pinninti, 1995). Bobon et al (1982) stated that 
discrepancies in results with the same drug may be largely due to differences in the 
methods of measuring critical flicker fusion, but goes on to say that if certain criteria 
are met then critical flicker fusion can provide a reliable measure of central processing 
capacity.
In addition to the above, motivational factors may also influence findings, i.e. subject 
or experimenter expectations (Hindmarch, 1980) can interfere with the experiment. 
Taking all of these into account, it must be stressed that, in order to assess the effects 
of psychoactive drugs and to demonstrate reproducible results, several factors, 
including those recommended by Hindmarch (1980) must be controlled. Firstly, the 
behavioural model must be well defined, and tests chosen carefully. The tests should 
be easy to administer, understand and score. Double blind experimental designs must 
be adopted so that neither the subject nor the experimenter are aware of the treatment 
regimen. As illness or medication can confound results, subjects should be carefully 
screened to ensure that they are healthy, and concomitant substances (including 
alcohol, nicotine, caffeine, psychoactive drugs) should be avoided. Tests should be 
carried out by trained experimenters. Due to the fact that a drug effect may be masked 
by the nature of the task itself, a verum, or positive internal control should be
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incorporated to validate the experimental results. The inclusion of a verum also 
demonstrates whether or not the tests are sensitive to drug effects. The vera used in 
the experiments presented in the following chapter have all been shown previously to 
impair cognitive and psychomotor performance (e.g. amitriptyline - Liljequist et al, 
1978; Hindmarch et al, 1988; Kinirons et al 1993; dothiepin - Hindmarch 1987; Allen 
et al, 1993; Ramaekers et al, 1995; lorazepam - Hindmarch and Gudgeon, 1980; 
Subhan et al, 1986).
All of the above caveats have been considered in the design of the experiments 
reported in this thesis. They all employ similar designs, populations and methods 
thereby allowing between-study comparisons of drug-placebo differences. What 
follows is a description of the measures employed to evaluate the effects of 
antidepressants.
3.2 Measures
Many of the tests used in human psychopharmacology lack a history of validity and 
reliability (Hindmarch, 1980; Parrott 1991a; 1991b; 1991c), and indeed this appears to 
be the case in several of the studies reviewed in Chapter 2. In short, a valid test 
measures what it claims to measure, however any test may be valid for one purpose 
but not another (Parrott, 1991b). More importantly, the reliability of a test is an 
indication of the consistency between two independent sets of scores, i.e. a test with 
high reliability will produce similar scores on different occasions (Parrott, 1991a). The 
reliability of a test is of great importance in repeated measures designs.
Since the 1970s, research at the  ^Human Psychopharmacology Research Uniyhas
centred on a battery of tests which(have/been shown to/valid and reliable indicators of ^  ,
^  Kc ------------------------     * o '
drug action (Hindmarch, 1975; 1980; Parrott, 1982; Sherwood and Kerr, 1993). Over '
\
the years these tests have been computerised and so stimulus presentation and 
recording of results are nowjautomaticall^ controlled thereby allowing accurate data 
collection. These tests are highly reliable as they are devoid of human recording errors 
and by utilising the same systems across studies reduce inter-test variability.
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In light of all of the above, it was decided to use this standardised battery of tests to
assess the effects of antidepressants on aspects of information processing. These tests
assess the skills and abilities which are necessary for the completion of the tasks
of-
encountered in everyday life, from the simple rem em bering telephone number to the 
more complex driving through town during rush hour. Utilising the same tests in 
different experiments allows valid comparisons across studies to be made. The 
measures adopted have been classified according to the model of information 
processing (Figure 3.1). As each test measures different aspects of information 
processing the results from such a test battery can provide a psychopharmacodynamic 
profile of an antidepressant rather than indicating overall “sedation”.
The core battery of tests consists of Critical Flicker Fusion (CFF), Choice Reaction 
Time (CRT), Sternberg Memory Scanning Test (SMT) and a Compensatory Tracking 
Task (CTT). Visual analogue scales are used to obtain subjective ratings and they 
include the Leeds Sleep Evaluation Questionnaire (LSEQ), Line Analogue Rating 
Scales (LARS) and the Milford Epworth Sleepiness Scale (MESS). Other 
“occasional” tests and questionnaires are the Stroop Test (STR), Word Recognition 
(WR), Kim’s Game (KIM), Cognitive Failures Questionnaire (CFQ), Serial 
Subtraction of Numbers (SSN) and Actigraphy (ACT).
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3.2.1 Core Test Battery
Critical Flicker Fusion (CFF)
CFF has been used as a research tool for many years in areas of psychology and 
physiology, and is now one of the most widely use tests in human 
psychopharmacology. The critical flicker frequency is the point where a flickering 
light is subjectively perceived as a steady light, and the opposite of this is the fusion 
frequency. CFF measures have been regarded as “reliable and valid indicators of 
vigilance and cortical arousal” (Levander, 1982) and “indicator(s) of unspecific CNS 
arousal” (Gortelmeyer and Weimann, 1982). Within the model of information 
processing (see Chapter 2) a change in CFF is associated with changes in the capacity 
or efficiency of processing discrete “bits” of information (Hindmarch, 1980; 1982). 
An increase in CFF threshold is indicative of CNS arousal, where a reduction in 
threshold accompanies cognitive impairment and sedation.
Several researchers have reviewed the use of CFF in psychopharmacology (Turner, 
1968; Smith and Misiak, 1976; Hindmarch, 1982) and have concluded that if 
standardised methods and controls are adopted, then this technique offers an accurate 
method for determining the action of drugs on the CNS.
Procedure
All CFF measurements were made using the Leeds Psychomotor Tester (Hindmarch, 
1975). The test device comprises of four light emitting diodes set in the comers of a 
10mm square on a black background. The subject sits facing the CFF in a darkened 
room, and the diodes are binocularly viewed from one metre and are so held in foveal 
fixation. The diodes flicker on and off at a constantly increasing or decreasing rate 
(1Hz over a range of 12-50Hz) and subjects are required to discriminate flicker from 
fusion by pressing the response button. Individual thresholds are determined by the 
psychophysical methods of limits as an average of responses on three ascending 
(flicker to fusion) and three descending (fusion to flicker) alternate presentations 
(Woodworth and Schlosberg, 1958).
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Validity and Reliability
The validity of this test as a measure of central arousal and information processing has 
been proved by its close correlation with other measures of CNS function e.g. visual 
line analogue rating scales (Hindmarch, 1979; Parrott, 1982) and EEG (Gortelmeyer 
and Weimann, 1982). CFF is sensitive to drug effects in that it can discriminate
between psychosedatives which reduce CFF (e.g. diazepam) and psychostimulants
\
which elevate CFF (e.g. amphetamine) (Hindmarch, 1982). In addition, CFF can 
differentiate compounds of the same therapeutic class e.g. hypnotics (Hindmarch and 
Fairweather, 1994), antidepressants (Fairweather et al, 1993a), antihistamines 
(Rombaut and Hindmarch, 1994), anxiolytics (Hindmarch, 1979), neuroleptics 
(Hindmarch, 1994) and nootropics (Curran and Hindmarch, 1992). This technique has 
also been shown to detect differences in varying doses of the same drug e.g. sertraline 
(Hindmarch et al, 1990) and oxazepam (Kerr et al, 1992a) and is sensitive enough to 
detect changes in information processing produced by nicotine (Sherwood, 1993), 
caffeine and alcohol (Kerr et al, 1991). Kilminster (1991) demonstrated that, in a 
longitudinal study of 3.5 years, no significant regression effects on CFF were 
observed in a population of healthy elderly volunteers.
The procedure used to measure CFF has been shown to be reliable and consistent. 
Parrott (1982) demonstrated that the split-half reliabilities of CFF from a series of five 
studies (with 101 subjects) were of the same magnitude, ranging from r = +0.92 to r = 
+0.97. Test-retest reliability has also shown to be high, mostly above +0.9, and only 
rarely below +0.85 (Levander, 1982).
Choice Reaction Time (CRT)
Another popular method in psychopharmacology is the assessment of reaction time. 
Reaction time responses are inherent in many of the skilled activities used everyday 
which often requires rapid but co-ordinated responses, e.g. driving a car. Where 
simple reaction time involves a motor response to a single stimulus, CRT is more 
dependent on attentional monitoring abilities as the stimulus is one of a number of 
possible alternatives (Hindmarch, 1980), and therefore provides an indication of 
psychomotor performance.
125
Procedure
All CRT measurements were made using the Leeds Psychomotor Tester (Hindmarch, 
1975). From a central starting position subjects are required to extinguish one of the 
six randomly illuminated red light emitting diodes, by touching the appropriate 
response button. The light/button combinations are arranged in a 120° arc of a 15cm 
radius circle centred on the start button. Subjects are instructed to use the forefinger of 
their preferred hand. Using this arrangement it is possible to automatically measure 
three components of reaction time: the total reaction time (TRT) from stimulus onset 
to completion of response; the movement time (MRT) between the start and response 
buttons and the processing or recognition time (RRT), obtained from subtracting MRT 
from TRT. Mean reaction times (ms) are obtained from 20 consecutive trials.
Validity and Reliability
A substantial number of studies have been performed which show the CRT to be valid 
and reliable. It has been suggested that CRT measurements are similar to on-the-road 
brake reaction times (Hindmarch et al, 1983) and impairments in CRT have been 
shown to reflect CFF decrements (Parrott, 1982). Furthermore, this test has been 
shown repeatedly to be sensitive to the effects of psychoactive drugs. Like CFF, CRT 
can differentiate between psychosedatives which prolong CRT e.g. amitriptyline, and 
.psychostimulants ^ yiuclmdcrea^ speed of reaction e.g. nomifensine (Hindmarch et al, 
1988). CRT has also been shown to discriminate between compounds from the same 
pharmacological classifications as those listed above for CFF. In addition, no 
significant regression effects of CRT were observed in a repeated measures 
longitudinal study of 3.5 years duration in healthy elderly volunteers (Kilminster, 
1991).
Krause and Bittner (1982) calculated the reliability of several CRT tasks and reported 
that, once subjects’ performance had reached the top of the learning curve, test-retest 
reliability was found to be greater than +0.58.
Sternberg Memory Scanning Task (SMT)
In order to examine the effects of antidepressants on short term memory, high speed 
scanning and retrieval from short term memory are assessed using a reaction time 
technique (Subhan and Hindmarch, 1984a) adapted from Sternberg (1966; 1969). The 
SMT evaluates the speed of recall of recently memorised information. Sternberg 
proposed that the reaction process utilised in such a task occurs in three stages. Firstly, 
assuming that stimulus set is stored in the short term memory, the subject must 
perceive and encode the probe digit. This probe is then compared to the digits in the 
stimulus set, and finally a response is made on the basis of that comparison.
Procedure
Subjects are required to memorise a series of one, three or five digits (the stimulus set) 
presented sequentially on a VDU. Following presentation of the final digit, an 
auditory signal is given, then a series of probe digits is presented. Subjects are 
required to respond either yes (if the probe digit was contained in the memorised list) 
or no (if it was not) to each of the probes by using a two button mouse. Response 
times are recorded for correct identifications.
Validity and Reliability
The SMT has been shown to be reliable in identifying drugs which interfere with 
memory processes. For example, several studies have shown that some of the 
benzodiazepines impair performance on this task, from one hour post dose through to 
effects the following day (e.g. Subhan and Hindmarch, 1984a; Sherwood et al, 1992; 
Hindmarch and Fairweather, 1994). The antidepressants amitriptyline (Kerr et al, 
1996), mianserin and trazodone (Hindmarch and Subhan, 1986) all impaired SMT, 
even more so when given with alcohol. On the other hand, improved performance on 
the SMT has been reported with nootropic compounds such as vinpocetine (Subhan 
and Hindmarch, 1985), ginkgo biloba extract (Subhan and Hindmarch, 1984b), HWA- 
285 (Hindmarch and Subhan, 1985) and even nicotine (Sherwood et al, 1990).
Sherwood and Kerr (1993) reported that SMT was reliable in detecting memory 
impairments, where test-retest correlation coefficients were found to be higher than 
+0.7 (from Carter et al, 1980). As with CFF and CRT, no significant regression effects
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were observed on this task in a longitudinal study of 3.5 years duration (Kilminster, 
1991).
Compensatory Tracking Test (CTT)
The CTT assesses response output mechanisms which are required for fine motor 
control, in contrast to the gross motor control required for CRT. This interactive task 
of sensorimotor function requires the subject to divide his attention between the 
tracking and the reaction time components, thereby utilising skills which are inherent 
to tasks such as car driving. This task has been shown to be sensitive to the effects of 
psychoactive drugs on sensorimotor skills.
Procedure
In this task, subjects are required to attend to two tasks. The first involves tracking a 
moving arrow on a VDU screen, using a joystick. The response measure is the mean 
deviation from the track program over a one minute trial period, where lower scores 
are indicative of more accurate tracking. In addition, a peripheral awareness task 
(PRT) is included in which the subject has to respond to a stimulus presented at 
random in the periphery of vision (i.e. in one of the comers of the VDU), while 
simultaneously attending to the tracking test. Tracking accuracy (RMS) and response 
times (RT) are recorded at each session.
Validity and Reliability
In a review by Hindmarch (1986) CTT was shown to be as efficient as on-the-road 
tests of car manoeuvering and braking in identifying dmgs which impaired driving. 
This suggests that CTT possesses a high degree of face validity in that it resembles the 
skills required in everyday tasks such as car driving (Hindmarch, 1988). The CTT has 
been shown to be sensitive to the effects psychoactive dmgs in that it can, like the 
tests outlined above, differentiate compounds of the same therapeutic class e.g. 
hypnotics (Hindmarch and Fairweather, 1994), antidepressants (Hindmarch and 
Harrison, 1988; Fairweather et al, 1993a), antihistamines (Rombaut and Hindmarch, 
1994) and anxiolytics (Hindmarch, 1985). Furthermore, the CTT is sensitive enough 
to detect changes in information processing produced by nicotine, caffeine and
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alcohol (Kerr et al, 1991). In Kilminster’s longitudinal study (1991), there were no 
significant regression on CTT performance.
Test-retest reliability in stabilised studies was calculated to be +0.78 for CTT 
(Kennedy et al, 1981).
3.2.2 Visual analogue scales (VAS)
In addition to tests which objectively measure drug effects it is useful to obtain a 
subjective assessment, i.e. a subject’s reaction as to how they feel or how they would 
rate themselves. Aitken (1969) concluded that visual analogue rating scales were by 
far the most accurate, reliable and valid means of obtaining changes in subjective 
feelings. This technique has since been developed for the evaluation of the effects of 
psychoactive drugs on subjective ratings (Bond and Lader, 19^4). These rating scales 
usually consist of 100mm horizontal lines and Aitken (1969) stated that measurement 
to the nearest millimetre is sufficiently sensitive to detect change. The extreme states 
of the specific variable are defined at either ends of the line (e.g. drowsy, not drowsy) 
and subjects are required to mark the line according to how drowsy (for example) they 
feel. These marking are then measured with a standard ruler.
Rating concepts on specific VAS differ between researchers, and although there is a
Cc'W'h
degree of cemmunaM-tydn the type of questions asked (Parrott and Hindmarch, 1980), 
the actual wording of the questions vary, which may lead to ambiguity. For these 
reasons, the VAS adopted here are used consistently across studies.
The Leeds Sleep Evaluation Questionnaire (LSEQ)
A significant improvement in the ease of getting to sleep and the perceived quality of 
sleep, reflecting reduced waking and improved rest, are arguably the two most 
important aspects of subjective sleep (Parrott and Hindmarch, 1978). The LSEQ 
consists of ten questions on aspects of subjective sleep and early morning behaviour 
which have been factor analysed (Parrott and Hindmarch, 1980) into four categories: 
Getting to Sleep (GTS), Quality of Sleep (QOS), feelings on Awakening from Sleep 
(AFS), and integrity of Behaviour following Waking (BFW). The LSEQ is completed
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on the morning following the day of medication and subjects are required to rate each 
of these aspects in relation to their normal (non-drug) performance. This VAS has 
been used extensively since 1975 (Hindmarch, 1975) and has been shown to be 
sensitive to drugs which affect sleep and can differentiate between different drug 
classes (e.g. Parrott and Hindmarch, 1980; Hindmarch, 1983).
Line Analogue Rating Scales (LARS)
Subjective evaluation of sedation is obtained from mean scores of ratings of 
"tiredness", "drowsiness", and "alertness" (which are included amongst distractor 
scales of anxiety, happiness, relaxation, dizziness, clumsiness, energy, sadness and 
depression). Subjects are required to indicate their feelings at that time on the scale in 
relation to their normal state of mind (mid scale). The advantage of this scale is that it 
can be administered quickly at several time points throughout the day. The LARS has 
been used extensively to detect subjective sedation with many different classes of 
compounds (Hindmarch and Gudgeon, 1980; Hindmarch and Subhan, 1986; 
Fairweather et al, 1993a; Rombaut and Hindmarch, 1994) and correlates well with 
objective tests (e.g. Parrott, 1982).
Milford Epworth Sleepiness Scale (MESS)
The Epworth Sleepiness Scale, first described by Johns (1991; 1992), was designed to 
ask subjects to rate their chance of dozing in a number of everyday situations using a 
scale of zero (would never doze), one (slight chance of dozing), two (moderate chance 
of dozing) or three (high chance of dozing). The MESS is a validated variant of the 
Epworth Sleepiness Scale (Fairweather et al., 1996a; 1996b) where subjects are 
required to rate the likelihood of their falling asleep by means of 100mm VAS. The 
overall mean score represents the level of sleepiness during the day.
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3.2.3 Other Tests
The following tests did not form the core battery and were only used occasionally. 
Stroop Test (STR)
The Stroop test (Stroop, 1935; Jensen and Rohwer, 1966) presents conflict or 
interference of information where the subject is presented with a colour word written 
in coloured ink, and is required to name the colour of the ink when the colour of the 
ink and the word are incongruous. Stroop (1935) demonstrated that it took longer for 
subjects to name the colour of the ink than to read the colour-word. A computerised 
version of the Stroop test was used here as a measure of selective information 
processing ability (Stroop, 1935; Hindmarch, 1980). Subjects were required to 
respond to the presentation of colour names which may be presented in a congruent or 
discrepant colour, by pressing the appropriate button on a choice response box. The 
"yes" button is pressed when the colour word matches the colour of the "ink" 
(matched response), and the "no" button when the two do not match (unmatched 
response). The response time (ms) was multiplied by np/nc (where np=number of 
presentations and nc=number of correct responses) with the result that reaction times 
were increased as errors were made. Finally, the log of each new reaction time was 
taken to counter the skew introduced by the transformation. (The use of the Stroop 
phenomena has been extensively reviewed by Dyer (1973)).
Word Recognition Task
This task was based on the Sternberg reaction time method of memory research 
(Sternberg, 1966; 1969) described above. Subjects were asked to memorise a list of 
fourteen words, presented individually. They were then required to indicate whether 
these words appeared in a second list, by responding yes* or W 'using a two button 
response mouse. Mean reaction times to correct responses were recorded.
Kim’s Game
Another assessment of short term memory, this test requires subjects to remember as 
many items as possible from a pictorial scene of 30 items shown to them for one 
minute. Subjects are then required to recall the items. Different items and different
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backgrounds are used each time the test is presented. This test is based on an object 
recognition task used for the assessment of short term memory (Paes de Sousa et al, 
1981).
Serial Subtraction of Numbers (SSN)
The speed and accuracy of repetitive mental subtractions provide an index of the 
integrity of the cognitive processing systems. Subjects are asked to subtract the 
numbers three, seven and seventeen successively from a five figure number. The 
performance parameters were the number of errors made and the time taken to 
complete the task (Hindmarch, 1977b).
Cognitive Failures Questionnaire (CFQ)
The CFQ is a measure of self reported failures in perception, memory and motor 
function (Broadbent et al, 1982). The subject is asked to indicate the frequency of 
each of 25 possible failures that they have experienced (very often, quite often, 
occasionally, very rarely or never).
Activity Monitoring (ACT, Wrist Actigraphy)
Activity monitors have been shown to be valid indicators of levels of motor activity in 
psychiatry, particularly in depressed patients where levels of activity and severity of 
depression correlate (Royant-Parola et al, 1986; Teicher, 1995). A novel use for these 
tools is to investigate the effects of drugs on activity (Stanley, 1996). Actigraphs (dual 
tracked AMI AMA-32 Motionloggers) are small wrist watch size devices which are 
worn on the non-dominant wrist on study days. Actigraphs contain a piezoelectric 
transducer that detects motion and generates a signal voltage. Data is downloaded 
from the actigraph onto a dedicated PC and the data is analysed using ACTION3 
software, which measures mean activity for the pre-set epoch. This device gives an 
indication of day-time and / or night-time activity (Stanley, 1996).
A summary of which tests where employed in each experiment is presented in Table 
3.1.
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Table 3.1: A summary of the test battery of each study
Experiment
Test 1 2 3 4 5 6 7 8
CFF X X X X X X X X
CRT X X X X X X X
SMT X X X X X X X
STR X X
WR X
CTT X X X X X X X
LARS X X X X X X X
LSEQ X X X X X X
MESS X X X
ACT X X
KIM X
CFQ X X
Critical Flicker Fusion (CFF); Choice Reaction Time (CRT); Compensatory Tracking Task (CTT); 
Sternberg Memory Scanning Task (SMT); Word Recognition Task (WR); Stroop Test (STR); Line 
Analogue Rating Scales for Sedation (LARS), Leeds Sleep Evaluation Questionnaire (LSEQ); Milford 
Epworth Sleepiness Scale (MESS), Actigraphy (ACT), Kim’s Game (KIM), Serial Subtraction o f  
Numbers (SSN), Cognitive Failures Questionnaire (CFQ)
3.3 Methods
In addition to the diverse range of measures encountered in the literature review, the 
methods adopted by different researchers have varied. The experiments presented here 
were all performed in a controlled environment where the protocol was strictly 
adhered to.
The general study procedures are outline below.
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3.3.1 General study procedures
All studies were performed in accordance with the Declaration of Helsinki (Tokyo and 
Venice amendments) and EC Good Clinical Practice guidelines. Each study protocol 
was approved by an independent local research ethics committee
Experiments 1-7 were carried out in healthy volunteers and were single-centre 
laboratory based studies, either carried out at or co-ordinated by the Human 
Psychopharmacology Research Unit (HPRU), University of Surrey, Milford Hospital. 
Experiment 8 was a multi-centre study which investigated the effects of 
antidepressants in depressed out-patients in general practice surgeries in the Surrey 
area.
3.3.2 Experiments 1-7 (healthy volunteers)
Subjects
For Experiments 1-7 subjects who fulfilled the relevant inclusion / exclusion criteria 
were selected from the HPRU volunteer database. These were healthy volunteers of 
either sex, with age ranges from 18-85. No subject participated in more than one 
experiment at a time.
The inclusion / exclusion criteria were as follows:
Inclusion criteria
1. Aged between 18-85 years inclusive
2. Body mass index between 18-30
3. Able and willing to give informed consent
4. The consent of the subject’s General Practitioner
Exclusion criteria
1. Concomitant psychotropic medication
2. History of mental illness, drug allergy, malignancy or chronic drug abuse 
(including alcohol but excluding nicotine)
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3. Significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, 
endocrine, neurological or haematological disease or abnormality
4. Marked laboratory, biochemical or haematological abnormalities 
considered to be clinically significant
5. Pregnant or lactating females
6. Females of child bearing potential not using adequate contraception
7. Current participation in any clinical study or participation in the previous 
three months
8. Any subject that, in the opinion of the investigator, was unsuitable 
Informed Consent
Prior to entering a study, subjects gave their written informed consent. During the 
consent procedure, the aims of the study and any risks associated with subject 
participation were explained. It was also made clear that subjects were permitted to 
withdraw from the study at any time without giving a reason, and that they could be 
withdrawn from the study by the investigator. Subjects were given two copies of the 
consent form, signed by the investigator and a witness, to take home for consideration. 
If they agreed to take part in the study, they were asked to sign the consent forms and 
to return one copy to the study nurse, keeping a copy for their own records. Subjects 
were also given an information sheet describing the study in clear, comprehensible 
terms.
Subjects were instructed that if they agreed to participate in the trial they must adhere 
to the instructions. These included that subjects should not be working overnight nor 
be employed in shift-work, and that they should go to bed at their usual time the night 
before a study day. Subjects were also required to abstain from caffeine, nicotine and 
alcohol on tests days and were requested to restrict intake of these substances for the 
duration of the study. Standardised meals were provided for subjects on study days 
(diet was unrestricted otherwise).
The subject’s general practitioner was informed and agreement for their patient to 
enter the study was obtained.
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Medical Examination
When subject and general practitioner consents were obtained, subjects were asked to 
attend the HPRU for a medical examination. During this examination, blood samples 
were taken for biochemical and haematological tests. Vital signs were measured and 
medical history was discussed. Urine samples were screened for drugs of abuse and 
pregnancy. A medical examination was also carried out at the end of a subject’s 
participation in the study.
Prior to the first study day, subjects were trained on the battery of psychometric tests 
and familiarised with the study procedures. Transport to and from the laboratory was 
provided.
3.3.3 Experiment 8 (patients)
Unlike Experiments 1-7, Experiment 8 was carried out in depressed patients in general 
practice.
Subjects
Subjects were patients who presented themselves to their general practitioner. They 
were male and female outpatients who fulfilled the following inclusion / exclusion 
criteria:
Inclusion criteria
1. Aged between 18-70 years inclusive
2. Able and willing to give informed consent
3. Satisfying DSMIII-R criteria for major depression (i.e. criteria 296.2 and
296.3 with the exclusion of suicidal ideation)
Exclusion criteria
1. Current or previous participation in a fluoxetine clinical trial (or in any 
clinical study within three months)
2. Evidence of bipolar affective disorder
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3. Patients who had received antidepressants for a previous episode of 
depression within the last six months
4. Experience of a depressive episode within the last six months
5. Current long term use of benzodiazepines
6. Concomitant psychotropic medication
7. History of organic brain disease
8. Pregnant or lactating females
9. Females of child bearing potential not using adequate contraception
10.History of or current drug allergy, malignancy or chronic drug abuse 
(including alcohol)
11 .Cardiovascular disease, especially patients with conduction defects
12.Hypertension, glaucoma, thyroid disease or renal failure
13. Any subject that, in the opinion of the investigator, was unsuitable
Informed Consent
Informed consent was obtained as described above.
Medical Examination
Following the informed consent process, a medical examination was carried out to 
ensure that patients fulfilled the inclusion / exclusion criteria outlined above. This was 
repeated at the end of a patient’s participation in the study.
Patients were trained on the battery of psychometric tests and familiarised with the 
study procedures.
3.4 Experimental design
A summary of the study designs is presented in Table 3.2. All experiments were 
performed and analysed under double blind conditions, where neither the subject nor 
the experimenter were aware of which treatment had been given. All treatments were
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indistinguishable from each other. A copy of the treatment code break was held at a 
secure central location should it be required in an emergency.
Experiments 1-7 were carried out in healthy volunteer subjects, and Experiment 8 
investigated drug effects in depressed patients (this study will be discussed 
separately). In all of these studies treatments were allocated in a random order. In 
Experiments 1-6, treatments were randomised in a cross-over fashion according to a 
Latin square, thus each subject acted as their own control and treatment sequences 
were balanced for carry over effects. A drug-free washout period occurred between 
treatments. Experiment 7 followed a parallel design, where equal numbers of subjects 
received a different condition. The use of parallel group studies in healthy volunteer 
subjects has been criticised previously (see Chapter 2), however, this was the design 
favoured by the company sponsoring this study. A placebo condition was incorporated 
into each volunteer subject experiment, and a verum was included in all but one 
(Experiment 5).
Adverse events and concomitant medication were recorded during all of the 
experiments, but as this thesis is concerned with the effects that antidepressants have 
on performance tests, these factors are not discussed.
Experiment 8 was performed in a population of patient with major depression, and so 
there were fundamental differences in the design criteria, particularly with the use of a 
parallel group design. For reasons discussed previously (Chapter 2), a placebo group 
was not included, however a verum was. Experimental design has been discussed 
critically in the previous chapter (section 2.5.2).
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Table 3.2: A summary of experimental designs
Experiment
Design 1 2 3 4 5 6 7 8*
Randomised X X X X X X X X
Double Blind X X X X X X X X
Cross-over X X X X X X - -
Placebo X X X X X X X -
Verum X X X X - X X X
Washout X X X X X X - -
*this study was carried out in patients and so different design criteria were adopted
3.4.1 Statistical analysis
All data were analysed using analysis of variance (ANOVA) techniques. If this 
revealed an overall significant effect then differences between means were evaluated 
using post-hoc tests. In the presentation of the results (Chapter 4), standard statistical 
notation is used. That is, F(a, b) = X, p<Y, where F stands for F-ratio; a and b are the 
degrees of freedom associated with the effect and error variance respectively; X is the 
particular value of F; p stands for the probability that the result was due to chance, and 
Y is the particular value of that probability. This is normally set at 0.05.
3.5 Experiments
The experiments carried out are listed in Table 3.3. All follow the measures and 
methods outlined above and in order to avoid repetition, the specifics of each study 
are detailed in Chapter 4.
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Table 3.3: Experiments
Experiment Title
1 The effects of moclobemide on psychomotor performance and 
cognitive function
2 The effects of brofaromine alone and in conjunction with alcohol on 
cognitive function, psychomotor performance, mood and sleep in 
healthy volunteers
3 The effects of paroxetine, alone and in combination with alcohol on 
psychomotor performance and cognitive function
4 The effects of fluvoxamine and dothiepin on psychomotor abilities in 
healthy volunteers
5 The psychomotor and cognitive effects of litoxetine in healthy 
volunteers
6 A double blind study of psychomotor function following citalopram 
and dothiepin
7 An evaluation of the pharmacodynamics of fengabine vs amitriptyline 
in healthy volunteers
8 The effects of fluoxetine and dothiepin on cognitive function and 
activity in depressed patients in general practice
3.6 Summary
This chapter has outlined the general methods and measures which have been adopted 
in order to evaluate the effects of second generation antidepressants on psychomotor 
and cognitive function. The test battery has been described, together with information 
on specific tests and the importance of validity and reliability. Aspects of subject 
selection, informed consent, experimental design and statistical analysis have been 
outlined. Each experiment will be discussed individually in the following chapter.
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CHAPTER 4: ANTIDEPRESSANTS AND PERFORMANCE - 
EXPERIMENTAL RESULTS
4.0 Chapter outline
The general methodology and the measures employed in each of the following 
experiments have already been described in the previous chapter. In the current 
chapter the specific procedures of each study are outlined, together with a description 
of the statistical techniques. The results for individual tests are presented, following 
which a short discussion of the results are provided. A summary of all of the 
experimental results is given at the end of this chapter and the findings will de 
discussed in detail in Chapter 5. The publications arising from this work are included 
in Appendix I.
4.1 Experiment 1: The effects of moclobemide on psychomotor performance 
and cognitive function
4.1.1 Objective
The aim of this experiment was to assess the effects of single doses of moclobemide 
200mg and moclobemide 400mg on cognitive and psychomotor function in healthy 
volunteers. Amitriptyline 50mg was included as verum.
4.1.2 Methods and measures
The general methods and measures adopted in this experiment are outlined in Chapter
3.
Subjects'. 16 healthy male volunteers aged 19-39 years old (mean 26.3) participated in 
the study. All of these completed the study and none suffered serious adverse events.
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Design: This study was a double blind, randomised placebo controlled four way 
cross-over design where each subject acted as their own control. The treatment 
sequence was balanced for residual effects using a Latin square design.
Drugs: The treatments were single doses of moclobemide 200mg, moclobemide 
400mg, amitriptyline 50mg and placebo. There was a one week washout period 
between each treatment.
Procedure’. Following consent and medical examination visits, subjects were required 
to attend the test centre on four occasions. On each of these they were tested pre-dose, 
then at 1, 2, and 4 hours post dose. Subjects were required to stay at the test centre 
overnight, and to complete the Leeds Sleep Evaluation Questionnaire (LSEQ) the 
following morning.
Test Battery: The test battery consisted of Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), Compensatory Tracking Task (CTT), Sternberg Memory 
Scanning Task (SMT) and Line Analogue Rating Scales for sedation (LARS). The 
Leeds Sleep Evaluation Questionnaire (LSEQ) was completed the following morning.
Analysis: Analyses of covariance (ANCOVA) were performed on the psychometric 
data, with baseline scores acting as the covariate. ANCOVA were also performed at 
each individual time point. Post hoc testing for differences between individual means 
were carried out using Sidak’s test. Significance was set at p<0.05.
4.1.3 Results
The mean response data are presented in Table 4.1.
CFF: The results of the ANCOVA on the CFF data revealed that there was a 
significant effect of drug (F(3, 15) = 27.48, pO.OOl) but that there was no interaction 
between treatment and time. Post hoc testing showed that amitriptyline significantly
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reduced CFF at all test points. There were no significant differences between either 
dose of moclobemide and placebo (Figure 4.1).
CRT\ A main drug effect was apparent in the ANOVA of recognition reaction time 
(RRT) where F(3, 15) = 6.11, pO.OOl) and motor reaction time (MRT) (F(3, 15) = 
13.34, p<0.0001) where responses with slower with amitriptyline compared to 
placebo. The total of the two (TRT) also showed this pattern (F(3, 15) = 17.40, 
p<0.0001) as well as an interaction between drug and time (F(6, 90) = 2.39, p<0.05). 
Post hoc tests revealed that amitriptyline significantly impaired TRT at 1 and 2 hours 
post dose when compared to placebo (Figure 4.2). Moclobemide 200mg also 
increased TRT at this time point, but this did not reach significance. MRT was also 
impaired by amitriptyline at 2 hours.
CTT: The main effect of drug on tracking accuracy (RMS) was not significant, 
however there was an interaction between time and treatment (F(6, 90) = 2.31, 
p<0.05). Post hoc analysis revealed that amitriptyline significantly impaired RMS at 2 
and 4 hours post dose and moclobemide 400mg at 2 hours post dose (Figure 4.3). A 
significant main drug effect was apparent on the reaction time component (RT) (F(3, 
15) = 9.68, p<0.0001). Post hoc tests showed that both amitriptyline and 
moclobemide 400mg slowed RT at the 2 hours test point (pO.OOl).
SMT: No significant effects were detected between treatments in the SMT task.
LARS: Amitriptyline appeared to be more sedative than all other treatments, but 
this trend was not significant.
LSEQ: A main treatment effect (F(3, 15) = 4.53, p<0.01) was found in the ease of 
getting to sleep (GTS). This was due to amitriptyline having significantly better scores 
than moclobemide 400mg, however no differences from placebo were found in any of 
the components of the LSEQ.
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4.1.4 Discussion
In this experiment (Fairweather et al, 1993c), the verum amitriptyline, had detrimental 
effects on the majority of test variables, e.g. it impaired critical flicker fusion at every 
test point whereas both doses of moclobemide were no different to placebo. 
Amitriptyline also slowed choice reaction times up to 2 hours post dose but returned 
to placebo levels at 4 hours. In addition, the two components of the compensatory 
tracking task were shown to be impaired by amitriptyline. Despite these findings, no 
such effect was observed on the speed of reaction in the Sternberg memory task. 
Moclobemide exhibited a different profile of action to amitriptyline in that there were 
very few effects. The only significant impairment was observed at one test point on 
the compensatory tracking task where the effects of the two doses of moclobemide 
varied, i.e. moclobemide 200mg significantly increased tracking error and 
moclobemide 400mg slowed reaction time (both these scores returned to placebo 
levels by the 4 hour test point). A cursory glance at the subjective ratings data (Table 
4.1) suggests that amitriptyline, but not moclobemide, was perceived to be more 
sedative and also improved the ease of getting to sleep, however neither of these drug- 
placebo trends were significant. These results suggest that, although amitriptyline 
impaired performance on the majority of the tests, subjects were not aware of the 
sedation that was so evident in the objective assessments.
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Table 4.1: Experiment 1 - The effects of moclobemide (M) 200mg,
moclobemide (M) 400mg and amitriptyline (A) 50mg on a battery 
of tests (see text for abbreviations of tests). SDs are given in 
parentheses.
Baseline 1 hour 2 hours 4 hours
CFF (Hz)
M200mg 30.3 (3.0) 29.9 (2.9) 29.5 (3.1) 29.6 (3.0)
M400mg 29.8 (2.5) 29.8 (2.0) 29.3 (2.4) 29.4 (2.6)
A50mg 30.5 (2.6) 29.1(2.5) 28.2 (2.5) 28.2 (3.2)
Placebo 30.3 (2.6) 30.0 (2.3) 29.9(2.1) 29.8 (2.0)
RRT (ms)
M200mg 405 (45) 414(76) 447(110) 418(71)
M400mg 400 (45) 416(61) 439 (79) 397 (57)
A50mg 424 (71) 461 (56) 496 (92) 421 (48)
Placebo 410(56) 415 (53) 417 (45) 416(49)
MRT (ms)
M200mg 194 (52) 194 (65) 204 (54) 199 (60)
M400mg 202 (55) 206 (55) 189 (50) 194 (40)
A50mg 201 (55) 228 (67) 238 (79) 239 (73)
Placebo 193 (54) 191 (59) 184 (48) 210 (63)
TRT (ms)
M200mg 600 (78) 608(103) 654(119) 617(102)
M400mg 602 (80) 622 (96) 627 (106) 591 (78)
A50mg 625 (104) 689 (89) 734 (129) 664(101)
Placebo 603 (91) 606 (88) 600 (71) 626 (102)
SMT (ms)
M200mg - 610(185) 675 (235) 636 (197)
M400mg - 687 (229) 661 (181) 599 (267)
A50mg - 646 (222) 780 (413) 721 (334)
Placebo - 602 (190) 586 (159) 615 (201)
RMS (rms)
M200mg - 8.9 (5.0) 11.6(10.7) 8.1 (3.8)
M400mg - 10.9 (8.0) 16.3 (15.7) 12.5 (9.4)
A50mg - 11.4 (8.3) 15.6 (8.2) 17.7(12.1)
Placebo - 9.8 (5.2) 8.6 (2.9) 10.2 (6.3)
RT (ms)
M200mg - 431 (85) 471 (120) 425 (64)
M400mg - 446 (81) 474 (114) 490(141)
A50mg - 437 (70) 484 (75) 482 (96)
Placebo - 412(69) 419(62) 448 (139)
LARS (mm)
M200mg 51.8 (5.6) 54.1 (7.0) 55.6(10.1) 52.9 (6.7)
M400mg 52.3 (5.9) 54.8 (8.8) 55.5 (11.9) 51.4 (10.6)
A50mg 52.0 (5.3) 53.6 (11.5) 62.7 (12.3) 63.4(13.1)
Placebo 50.7 (2.6) 54.7 (5.0) 54.3 (5.3) 51.8(3.7)
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Table 4.1: Experiment 1 - The effects of moclobemide (M) 200mg,
moclobemide (M) 400mg and amitriptyline (A) 50mg on a battery 
of tests (see text for abbreviations of tests). SDs are given in 
parentheses, (continued).
Daily Score
GTS (mm) QOS (mm)
M200mg 45.1 (5.9) 45.8 (9.7)
M400mg 45.9 (8.9) 44.1 (7.7)
A50mg 39.8 (12.0) 42.0 (14.6)
Placebo 44.6 (6.6) 46.4 (6.4)
AFS (mm) BFW (mm)
M200mg 47.1 (9.1) 50.3 (8.1)
M400mg 49.5 (9.4) 47.8 (7.9)
A50mg 46.1 (10.4) 48.4 (10.2)
Placebo 49.2 (6.8) 47.6 (3.2)
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4.2 Experiment 2: The effects of brofaromine alone and in conjunction with 
alcohol on cognitive function, psychomotor performance, mood and 
sleep in healthy volunteers
4.2.1 Objective
The aim of this study was to evaluate the effects of single doses of brofaromine 50mg, 
brofaromine 75mg and the verum amitriptyline 50mg on psychomotor and cognitive 
function. All drug conditions were evaluated in the presence and absence of alcohol in 
order to determine whether any drug-alcohol interaction occurred.
4.2.2 Methods and measures
The general methods and measures adopted in this experiment are outlined in Chapter
3.
Subjects: 16 healthy male and female volunteers aged 18-45 years old (mean 28.1) 
participated in the study. One subject dropped out due to work commitments and was 
replaced. There were no serious adverse events.
Design: A randomised double blind placebo controlled eight way cross-over design 
was used where each subject acted as their own control. The treatment sequence was 
balanced for residual effects using a Latin square design.
Drugs: The treatments were single doses of brofaromine 50mg, brofaromine 75mg, 
amitriptyline 50mg and placebo. All treatments were given with and without alcohol 
(0.7g/kg body weight for males; 0.5g/kg body weight for females). Alcohol was 
administered as vodka (37.5 per cent by volume) made up to 200ml with orange juice 
and essence of rum. Alcohol placebo was 200ml orange juice and essence of rum. The 
drinks were consumed within five minutes. There was a one week washout period 
between each treatment.
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Procedure: Following consent and medical examination visits, subjects were required 
to attend the test centre on eight occasions. On each of these they were tested pre­
dose, then alcohol or alcohol-placebo was administered at 2.5 hours post dose (and 
consumed within 5 minutes). The test battery was repeated at 3, 6, and 12 hours post 
dose. Subjects were required to stay at the test centre overnight. The following 
morning they were asked to complete the Leeds Sleep Evaluation Questionnaire 
(LSEQ).
Test Battery: The test battery consisted of Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), Compensatory Tracking Task (CTT), Sternberg Memory 
Scanning Task (SMT), Sternberg Word Recognition (WR) and Line Analogue Rating 
Scales for sedation (LARS). The Leeds Sleep Evaluation Questionnaire (LSEQ) was 
completed the following morning.
Analysis: Analyses of covariance (ANCOVA) were performed on the psychometric 
data, with baseline scores acting as the covariate. ANCOVA were also performed at 
each individual time point. Post hoc testing for differences between individual means 
were carried out using two-tailed /-tests, based on the Bonferroni inequality, using a 
Type I error rate of 0.05/6 = 0.0083.
4.2.3 Results
The mean response data are presented in Table 4.1.
CFF: ANCOVA over all treatment times revealed a significant drug effect (F(3, 
94) = 32.53; p<0.0001) and an interaction between drug and alcohol (F(3, 94) = 2.94, 
p<0.05). Post hoc tests showed that amitriptyline significantly lowered CFF compared 
to placebo at all test points (Figure 4.4). Brofaromine 75mg and 50mg did not 
significantly differ from placebo. Placebo scores were slightly lower in the presence 
of alcohol. The impairing effect of amitriptyline + alcohol was significantly worse 
than alcohol alone at every test point, and at one test point (3 hours) there was a
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potentiation of effects. Both doses of brofaromine appeared to reverse this alcohol 
induced decrement, brofaromine 75mg significantly so at 6 hours (Figure 4.5).
CRT: Significant drug effects were evident on the total (TRT) (F(3, 93) = 7.39, 
p<0.0002) and motor (MRT) (F(3, 92) = 11.62, p<0.0001) components but not the 
recognition component (RRT) of reaction time. All components, including placebo, 
revealed a main effect of alcohol (p<0.01) but no potentiation of effect was recorded. 
Further analyses showed that amitriptyline impaired TRT and MRT at 3 hours post 
dose and MRT at 6 hours post dose (Figures 4.6 and 4.7). Brofaromine was not 
significantly different from placebo and no significant within drug between alcohol 
effects were found.
CTT: Significant main effects of drug and alcohol were revealed by ANCOVA for 
both tracking accuracy (RMS) (F(3, 95) = 32.04, p<0.0001) and reaction time (RT) 
(F(3, 94) = 20.07, p<0.0001). Further analyses demonstrated that amitriptyline 
impaired both RMS and RT at 3 and 6 hours post dose (p<0.05) (Figures 4.8 and 4.9). 
The effect of the combination of alcohol + amitriptyline on RMS was greater than that 
of either compound alone. Brofaromine 50mg, amitriptyline and placebo all impaired 
RT at 3 hours in the presence of alcohol, but only amitriptyline + alcohol was 
different to alcohol alone. Neither brofaromine 50mg nor 75mg alone could be 
distinguished from placebo at any time point.
SMT: The overall ANCOVA showed significant effects for both drug (F(3, 80) = 
23.13, p<0.0001) and alcohol (F(3, 80) = 6.74, p<0.02), however, there were no 
overall interactions between drug and alcohol. ANCOVA and post hoc tests at the 
separate time points demonstrated that amitriptyline impaired performance at 3 and 6 
hours post dose (p<0.05). No significant differences were demonstrated with 
brofaromine, although performance was consistently superior to placebo throughout.
WR: No significant main effects of drug or alcohol were revealed by ANCOVA in 
this task, however there was a significant interaction of the two (F(3, 93) = 4.11, 
p<0.01). At 6 hours post dose a significant effect of alcohol was observed (p<0.05),
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where performance was worse when placebo or brofaromine 50mg were taken in 
conjunction with alcohol than when taken alone.
LARS: Overall main effects of drug (F(3, 94) = 14.91, pO.OOOl) and alcohol (1, 
94) = 8.08, p<0.01) were revealed on subjective ratings of sedation (LARS), but there 
was no drug - alcohol interaction. Ratings of sedation were increased with 
amitriptyline at 3, 6 and 12 hours post dose (Figure 4.10). There was a main effect of 
alcohol at 3 and 6 hours for all treatments including placebo.
LSEQ: Significant differences were observed in getting to sleep (GTS) (F(3, 98) = 
9.33, pO.OOOl) and quality of sleep (QOS) (F3, 98) = 6.15, p<0.001). Amitriptyline 
improved ratings of GTS (p<0.002) and QOS (p<0.05) compared to both doses of 
brofaromine, but there were no differences from placebo. There was also main effects 
of alcohol on these variables, but no significant drug-alcohol interactions were 
evident.
4.2.4 Discussion
The impairing effects of the verum observed in the first experiment were also evident 
here (Kerr et al, 1993). At all test points amitriptyline (without alcohol) significantly 
lowered critical flicker fusion thresholds and resulted in increased reports of 
subjective sedation. It is interesting to note that in this experiment subjects did 
perceive themselves to be sedated, whereas in Experiment 1 the same dose of 
amitriptyline did not significantly alter subjective ratings, even though objectively 
they were sedated. At 3 and 6 hours slowed choice reaction time, impaired tracking 
accuracy, tracker reaction time and impaired performance on the Sternberg memory 
test were also observed with amitriptyline. By 12 hours post dose, all performance 
variables, except critical flicker fusion and ratings of subjective sedation, had returned 
to placebo levels. It is possible, however, that between the 6 and 12 hour test points, 
the impairing effects of amitriptyline may have been evident, but as no test battery 
was included during that time no assumptions can be made. No drug-placebo 
differences were observed in the Leeds Sleep Evaluation Questionnaire, although
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amitriptyline did improve the ease of getting to sleep and the quality of sleep when 
compared to brofaromine. Unlike amitriptyline, both doses of brofaromine were no 
worse than placebo on any of these measures. If anything, performance was enhanced 
in the presence of brofaromine, although these trends were not significant.
When alcohol and the drugs were administered on the same day, scores were 
generally lower overall, and the pattern of results was similar to the non-alcohol 
conditions. The effects of alcohol on the critical flicker fusion task were potentiated 
by amitriptyline at 3 hours. Brofaromine, however, had the opposite effect in that both 
doses appeared to reverse alcohol-induced impairments, and at 6 hours this was 
significant with the higher dose (75mg) on critical flicker fusion thresholds.
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Table 4.2: Experiment 2 - The effects of brofaromine (B) 50mg, brofaromine 
(B) 75mg and amitriptyline (A) 50mg with (+) and without alcohol 
(see text for abbreviations of tests). SDs are given in parentheses.
Baseline 3 hour 6 hours 12 hours
CFF (Hz)
B50mg 30.8 (3.2) 30.1 (3.0) 30.1 (3.2) 30.2 (3.2)
B50mg+ 30.5 (2.5) 29.9 (2.3) 30.2 (2.5) 30.9 (2.6)
B75mg 29.9(2.5) 29.4 (2.3) 30.0 (2.8) 29.9 (3.0)
B75mg+ 30.2 (2.9) 29.9 (2.9) 30.4 (3.0) 30.7 (3.6)
A50mg 29.9 (2.7) 28.5 (3.3) 27.9 (2.3) 28.7 (2.5)
A50mg+ 30.2 (2.9) 27.2 (3.0) 28.0 (2.8) 28.7 (3.2)
Placebo 30.3 (2.8) 30.1 (2.8) 30.1(2.6) 29.9 (2.8)
Placebo+ 29.9 (2.6) 28.9(2.1) 29.2 (2.7) 30.0 (3.3)
RRT (ms)
B50mg 413 (58) 430 (126) 437 (80) 415 (76)
B50mg+ 413 (71) 453 (94) 422 (91) 423 (61)
B75mg 414 (71) 406 (62) 430 (69) 414 (83)
B75mg+ 423 (94) 527(203) 451 (90) 422 (72)
A50mg 409 (63) 477 (121) 447 (79) 411 (55)
A50mg+ 438 (88) 542 (204) 431(83) 423 (91)
Placebo 429 (102) 425 (81) 416(85) 405 (70)
Placebo+ 429 (69) 484 (147) 448 (128) 409 (68)
MRT (ms)
B50mg 207 (76) 195 (85) 198 (75) 195 (68)
B50mg+ 208 (66) 223 (59) 208 (70) 209(85)
B75mg 204 (70) 179 (54) 199 (66) 206 (70)
B75mg+ 206 (62) 214(61) 207 (76) 206 (68)
A50mg 205 (65) 240 (61) 225 (57) 206 (70)
A50mg+ 200 (62) 273 (93) 226 (68) 208 (80)
Placebo 212(87) 196 (63) 208 (67) 193 (64)
Placebo* 203 (63) 223 (74) 234 (68) 193 (64)
TRT (ms)
B50mg 620(111) 625 (164) 635 (125) 610(116)
B50mg+ 621(113) 676(119) 630(118) 630(110)
B75mg 618(107) 595 (78) 629 (102) 621(122)
B75mg+ 629 (126) 765 (239) 659 (142) 628 (103)
A50mg 614(105) 717 (140) 672 (108) 617(106)
A50mg+ 638 (118) 816 (246) 657 (114) 631 (124)
Placebo 641(157) 622 (121) 623 (134) 598 (103)
Placebo+ 632 (108) 707 (173) 681 (156) 602 (95)
RMS (rms)
B50mg 9.6 (3.8) 9.7 (4.6) 9.6 (4.5) 9.4 (4.0)
B50mg+ 9.2 (3.9) 12.2 (5.2) 9.8 (3.9) 8.4 (2.9)
B75mg 9.1 (3.7) 9.3 (3.8) 9.2 (3.9) 8.0 (2.9)
B75mg+ 9.2 (3.8) 11.6 (5.0) 10.7 (5.3) 9.2 (4.8)
A50mg 9.5 (4.0) 14.9 (5.7) 18.6(11.5) 9.3 (2.4)
A50mg+ 10.1 (4.0) 18.8 (9.8) 23.4(15.1) 9.2 (3.6)
Placebo 9.4 (4.3) 9.5 (4.7) 9.7 (4.1) 8.2 (3.2)
Placebo* 9.4 (2.9) 12.2 (5.9) 11.0 (3.9) 8.7 (3.0)
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Table 4.2: Experiment 2 - The effects of brofaromine (B) 50mg, brofaromine
(B) 75mg and amitriptyline (A) 50mg with (+) and without alcohol 
(see text for abbreviations of tests). SDs are given in parentheses. 
(Continued).
Baseline 3 hour 6 hours 12 hours
RT (ms)
B50mg 390 (60) 400 (50) 400 (70) 390 (60)
B50mg+ 380 (60) 460 (90) 410(60) 390 (50)
B75mg 380 (50) 410 (60) 390 (60) 390 (60)
B75mg+ 380 (40) 460 (100) 420 (80) 390 (50)
A50mg 390 (70) 440 (90) 480 (100) 410(80)
A50mg+ 380 (70) 520(110) 480 (90) 380 (60)
Placebo 390 (70) 400(80) 410(60) 380 (50)
Placebo+ 380 (50) 470(110) 410 (60) 380 (40)
SMT (ms)
B50mg 634 (183) 620 (145) 620 (167) 615 (188)
B50mg+ 629 (147) 678 (207) 640(163) 605 (143)
B75mg 681(169) 651(167) 632(178) 624(211)
B75mg+ 613 (138) 661(159) 630 (132) 603 (152)
A50mg 667(188) 739(181) 788 (203) 630(157)
A50mg+ 675 (193) 818(226) 921 (389) 648(181)
Placebo 654 (143) 661(176) 670 (216) 609 (145)
Placebo+ 653(183) 690 (208) 669(199) 607(193)
WR (ms)
B50mg 714(102) 680(105) 684 (85) 715(139)
B50mg+ 704 (93) 780 (227) 785(186) 716(151)
B75mg 711(124) 752(136) 763 (129) 695 (86)
B75mg+ 711(121) 784(199) 708(119) 714(133)
A50mg 752 (186) 727 (179) 733 (112) 702 (147)
A50mg+ 775 (173) 777(185) 749 (129) 729 (109)
Placebo 698 (94) 721(134) 789 (165) 717(152)
Placebo+ 704(121) 746 (228) 695 (156) 668 (97)
LARS (mm)
B50mg 51.3 (1.8) 52.6 (5.6) 51.8 (3.0) 50.2(1.5)
B50mg+ 52.4 (5.9) 54.9 (13.5) 58.3 (8.9) 52.4 (4.0)
B75mg 52.9 (3.4) 51.8(3.3) 51.8 (1.8) 50.8(1.6)
B75mg+ 51.8(3.5) 56.3 (10.8) 56.0 (7.0) 52.6 (3.9)
A50mg 51.4(2.7) 61.7(12.1) 63.8 (14.4) 57.5 (9.8)
A50mg+ 50.3 (2.3) 63.4(11.4) 63.4(12.1) 56.8(10.1)
Placebo 52.1 (3.8) 52.3 (4.2) 52.6 (5.2) 50.6 (2.6)
Placebo+ 51.9 (3.3) 56.4 (8.1) 58.0 (7.1) 51.7(2.7)
156
Table 4.2: Experiment 2 - The effects of brofaromine (B) 50mg, brofaromine
(B) 75mg and amitriptyline (A) 50mg with (+) and without alcohol 
(see text for abbreviations of tests). SDs are given in parentheses, 
(continued).
Daily Score
GTS (mm) QOS (mm)
B50mg 50.5 (7.1) 53.4 (9.6)
B50mg+ 54.3 (13.9) 62.7 (17.8)
B75mg 50.1 (4.2) 52.4 (7.3)
B75mg+ 56.0(11.7) 61.7(12.9)
A50mg 39.5 (12.5) 45.0 (14.3)
A50mg+ 41.9(13.1) 45.4 (15.2)
Placebo 46.3 (5.0) 49.2 (10.2)
Placebo+ 52.0 (13.4) 55.1 (13.8)
AFS (mm) BFW (mm)
B50mg 46.7 (7.4) 49.4 (3.4)
B50mg+ 45.4 (10.7) 52.4 (7.4)
B75mg 48.8 (4.6) 49.4 (3.1)
B75mg+ 46.6(13.1) 51.0 (8.6)
A50mg 53.0 (8.5) 51.8 (7.1)
A50mg+ 49.1 (8.7) 51.7 (5.3)
Placebo 49.4 (7.3) 50.1 (3.1)
Placebo+ 49.5 (7.0) 49.5 (8.3)
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4.3 Experiment 3: The effects of paroxetine, alone and in combination with 
alcohol on psychomotor performance and cognitive function
4.3.1 Objective
The aim of this study was to assess the effects of paroxetine 20mg on psychomotor 
and cognitive function following single and repeated dosing after 14 days in elderly 
healthy volunteers. Lorazepam lmg was introduced as a verum in order to ensure test 
sensitivity. The effects of a drug-alcohol combination were investigated on days 1 and 
14.
4.3.2 Methods and measures
The general methods and measures are outlined in Chapter 3.
Subjects: 16 healthy male volunteers aged 60-85 years old (mean 72.3) entered the 
study. One subject dropped out prior to the first test day (for non-medical reasons) and 
so 15 completed the study. No subjects suffered any serious adverse events.
Design: A randomised double blind three way cross-over design was used where each 
subject acted as their own control. The treatment sequence was balanced for residual 
effects using a Latin square design.
Drugs: The treatments were paroxetine 20mg once daily for 14 days, lorazepam lmg 
on days 1,13 and 14 (with matching placebo on days 2-12), and placebo. Alcohol was 
given on days 1 and 14 as vodka (0.6g/kg body weight, 37.5 per cent by volume) 
made up to 200ml orange juice. Drinks were consumed in five minutes or less. There 
was a two week washout period between each treatment phase.
Procedure: Following consent and medical examination visits, subjects were required 
to attend the test centre on nine occasions (days 1,13 and 14 of each treatment phase). 
On each of these they were tested pre-dose, then at 1, 5 and 10 hours post dose. On
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days 1 and 14 alcohol was given 30 minutes post drug. Subjects were required to stay 
at the test centre overnight. The following morning they were asked to complete the 
Leeds Sleep Evaluation Questionnaire (LSEQ) and Line Analogue Rating Scales for 
sedation (LARS).
Test Battery: The test battery consisted of Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), Compensatory Tracking Task (CTT), Sternberg Memory 
Scanning Task (SMT), the Stroop Task (STR) and LARS. The LSEQ and LARS were 
completed the morning after each test day.
Analysis: The data from the psychometric tests were analysed using repeated 
measures analyses of covariance (ANCOVA) with pre-treatment scores on day one 
acting as the covariate. Separate ANCOVAs were performed for each post dose test 
point. One subject dropped out of the study and so specific comparisons of pairs of 
treatments were made using least-squares means, adjusted for covariate and unequal 
frequencies using two-tailed /-tests. Statistical significance was set at p<0.05/3 = 
0.017.
4.3.3 Results
The mean response data are presented in Table 4.3.
CFF: Significant main effects of drug were present on day 1 at every test point 
except day 1 baseline. At 1, 5 and 10 hours post dose on day 1 the levels were F(2, 23) 
= 11.95, p<0.0005; F(2, 23) = 13.12, p<0.0005 and F(2, 23) =19.31, p<0.0002 
respectively. Similar levels of significance were apparent on days 13 and 14. Post hoc 
testing demonstrated that, on day 1, the combination of lorazepam+alcohol 
significantly lowered CFF at 1 and 5 hours post dose (p<0.001) compared to 
placebo+alcohol. The combination of paroxetine+alcohol, however, significantly 
raised CFF scores at 10 hours versus placebo (p<0.0005) and at 1, 5 and 10 hours 
when compared to lorazepam (pO.OOOl) (Figure 4.11). A similar pattern was 
observed with paroxetine on day 14 (p0.005), but lorazepam did not differ
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significantly from placebo. On day 13 (without alcohol) paroxetine scores were 
significantly higher than placebo at baseline (p<0.017), 1 (p<0.005) and 5 (p<0.017) 
hours and lorazepam at 1, 5 and 10 hours post dose (p<0.005).
CRT: Significant drug differences on total reaction time (TRT) were revealed at 5 
hours on days 13 (F(2, 23) = 6.19, p<0.01) and 14 (F(2, 23) = 2, 23) = 2.92, p<0.05). 
Significant differences were also observed on recognition reaction time (RRT) on day 
14 at 5 hours post dose (F(2, 23) = 3.83, p<0.05) and motor reaction time (MRT) at 5 
hours on day 13 (F(2, 23) = 2.6, p<0.05) and at 10 hours on day 14 (F(2, 23) = 5.09, 
p<0.05). Post hoc analyses revealed that paroxetine could not be differentiated from 
placebo on TRT, RRT or MRT at any time point though it did produce significantly 
faster TRT and RRT times than lorazepam. Lorazepam significantly slowed TRT 
(Figure 4.12) on day 13 at 5 hours when compared to placebo and also potentiated the 
effect of alcohol on day 14 at 1 hour post dose (both p<0.01). For RRT, the only 
difference observed was that lorazepam+alcohol significantly impaired performance 
at 5 hours on day 14 (p<0.017) when compared to placebo+alcohol. No other 
differences were observed in this parameter. There were no significant deviations 
from placebo on MRT, however paroxetine and lorazepam could be differentiated on 
day 13 at 5 hours and day 14 at 10 hours post dose (p<0.005).
CTT: Significant main drug effects were apparent on tracker accuracy (RMS) at 5 
hours post dose on day 1 (F(2, 21) = 5.09, p<0.05), 5 hours (F(2, 23) = 13.58, 
pO.OOOl) and 10 hours on day 13 (F(2, 23) = 5.31, pO.05) and at 1 hour post dose 
on day 14 (F(2, 23) = 7.55, p0.005). Post hoc tests revealed that lorazepam impaired 
RMS on days 1 and 13 at 5 hours (pO.Ol) and day 14 at 1 hour post dose (pO.Ol) 
(Figure 4.13). Paroxetine produced scores at around placebo level or better and at 10 
hours on day 13, significantly less errors were recorded with paroxetine than with 
placebo (p<0.017). In addition, paroxetine significantly improved RMS compared to 
lorazepam, both with and without alcohol.
A main effect of treatment was detected on the reaction time (RT) component at 5 
hours (F(2, 23) = 8.27, p<0.005) and 10 hours (F(2, 23) = 7.19, p<0.005) on day 13
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and at 10 hours on day 14 (F(2, 23) = 3.57, p<0.05). Post hoc analyses showed that 
lorazepam disrupted performance on RT at 5 hours on day 13 (p<0.001). Paroxetine 
was no different to placebo, but was significantly faster than lorazepam on day 13 at 
times 5 and 10, and on day 14 at 10 hours (p<0.01).
SMT: A significant effect was observed in the overall analysis at baseline (F(2, 24) 
= 6.32, p<0.01) and 5 hours post dose (F(2, 19) = 6.99, p<0.01) on day 13. Further 
analyses revealed that this was due to both lorazepam and paroxetine scoring 
significantly worse than placebo on day 13 pre-drug tests (p<0.017) and lorazepam 
impairing performance at 5 hours (p<0.005) (Figure 4.14).
STR: An effect was observed pre-drug on day 1 (F(2, 24) = 4.82, p<0.02) and this 
was shown to be due to the fact that the paroxetine group had significantly slower 
responses prior to drug administration for matched responses (p<0.01).
LARS: No significant differences were observed in subjective ratings of sedation.
LSEQ: No subjective differences between drugs were found in the ease of getting 
to sleep (GTS), the perceived quality of sleep (QOS) or in the ease of awakening from 
sleep (AFS). The only main effect detected was on day 13 (F(2, 24) = 4.42, p<0.05), 
and post hoc testing demonstrated that paroxetine significantly improved the integrity 
of behaviour following awakening on the morning of day 14 (i.e. following dosing on 
day 13) when compared to lorazepam (pO.Ol). Neither paroxetine nor lorazepam 
affected the LSEQ compared to placebo.
4.3.4 Discussion
Paroxetine exhibited an interesting profile on critical flicker fusion, where thresholds 
were always above placebo levels (Kerr et al, 1992b). On day 13 (no alcohol) 
paroxetine scored significantly higher than placebo during the day, whereas on days 1 
and 14 significance was only reached at 10 hours post dose. On these days alcohol 
was administered 30 minutes post drug, and it may be presumed that paroxetine could 
antagonise the effects of alcohol only when the effects had worn off at 10 hours.
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Paroxetine had no effect on choice reaction time or tracker reaction time, but did
result in more accurate tracking on day 13. Conversely, lorazepam lowered critical
flicker fusion on day 1, but by days 13 and 14 subjects appeared to have developed
tolerance to this effect. Lorazepam also impaired choice reaction time and disrupted
performance on the compensatory tracking and memory tasks, both with and without
alcohol. A negative effect of paroxetine was observed on short term memory at the
baseline test point on day 13, however given that this was an isolated occurrence, a
Type I error may account for this finding. No difference between drugs and placebo 
uwere reported in subjective ratings of daytime sedation or sleep.
The profile of paroxetine in this age group is intriguing. As paroxetine improved 
performance in critical flicker fusion and compensatory tracking task and appeared to 
antagonise the detrimental effects of alcohol on cognition, it may be that this SSRI has 
a role to play in the pharmacotherapy of age-related performance deficits.
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Table 4.3: Experiment 3 - The effects of paroxetine (P) 20mg and lorazepam
(L) lmg with and without alcohol on a battery of tests (see text for 
abbreviations of tests). Standard errors are given in parentheses.
Base­
line
1
hour
5
hours
10
hours
Base­
line
1
hours
5
hours
10
hours
Base­
line
1
hour
5
hours
10
hours
CFF (Hz)
P20mg 27.4
(0.2)
26.9
(0.2)
27.9
(0.3)
28.2
(0.2)
28.5
(0.3)
28.2
(0.2)
28.3
(0.3)
28.3
(0.3)
28.6
(0.3)
28.0
(0.3)
28.3
(0.3)
28.7
(0.3)
Llm g 27.1
(0.2)
25.7
(0.2)
26.0
(0.3)
26.9
(0.2)
27.5
(0.3)
26.8
(0.2)
26.3
(0.3)
26.9
(0.3)
27.3
(0.3)
26.4
(0.3)
26.6
(0.3)
27.4
(0.3)
Placebo 27.4
(0.2)
26.7
(0.2)
27.1
(0.3)
27.3
(0.2)
27.1
(0.3)
26.9
(0.2)
27.1
(0.3)
27.6
(0.2)
27.5
(0.3)
27.3
(0.3)
27.6
(0.3)
27.4
(0.3)
RRT (ms)
P20mg 441
(14)
478
(29)
453
(27)
429
(9)
434
(16)
435
(9)
438
(12)
422
(7)
404
(11)
460
(18)
432
(14)
433
(13)
Llm g 458
(14)
530
(28)
483
(26)
449
(9)
454
(16)
429
(9)
451
(12)
437
(7)
432
(11)
508
(18)
472
(14)
435
(13)
Placebo 460
(14)
520
(28)
497
(28)
444
(9)
413
(16)
435
(9)
420
(12)
427
(7)
409
(11)
459
(18)
422
(14)
415
(13)
MRT (ms'
P20mg 231
(10)
243
(19)
247
(14)
224
(8)
241
(10)
233
(10)
218
(7)
239
(13)
233
(6)
226
(8)
228
(5)
219
(9)
Llm g 226
(10)
255
(19)
268
(14)
230
(8)
231
(10)
245
(10)
261
(7)
251
(13)
241
(6)
243
(8)
243
(5)
260
(9)
Placebo 236
(10)
231
(19)
252
(14)
248
(8)
239
(10)
224
(10)
236
(7)
229
(13)
227
(6)
236
(8)
230
(5)
231
(9)
TRT (ms)
P20mg 672
(17)
716
(35)
705
(30)
656
(12)
675
(19)
666
(11)
654
(13)
664
(11)
637
(13)
685
(21)
658
(15)
651
(16)
Llm g 684
(17)
788
(35)
747
(30)
677
(12)
686
(19)
675
(11)
713
(13)
687
(12)
673
(13)
752
(21)
716
(15)
696
(16)
Placebo 696
(17)
754
(35)
746
(30)
692
(12)
653
(19)
660
(11)
657
(13)
653
0 1 )
637
(13)
695
(21)
653
(15)
645
(16)
RMS (rms)
P20mg 8.5
(0.4)
9.5
(0.5)
8.1
(1.3)
9.4
(0.6)
8.2
(0.3)
7.9
(0.3)
7.7
(0.3)
7.2
(0.2)
7.7
(0.3)
8.0
(0.4)
7.6
(0.9)
7.3
(0.3)
Llm g 8.3
(0.4)
10.2
(0.5)
13.1
(1.2)
8.9
(0.6)
8.0
(0.3)
8.4
(0.3)
10.1
(0.3)
8.3
(0.2)
8.0
(0.3)
10.2
(0.4)
9.5
(0.9)
8.4
(0.3)
Placebo 8.5
(0.4)
8.5
(0.5)
8.3
(1.3)
7.7
(0.6)
8.1
(0.3)
8.2
(0.3)
8.0
(0.3)
8.2
(0.2)
7.4
(0.3)
8.6
(0.4)
9.3
(0.9)
7.9
(0.3)
RT (ms)
P20mg 409
(8)
504
(15)
442
(9)
444
(12)
405
(8)
443
(12)
440
(8)
423
(6)
405
(10)
477
0 1 )
439
(8)
427
(7)
Llm g 416
(8)
504
(14)
459
(9)
433
(12)
412
(8)
455
(12)
469
(7)
453
(6)
437
(10)
507
(11)
455
(8)
452
(7)
Placebo 414
(8)
464
(14)
441
(9)
436
(12)
400
(8)
422
(12)
426
(7)
438
(5)
413
(10)
470
(11)
445
(8)
434
(7)
SMT(ms)
P20mg 869
(27)
910
(38)
900
(39)
832
(21)
857
(22)
831
(27)
826
(23)
864
(22)
852
(23)
885
(31)
863
(22)
861
(42)
Llm g 821
(30)
837
(41)
898
(41)
872
(23)
882
(22)
877
(29)
938
(24)
873
(24)
849
(23)
891
(33)
882
(24)
897
(45)
Placebo 852
(28)
895
(35)
786
(43)
822
(21)
775
(22)
871
(27)
826
(23)
827
(22)
825
(23)
891
(31)
819
(23)
917
(40)
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Table 4.3: Experiment 3 - The effects of paroxetine (P) 20mg and lorazepam
(L) lm g with and without alcohol on a battery of tests (see text for 
abbreviations of tests). Standard errors are given in parentheses, 
(continued).
Base­
line
1
hour
5
hours
10
hours
Base­
line
1
hours
5
hours
10
hours
Base­
line
1
hour
5
hours
10
hours
STR (ms)
P20mg 871
(25)
848
(26)
770
(13)
770
(20)
855
(15)
816
(26)
783
(15)
803
(27)
755
(55)
799
(28)
789
(29)
737
(20)
Llm g 813
(25)
826
(25)
807
(13)
768
(19)
806
(15)
779
(25)
773
(15)
750
(27)
867
(55)
773
(28)
748
(29)
741
(20)
Placebo 813
(25)
837
(25)
788
(13)
758
(19)
792
(15)
813
(25)
764
(16)
783
(29)
746
(59)
727
(30)
745
(29)
739
(19)
LARS (mm)
P20mg 50.7
(1.0)
55.5
(1.2)
56.3
(1.7)
52.5
(1.5)
52.3
(1.0)
54.9
(1.2)
52.5
(0.8)
52.9
(1-3)
51.1
(0.7)
57.3
(0.9)
55.1
(1.3)
51.2
(0.9)
Llm g 50.8
(1.0)
58.6
(1.2)
56.6
(1.7)
51.8
(1.5)
52.5
(1.0)
53.5
(1.2)
53.3
(0.8)
51.1
(1.3)
51.7
(0.7)
56.2
(0.9)
52.8
(1.3)
50.0
(0.9)
Placebo 52.1
(1.0)
58.3
(1.2)
55.6
(1.8)
53.4
(1.5)
50.0
(1.0)
51.8
(1.3)
53.7
(0.8)
52.3
(1.3)
50.0
(0.7)
56.6
(0.9)
54.7
(1.3)
49.9
(0.9)
D ayl Day 13 Day 14 D ayl Day 13 Day 14
GTS (mm) QOS (mm)
P20mg 54.7 (2.7) 60.4 (2.7) 58.3 (2.2) 54.6 (3.0) 57.8 (2.5) 58.3 (2.3)
Llm g 60.0 (2.9) 55.7 (2.7) 60.1 (2.2) 57.6 (3.0) 52.3 (2.5) 52.6 (2.3)
Placebo 56.9 (2.7) 59.9 (2.7) 54.1 (2.2) 56.6 (3.0) 55.6 (2.5) 52.2 (2.3)
AFS (mm) BFW (mm)
P20mg 57.0 (2.0) 61.0(2.5) 55.5 (2.7) 53.9(1.2) 59.5 (1.6) 55.4(1.2)
L lm g 58.9 (2.0) 52.5 (2.4) 58.1 (2.7) 54.6(1.2) 52.7(1.6) 53.3 (1.2)
Placebo 58.1 (2.0) 53.7 (2.6) 57.3 (2.9) 55.0(1.2) 55.1 (1.6) 53.8(1.2)
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4.4 Experiment 4: The effects of fluvoxamine and dothiepin on 
psychomotor abilities in healthy volunteers
4.4.1 Objective
The aim of this study was to evaluate the effects of single doses of fluvoxamine 50mg 
and fluvoxamine lOOmg on tests of cognitive and psychomotor function in healthy 
volunteers. Dothiepin 75mg was included as a verum condition.
4.4.2 Methods and measures
The general methods and measures are outlined in Chapter 3.
Subjects: 12 healthy male volunteers aged 21-50 years old (mean ) entered the study. 
All of these completed the study and none suffered serious adverse events.
Design: The study was a randomised placebo controlled four way cross-over design in 
which each subject acted as their own control. The treatment sequence was balanced 
for residual effects using a Latin square design.
Drugs: The treatments were single doses of fluvoxamine 50mg, fluvoxamine lOOmg, 
dothiepin 75mg and placebo. There was a one week washout period between each 
treatment.
Procedure: Following consent and medical examination visits, subjects were required 
to attend the test centre on four occasions. On each of these they were tested pre-dose, 
then at 1, 2, 3, 4 and 6 hours post dose.
Test Battery: The test battery consisted of Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), Compensatory Tracking Task (CTT), Sternberg Memory 
Scanning Task (SMT), CFF, CRT, SMT, CTT and Line Analogue Rating Scales for
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sedation (LARS). The Milford Epworth Sleepiness Scale (MESS) was completed at 
the end of each study day. Actigraphs were worn for the duration of each study day.
Analysis: The data from the psychometric tests were analysed using repeated 
measures analyses of variance (ANOVA). Post hoc testing for differences between 
individual means were carried out using the Newman-Keuls test. Statistical 
significance was set at p<0.05.
4.4.3 Results
The mean response data are presented in Table 4.4.
CFF: The ANOVA revealed a significant treatment effect (F(3, 33) = 14.87, 
pO.OOOOl), time (F(5, 55) = 23.30, p<0.000001) and an interaction between 
treatment and time (F(15, 165) = 5.60, p<0.000001). Post-hoc analysis revealed that 
dothiepin results were significantly impaired compared to placebo at 2, 3, 4 and 6 
hours post dose (p<0.005). The higher dose of fluvoxamine increased the thresholds at 
3 and 6 hours post dose (p<0.05). Fluvoxamine 50 mg and placebo were statistically 
indistinguishable (Figure 4.15).
CRT: ANOVA showed a significant effect of treatment in the recognition (RRT) 
component of the CRT task (F(3, 33) = 5.71, p<0.005). An effect of time (F(5, 55) = 
7.49, p<0.00005) and an interaction between treatment and time were also apparent 
(F(15, 165) = 1.85, p<005). Post hoc tests demonstrated that dothiepin produced a 
significantly slower RRT than placebo (P<0.02) at 4 hours post dose whereas 
fluvoxamine had no effect. Significant treatment effects were also observed in motor 
(MRT) (F(3, 33) = 3.37, p<0.05) and total (TRT) (F(3, 33) = 5.79, p<0.005) reaction 
times. Post hoc analysis showed that dothiepin impaired MRT (p<0.05) and TRT 
(p<0.00005) at 4 hours post dose. Fluvoxamine lOOmg produced significantly faster 
MRT scores (P<0.05) than placebo at the 2 hour time point (Figure 4.16).
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CTT: No significant treatment effects were revealed, however there were 
differences at between the scores at the different time points (F(5, 55) = 5.10, p<0.05). 
This was mainly due to the fact that performance deteriorated over the test day. There 
were no significant treatment x time interactions.
SMT: There no significant differences observed in this variable.
LARS: A main treatment effect was observed in the ANOVA (F(3, 33) = 3.08, 
p<0.05) and post-hoc analysis showed that dothiepin produced significantly higher 
ratings of sedation than both doses of fluvoxamine (p<0.05). Although there was a 
trend for dothiepin to be more sedative than placebo, this did not reach significance 
(p=0.055).
MESS: ANOVA revealed a main effect of drug (F(3, 33) = 9.44, p<0.0002) and 
post hoc analysis of this effect found dothiepin to be significantly more sedative than 
placebo (p<0.005) (Figure 4.17).
Actigraphy: A  significant main effect of drug was apparent on the actigraph data 
(F(3, 33) = 4.38, p<0.02). This was mainly due to the fact that fluvoxamine 50mg and 
lOOmg significantly increased activity when compared to dothiepin but not placebo. 
The data revealed dothiepin to be more sedative compared to placebo, although this 
difference failed to reach significance (p=0.055).
4.4.4 Discussion
As with the verums in Experiments 1, 2 and 3, dothiepin impaired performance on the 
critical flicker fusion and choice reaction time tests (Fairweather et al, 1996a). The 
Milford Epworth Sleepiness Scale was used for the first time in this study, and was 
found to be sensitive to the sedating effects of dothiepin in that subjects rated 
themselves more likely to fall asleep in a number of every day situations. Although 
there was a trend for dothiepin to increase ratings of tiredness in the Line Analogue 
Rating Scales for Sedation relative to placebo, this just failed to reach significance
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(p=0.055). In contrast to the effects of dothiepin, the lower dose of fluvoxamine was 
no different to placebo on any of the tests, however, fluvoxamine lOOmg had a similar 
profile to paroxetine (Experiment 3) in that it significantly increased critical flicker 
fusion thresholds and increased speed of response on the choice reaction time task. 
The actigraphy data corresponded well with the objective findings and subjective 
reports in that activity throughout the day was less with dothiepin than with any other 
treatment (although this effect was not significant; p=0.055). No differences were 
found for dothiepin or fluvoxamine on the compensatory tracking task or short term 
memory.
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Table 4.4: Experiment 4 - The effects of fluvoxamine (F) 50mg, fluvoxamine 
(F) lOOmg and dothiepin (D) 75mg on a battery of tests (see text 
for abbreviations of tests). SDs are given in parentheses.
Baseline 1 hour 2 hours 3 hours 4 hours 6 hours
CFF (Hz)
F50mg 31.9(1.8) 31.0(1.7) 30.6(1.8) 30.6(2.1) 31.2(1.9) 30.5(1.6)
F lOOmg 31.3 (1.3) 30.5(1.6) 31.1 (1.8) 31.2(1.6) 31.2(1.7) 31.3(1.7)
D75mg 31.5(2.0) 30.2 (2.4) 28.8 (2.4) 28.4 (5.2) 28.9 (2.4) 28.8(1.9)
Placebo 31.8(1.7) 30.7(2.0) 30.6(2.0) 30.0(1.9) 30.1 (2.1) 29.9(1.7)
RRT (ms)
F50mg 407 (39) 419 (36) 415 (35) 416(35) 424 (40) 422 (40)
F lOOmg 405 (26) 411 (30) 433 (39) 415 (30) 419 (38) 415 (27)
D75mg 414 (35) 428 (49) 435 (38) 448 (49) 458 (45) 434 (40)
Placebo 414 (36) 433 (36) 424(41) 426 (35) 431 (44) 430 (33)
MRT (ms)
F50mg 221 (50) 230 (49) 239 (56) 239 (55) 225 (60) 216 (37)
F lOOmg 226 (44) 245 (58) 266 (44) 236 (48) 248 (52) 239 (49)
D75mg 222 (53) 236 (53) 258 (44) 261 (57) 280 (56) 254 (41)
Placebo 222 (50) 222 (56) 226 (49) 248 (43) 235 (54) 242 (58)
TRT (ms)
F50mg 628 (75) 650 (77) 654 (75) 656 (83) 649 (81) 638 (66)
F lOOmg 631(53) 655 (68) 699 (62) 651(63) 667 (67) 655 (59)
D75mg 635 (76) 664 (81) 693 (66) 710(95) 738 (77) 689 (70)
Placebo 636 (71) 654 (74) 650 (75) 674 (58) 666 (82) 672 (74)
SMT (ms)
F50mg 902 (75) 889 (84) 887 (80) 873 (90) 866 (75) 877 (95)
F lOOmg 941 (172) 922(119) 903 (115) 891 (101) 892 (103) 893 (111)
D75mg 913(116) 896 (106) 901 (101) 915(117) 919(138) 930(113)
Placebo 910(117) 906 (97) 913(117) 916(117) 874 (87) 904 (95)
RMS (rms)
F50mg 48.7(1.4) 50.2 (2.4) 50.2 (3.1) 48.5 (2.0) 49.4 (2.0) 48.7 (2.7)
F lOOmg 49.9 (1.6) 49.9 (1.9) 49.8 (2.2) 49.8 (2.2) 49.7 (2.7) 49.7 (2.0)
D75mg 49.2 (2.8) 49.7 (1.7) 48.7 (2.9) 49.9 (2.5) 50.2 (2.5) 51.1 (4.0)
Placebo 49.5 (2.7) 49.3 (3.0) 48.2 (2.6) 49.5 (1.8) 49.6 (2.5) 50.1 (2.3)
RT (ms)
F50mg 747 (72) 777(72) 768 (60) 790 (45) 777 (55) 801(97)
F lOOmg 733 (39) 796 (109) 781 (75) 771 (54) 761 (36) 772 (54)
D75mg 731 (62) 764 (65) 802 (56) 815(153) 814 (86) 802 (122)
Placebo 762 (45) 767 (40) 782 (65) 795 (57) 774 (40) 792 (42)
LARS (mm)
F50mg 51.5 (5.9) 51.3 (5.5) 50.5 (3.7) 49.7 (5.0) 51.6 (3.8) 51.0 (5.1)
F lOOmg 51.1 (3.5) 52.7 (4.3) 51.4(4.7) 50.3 (3.8) 51.2(4.4) 50.9 (3.8)
D75mg 51.6 (5.7) 53.3 (5.9) 53.2 (3.6) 55.2 (4.5) 53.1 (4.6) 54.0 (4.4)
Placebo 50.9 (4.7) 51.3 (8.0) 50.2 (4.7) 49.7 (6.7) 51.6(4.9) 51.1 (4.7)
Daily Score
MESS (mm) Actigraph (counts)
F50mg 43.1 (6.3) 38.4 (7.0)
FlOOmg 47.3 (8.8) 37.7 (5.8)
D75mg 42.7 (6.2) 35.8 (5.7)
Placebo 34.2 (9.2) 31.9 (5.8)
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4.5 Experiment 5: The psychomotor and cognitive effects of litoxetine in 
healthy volunteers
4.5.1 Objective
The objective of this experiment was to investigate the effects of a range of doses of 
litoxetine (2.5mg, 5mg, lOmg and 25mg) following single and repeated doses on a 
test battery of cognitive and psychomotor measures in young and middle-aged healthy 
volunteers.
4.5.2 Methods and measures
The general methods and measures are outlined in Chapter 3.
Subjects: 19 healthy female volunteers aged 18-35 years old or 40-65 years old 
entered the study. The overall mean age was 36.5 years. 19 subjects were enrolled to 
allow for the completion of 15. Only 10 subjects (7 middle aged, 3 young) completed 
all 5 treatment phases. Of the 9 dropouts, 5 were due to non-medical reasons, and 4 
were the results of adverse effects (a variable combination of headache, dizziness, 
syncope, somnolence, nausea and vomiting). There were no serious adverse events.
Design: The study was double blind, randomised placebo controlled five way cross­
over study where each subject acted as their own control. The treatment sequence was 
balanced for residual effects using a Latin square design.
Drugs: The treatments were litoxetine 2.5mg, litoxetine 5mg, litoxetine lOmg, 
litoxetine 25mg and placebo. Each treatment was given twice daily for four days and 
once on day five. There was a nine day washout period between each treatment.
Procedure: Following consent and medical examination visits, subjects were required 
to attend the test centre on 10 occasions (days 1 and 4 of each treatment period). On 
each of these they were tested pre-dose, then at 2, 4, 6, 8 and 12 hours post dose. A
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second dose of medication was administered at 12 hours following the initial dose. 
Subjects were required to stay at the test centre overnight, where they completed the 
LSEQ the following morning.
Test Battery: The test battery consisted of Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), Compensatory Tracking Task (CTT), Sternberg Memory 
Scanning Task (SMT), the Stroop Task (STR) and LARS. The LSEQ was completed 
the morning after each test day.
Analysis: The data from the psychometric tests were analysed using repeated 
measures analyses of variance (ANOVA). Comparisons between means were 
performed using two-tailed T-tests, with statistical significance set at p<0.05. In 
addition, the data from the individual time points were pooled together and averaged. 
The data from those subjects who withdrew from the study were excluded from the 
analysis.
4.5.3 Results
The mean response data are presented in Table 4.5.
CFF: For CFF a significant difference between drugs was found (F(4, 525) = 
23.17, p<0.00001). Post hoc tests showed that litoxetine lOmg and 25mg increased 
CFF scores compared to placebo on day 1 at 4, 6 and 8 hours post dose (Figure 4.18). 
CFF scores were higher with litoxetine 25mg at the 12 hour test point. No significant 
effects were observed on day 4 of treatment. The effects of litoxetine 5mg only 
reached significance when all data was averaged over time. The pooled data also 
demonstrated that the effects on CFF occurred in a dose dependent manner. Small 
differences were observed in the baseline scores but these were not significant.
CRT:. A  significant drug effect was evident in recognition (RRT) reaction time 
(F4, 525) = 2.48, p<0.05) and this was accounted by the fact that litoxetine 5mg 
produced faster responses than the 25mg dose at 4 hours post dose on day 1. No
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effects of drug were observed on motor (MRT) or total (TRT) reaction times and no 
differences from placebo were detected in any of the CRT components.
CTT: ANOVA demonstrated that there were significant drug effects for both the 
reaction time (RT) (F(4, 520) = 11.06, p<0.0001) and accuracy (RMS) (F(4, 520) = 
86.96, p<0.0001) components of this task. Further analysis revealed that litoxetine 
2.5mg impaired RT 2 hours post on day 4 compared to placebo and all other doses of 
drug. At 8 hours on day 4 litoxetine 2.5mg was significantly slower than litoxetine 
25mg. Litoxetine 25mg was only different to placebo when all data was pooled. For 
RMS, litoxetine 5mg was significantly less accurate than both placebo and litoxetine 
1 Omg at 12 hours on day 4 (Figure 4.19) and in the time-averaged data.
SMT: A significant main effect of drug was revealed (F(4, 519) = 4.50, 
p<0.002)and post hoc tests demonstrated that litoxetine 25mg was significant worse 
than lOmg at 2 and 4 hours post dose on day 1. Drug-placebo differences were only 
apparent when the data was pooled, i.e. litoxetine 5mg resulted in improved scores 
versus placebo.
STR: There were significant differences between drugs in both the matched (F(4, 
520) = 5.61, p<0.0001) and unmatched (F(4, 520) = 4.80, p<0.001) scores. In the 
former, litoxetine 5mg was significantly better than placebo and all other doses of 
litoxetine when the individual time points were averaged over time. There were no 
other significant differences from placebo at individual time points. In the unmatched 
analysis, the only significant finding was where litoxetine 5mg was better than lOmg 
a 8 hours on day 1.
LARS: No significant differences were evident in the LARS data.
LSEQ: There were no significant results in any of the LSEQ parameters, although 
all active treatments produced slightly poorer ratings of ease of getting to sleep (GTS) 
and perceived quality of sleep (QOS).
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4.5.4 Discussion
A range of doses of the SSRI litoxetine were evaluated in this study (Fairweather et al, 
1995a). A criticism of this experiment is that no verum condition was included; this 
was the decision of the company sponsoring this particular study. Nevertheless, the 
test battery was shown to be sensitive in that litoxetine was shown to significantly 
different to placebo in a number of tests. The two highest doses (lOmg and 25mg) had 
a similar profile to paroxetine 20mg and fluvoxamine lOOmg on critical flicker fusion 
on day 1, where significant improvements were observed. Following four days of 
dosing, these improvements were apparent but were not significantly different from 
placebo. The only other significant effects were observed on day 4 where litoxetine 
2.5mg impaired tracker reaction time and 5mg increased tracking error, however these 
differences were only detected at one time point and may be the result of a Type I 
error. Litoxetine had no effect on any component of the choice reaction time task, and 
did not affect subjective ratings of sedation or sleep. Any other main effects were 
weak in that differences could only be detected when data from individual time points 
were pooled over time, i.e. short term memory and Stroop tests. Even though only the 
two highest doses of litoxetine increased critical flicker fusion, significant dose related 
increases were observed when the separate data points were pooled together over 
time.
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Table 4.5: Experiment 5 - The effects of litoxetine (L) 2.5mg, litoxetine (L)
5mg, litoxetine (L) lOmg and litoxetine (L) 25mg on a battery of 
tests (see text for abbreviations of tests). SDs are given in 
parentheses.
Base­
line
2
hours
4
hours
6
hours
8
hours
12
hours
Base­
line
2
hours
4
hours
6
hours
8
hours
12
hours
CFF (Hz)
L2.5mg 26.8
(1.8)
26.9
(1.5)
26.9
(1.4)
26.9
(1.9)
27.3
(2.1)
27.3
(1.9)
27.5
(1.9)
26.9
(0.8)
27.0
(1.2)
27.0
(1.6)
27.2
(1.5)
27.0
(1.4)
L5mg 27.7
(2.0)
27.8
(1.7)
27.8
(1.7)
27.6
(1.7)
27.1
(1.9)
27.8
(1.7)
28.3
(2.0)
27.9
(2.0)
27.6
(1.8)
27.6
(1.3)
27.9
(1.6)
28.0
(1.3)
LlOmg 28.1
(1.8)
27.9
(1.8)
28.0
(2.7)
28.0
(1.4)
28.3
(2.1)
27.7
(1.2)
28.0
(1.4)
27.8
(1.8)
27.4
(1.5)
27.5
(1.4)
27.7
(1.5)
27.7
(1.7)
L25mg 27.2
(1.5)
27.5
(2.2)
27.9
(1.8)
28.0
(1.6)
28.3
(1.9)
28.2
(1.7)
28.1
(1.6)
28.1
(1.9)
2 7 .9
(1.8)
28.1
(1.9)
27.7
(1.8)
27.9
(2.0)
Placebo 27.6
(1.6)
26.8
(1.6)
26.6
(1.5)
26.7
(1.6)
26.9
(1.9)
26.8
(1.6)
27.1
(1.3)
27.1
(2.2)
26.8
(1.4)
26.9
(2.1)
27.3
(2.0)
27.3
(1.8)
RRT (ms
L2.5mg 396
(76)
441
(88)
414
(72)
406
(49)
434
(105)
399
(61)
408
(57)
433
995)
436
(980
428
(97)
407
(49)
389
(47)
L5mg 395
(54)
396
(49)
395
(59)
409
(50)
430
(59)
388
(44)
397
(54)
395
(39)
402
(50)
400
(52)
389
(56)
404
(52)
LlOmg 406
(41)
409
(53)
431
(78)
407
(51)
425
(87)
414
(70)
409
(35)
401
(41)
434
(51)
411
(54)
426
(50)
409
(80)
L25mg 410
(62)
431
(64)
461
(115)
435
(69)
410
(48)
410
(60)
393
(51)
407
(52)
391
(39)
405
(51)
411
(45)
402
(60)
Placebo 421
(56)
436
(99)
411
(60)
434
(51)
400
(72)
409
(52)
399
(53)
413
(51)
411
(46)
413
(48)
415
(68)
399
(42)
MRT(ms)
L2.5mg 254
(57)
543
(45)
244
944)
239
(49)
230
(43)
242
(54)
240
(31)
243
(47)
236
(44)
241
(55)
219
(40)
256
(45)
L5mg 245
(49)
245
(41)
242
(40)
235
(48)
249
(49)
251
(55)
239
(58)
245
(45)
25
(38)
234
(43)
231
(46)
240
(61)
LlOmg 245
(37)
248
(38)
250
(45)
247
(62)
234
(43)
252
(60)
240
(45)
243
(42)
233
(52)
240
(59)
236
(57)
229
(44)
L25mg 243
(57)
261
(59)
255
(39)
247
(44)
243
(58)
261
(47)
242
(41)
242
(56)
243
(55)
240
(46)
240
(41)
244
(57)
Placebo 243
(51)
248
(65)
241
(43)
248
(52)
249
(44)
250
(46)
249
(46)
237
(59)
237
(48)
229
(47)
235
(54)
243
(58)
TRT (ms)
L2.5mg 650
(111)
684
(109)
658
(93)
645
(83)
664
(141)
641
(95)
648
(73)
676
(123)
672
(126)
669
(128)
626
(75)
645
(72)
L5mg 640
(84)
641
(78)
637
(62)
644
(87)
678
(91)
639
(82)
636
(95)
640
(63)
653
(73)
633
(630
620
(87)
645
(95)
LlOmg 651
(67)
657
(62)
681
(86)
654
(65)
659
(105)
667
(106)
649
(57)
644
(67)
667
(76)
652
(89)
662
(97)
657
(107)
L25mg 653
(93)
692
(105)
717
(129)
682
(92)
652
(88)
671
(88)
635
(77)
649
(87)
634
(76)
645
(87)
651
(65)
646
(89)
Placebo 664
(85)
683
(101)
652
(86)
682
(76)
649
(79)
660
(68)
648
(70)
650
(75)
648
(79)
642
(74)
650
(90)
641
(80)
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Table 4.5: Experiment 5 - The effects of litoxetine (L) 2.5mg, litoxetine (L)
5mg, litoxetine (L) lOmg and litoxetine (L) 25mg on a battery of 
tests (see text for abbreviations of tests). SDs are given in 
parentheses. (Continued).
Base­
line
2
hours
4
hours
6
hours
8
hours
12
hours
Base­
line
2
hours
4
hours
6
hours
8
hours
12
hours
SMT (ms)
L2.5mg 587
(75)
620
(110)
611
(124)
661
(125)
636
(158)
626
(133)
654
(123)
654
(140)
626
(136)
652
(134)
618
(107)
630
(105)
L5mg 652
(145)
655
(130)
629
(52)
637
(63)
649
(161)
589
(84)
614
(106)
610
(114)
622
(HO)
616
(120)
605
(114)
561
(59)
LlOmg 646
(113)
647
(109)
628
(H I)
661
(88)
648
(123)
650
(84)
639
(135)
647
(108)
677
(127)
668
(123)
666
(92)
632
(121)
L25mg 682
(165)
708
(188)
708
(148)
693
(H I)
628
(123)
673
(130)
604
(113)
623
(HO)
649
(137)
652
(91)
596
(95)
618
(123)
Placebo 647
(119)
644
(153)
682
(198)
646
(145)
651
(128)
588
(82)
601
(109)
707
(176)
682
(167)
701
(183)
686
(215)
595
(106)
RMS (rms)
L2.5mg 10.5
(5.8)
11.7
(9.8)
11.7
(7.5)
9.32
(2.2)
10.5
(5.3)
10.2
(5.7)
9.9
(6.7)
11.5
(6.9)
10.0
(4.7)
10.8
(4.0)
10.8
(9.9)
8.0
(2.7)
L5mg 9.0
(2.8)
11.3
(7.4)
14.8
(13.8)
12.2
98.1)
11.4
(7.5)
9.6
(4.9)
9.3
(3.6
9.2
(3.1)
10.3
(5.9)
12.9
(14.0)
11.4
(8.7)
13.3
(11.8)
LlOmg 10.2
(5.1)
9.7
(3.6)
12.2
(12.7)
9.8
(2.8)
9.9
(3-9)
8.4
(1.9)
8.4
(2.9)
8.2
(2.3)
8.7
(2.70
9.8
(4.0)
8.9
(3.0)
8.0
(2.2)
L25mg 9.2
(3.0)
11.5
(5.4)
11.3
(6.3)
10.2
(4.1)
10.4
(4.3)
9.3
(3.7)
10.1
(5.3)
9.7
(4.4)
9.2
(2.9)
9.4
(2.7)
8.7
(2.9)
9.2
(4.5)
Placebo 10.1
(4.7)
12.0
(6.9)
10.6
(5.9)
9.4
(2.6)
9.2
(3-4)
8.7
(3.6)
9.8
(4.1)
8.7
(2.7)
7.8
(2.0)
8.4
(4.0)
8.9
(3.9)
7.7
(2.3)
RT (ms)
L2.5mg 401
(56)
435
(61)
430
(63)
461
(69)
434
(61)
455
(65)
414
(81)
483
(76)
443
(81)
465
(72)
474
(63)
437
(44)
L5mg 413
(104)
417
(66)
425
(82)
428
(69)
422
(83)
429
(67)
408
(84)
428
(77)
451
(85)
467
(86)
438
(68)
442
(89)
LlOmg 411
(65)
434
(73)
445
(57)
456
(68)
450
(74)
447
(58)
434
(65)
425
(42)
434
(45)
452
(59)
446
(38)
436
(55)
L25mg 380
(47)
406
(74)
410
(62)
416
(75)
426
(76)
409
(54)
408
(47)
422
(66)
416
(48)
436
(52)
422
(63)
411
(25)
Placebo 396
(68)
416
(69)
441
(55)
453
(68)
437
(53)
432
(50)
419
(61)
430
(56)
436
(52)
438
(59)
429
(64)
426
(44)
STR (ms)
L2.5mg 282
(7)
282
(7)
284
(7)
283
(8)
283
(12)
285
(11)
286
(10)
283
(10)
284
(9)
282
(8)
282
(5)
284
(9)
L5mg 281
(7)
282
(11)
282
(6)
284
(7)
280
(6)
280
(6)
280
(6)
281
(7)
281
(8)
280
(6)
282
(7)
278
(5)
LlOmg 284
(7)
283
(7)
290
(13)
284
(5)
285
(8)
281
(7)
284
(7)
280
910)
284
(7)
284
(9)
285
(7)
282
(7)
L25mg 288
(9)
286
(7)
287
(6)
287
(7)
285
(4)
288
(6)
283
(7)
282
(5)
284
(11)
279
(11)
281
(5)
282
(7)
Placebo 282
(7)
286
(13)
287
0 1 )
285
(8)
282
(6)
284
(7)
283
(7)
283
(7)
281
(7)
283
(9)
284
(15)
282
(9)
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Table 4.5: Experiment 5 - The effects of litoxetine (L) 2.5mg, litoxetine (L)
5mg, litoxetine (L) lOmg and litoxetine (L) 25mg on a battery of 
tests (see text for abbreviations of tests). SDs are given in 
parentheses. (Continued).
Base­
line
2
hours
4
hours
6
hours
8
hours
12
hours
Base­
line
2
hours
4
hours
6
hours
8
hours
12
hours
LARS (mm)
L2.5mg 51.3
(2.2)
55.3
(9.4)
56.8
(11.0)
57.4
(14.3)
52.0
(7.5)
53.9
(9.5)
52.3
(4.7)
53.4
(5.4)
52.6
(5.9)
55.0
(4.6)
52.5
(4.0)
51.6
(3.8)
L5mg 50.1
(1.0)
51.0
(1.5)
51.5
(2.7)
52.9
(5.2)
55.0
(8.1)
52.8
(2.9)
49.2
(3.4)
54.2
(8.0)
54.9
(5.2)
51.8
(3.0)
48.4
(6.8)
51.7
(3.5)
LlOmg 50.8
(2.7)
54.6
(6.2)
55.1
(11.4)
55.4
(6.6)
51.8
(8.5)
52.6
(6.5)
50.4
(0.9)
52.4
(4.5)
53.1
(3.4)
52.8
(4.6)
50.7
(2.6)
55.8
(12.0)
L25mg 50.0
(0.0)
52.9
(3.3)
53.6
(6.3)
52.6
(3.2)
50.5
(5.2)
51.9
(3.0)
50.5
(2.0)
51.8
(4.4)
51.6
(3.6)
51.2
(3.9)
52.3
(4.4)
51.2
(2.2)
Placebo 50.0
(0.0)
55.2
(7.3)
53.3
(4.5)
54.3
(6.7)
52.0
(3.2)
53.8
(7.6)
50.0
(0.0)
51.0
(2.2)
52.6
(3.3)
56.0
(5.0)
52.8
(4.6)
53.5
(6.4)
D ayl Day 4 D ayl Day 4
GTS (mm) QOS (mm)
L2.5mg 44.0 (10.7) 45.4(11.9) 44.9 (14.2) 46.5 (11.1)
L5mg 46.4 (7.1) 44.3 (8.4) 51.7 (9.6) 48.5 (8.0)
LlOmg 44.7 (14.0) 40.6 (16.3) 44.8 (9.4) 48.2 (15.4)
L25mg 45.4 (9.9) 47.4 (7.8) 43.2(11.1) 46.4(11.8)
Placebo 48.4 (10.8) 48.9 (7.6) 50.4 (9.4) 52.2 (8.0)
AFS (mm) BFW (mm)
L2.5mg 45.4 (12.9) 48.8 (9.4) 48.2 (10.4) 51.8 (5.9)
L5mg 48.6 (7.9) 48.1 (5.6) 51.7 98.2) 49.5 (8.2)
LlOmg 46.6 (7.7) 50.7 (15.7) 47.9(11.4) 51.6 (13.0)
L25mg 44.9 (9.0) 47.9 (9.0) 46.9 (9.4) 48.4 (9.2)
Placebo 48.1 (4.5) 51.0(4.7) 49.9 (6.4) 50.2(11.0)
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4.6 Experiment 6: A double blind study of psychomotor function following 
citalopram and dothiepin
4.6.1 Objective
The aim of this study was to compare the effects of a range of doses of citalopram 
(lOmg, 20mg and 40mg) following single and repeated dosing on a battery of 
cognitive and psychomotor tests. Dothiepin 75mg was included as a verum on days 1 
and 8 of drug administration.
4.6.2 Methods and measures
The general methods and measures are outlined in Chapter 3.
Subjects: 30 healthy male and female volunteers aged 18-60 years old were screened 
for the study to allow for 20 evaluable subjects. 14 of these (five males and nine 
females with a mean age of 29.3 years) completed the study. Of the 30 screened, nine 
were withdrawn due to exclusion criteria. A further seven dropped out during the 
study, two due to work commitments, one withdrew consent, three due to adverse 
events (twitching, dry mouth, headache, drowsiness, nausea and vomiting). One 
subject withdrew as a result of a serious adverse event, described as a “fit” however, 
no causal link was established between the event and any of the test medications.
Design: This study was a double blind, randomised placebo controlled five way cross­
over design where each subject acted as their own control. The treatment sequence 
was balanced for residual effects using a Latin square design.
Drugs: The treatments were citalopram lOmg, citalopram 20mg, citalopram 40mg 
daily for eight days and dothiepin 75mg once on days 1 and 8 (placebo on days 2-7). 
There was a six day washout period between each treatment phase. Medication was 
presented in a double blind, double dummy fashion. Each treatment phase lasted for 
eight days.
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Procedure: Following consent and medical examination visits, subjects were required 
to attend the test centre on 10 occasions (days 1 and 8 of each treatment). On each of 
these they were tested pre-dose, then at 2, 4, 5 and 8 hours post dose. On days 2-7 
subjects were required to self-administer the drugs.
Test Battery: The test battery consisted of Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), Compensatory Tracking Task (CTT), Sternberg Memory 
Scanning Task (SMT) and Line Analogue Rating Scales for sedation (LARS). The 
Milford Epworth Sleepiness Scale (MESS) was completed at the end of each test day.
Analysis: Three way repeated measures analyses of variance (ANOVA) were 
performed on the psychometric data. Post hoc testing for differences between 
individual means were carried out using Newman-Keuls test. Statistical significance 
was set at p<0.05.
4.6.3 Results
The mean response data are presented in Table 4.6.
CFF: ANOVA yielded significant effects of treatment (F(4,52)=20.41, p<0.000001) 
and time of testing (F(4,52)=4.81, p<0.01). There were also significant interactions 
between treatment and time (F(16, 208)=4.68, p<0.000001) and between treatment, 
day and time (F(16,208)=3.24, p=0.00005). Post hoc tests revealed that dothiepin 
significantly reduced CFF (p<0.05) at 2 and 4 hours post dose on day 1 and at 2, 4 and 
8 hours on day 8 (Figure 4.20). Citalopram significant increased CFF relative to 
placebo on day 1 (citalopram lOmg at 5 and 8 hours; citalopram 20mg and 40mg at 4, 
5 and 8 hours) and day 8 (citalopram lOmg at 2 hours; citalopram 40mg at 2, 4, 5 and 
8 hours).
CRT: No significant main effect of treatment was observed in the recognition 
component (RRT) though effects of day (F(l, 13) = 9.00, p=0.01) and time (F(4, 52) =
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2.77, p<0.05) were significant. Post-hoc tests revealed that dothiepin slowed RRT on 
day 1 at 5 hours post dose (Figure 4.21) compared to placebo (and citalopram 20 and 
40mg). No significant differences were revealed on day 8. Citalopram was not 
significantly different to placebo.
There were significant differences between treatments (F(4, 52) = 2.91, p<0.05) 
and test time (F(4, 52) = 5.96, p=0.0005) on motor reaction time (MRT). Further 
analysis demonstrated that dothiepin (dayl; 2 and 4 hours post dose) and citalopram 
lOmg (dayl; 4 hours post dose) significantly slowed reaction time compared to 
placebo (p<0.05). The ANOVA on the total reaction time (TRT) data produced 
significant main effects of day (F(l, 13) = 5.44, p<0.05) and time (F(4, 52) = 4.10, 
p<0.01) but not of treatment. Post hoc tests showed that the only significant difference 
(p<0.05) was found with dothiepin compared to all the other treatments (except 
citalopram lOmg) at 5 hours on day 1.
CTT. The results obtained from this task were variable and no significant 
differences were revealed.
SMT: Here, there was a significant main effect of day, with day 8 producing faster 
responses overall (F(l, 13) = 23.07, p<0.0005). There was also a significant 
interaction between treatment and time of testing (F(16, 208) = 2.00, p=0.01), with 
dothiepin causing an increase in reaction time (poorer short-term memory) over the 
testing period, an effect not apparent with the other treatments. Dothiepin was 
significantly different from placebo on day 1 at 5 hours (p<0.05). Citalopram was not 
significantly different to placebo at any time point (Figure 4.22).
LARS: Significant effects of treatment (F(4, 44) = 2.92, p<0.05) and time (F(4, 44) 
= 6.18, p<0.0005) were obtained from subjective ratings of sedation (LARS). This 
was mainly due to increased ratings of sedation with dothiepin as compared to 
citalopram lOmg on day 1, and to elevated scores for dothiepin, citalopram 20mg and 
citalopram 40mg compared to citalopram lOmg on day 8. Ratings were higher 
(indicating more subjective sedation) on sub-chronic dosing, though there was no 
significant day effect. There were no significant drug-placebo differences at any time.
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MESS: There was a main effect of treatment on the MESS, almost entirely due to 
dothiepin producing increased ratings of sleepiness on day 1 (F(4, 48) = 2.56, 
p=0.05). Post hoc analysis revealed that dothiepin was significantly more sedative 
than placebo on day 1 (Figure 4.23). Citalopram was not significantly different to 
placebo.
4.6.4 Discussion
In this experiment citalopram and placebo were administered for eight days whilst 
dothiepin was restricted to test days only (days 1 and 8) (Fairweather et al, 1996b). 
The results show that verum dothiepin impaired performance on all of the tests except 
for compensatory tracking. All doses of citalopram on the other hand, significantly 
elevated critical flicker fusion thresholds, and this effect persisted for eight days with 
the highest dose. Citalopram lOmg slowed motor reaction time at one test point, 
however the data for this test were very variable and caution must be exercised in 
interpreting these results. Given the patterns seen in the other psychometric data, and 
the results for this test with 20mg and 40mg, it is possible that the citalopram lOmg 
result is a Type I error. Interestingly, increased subjective sedation was reported on 
the Milford Epworth Sleepiness Scale (MESS) with dothiepin on day 1, but no drug- 
placebo differences were noted on the Line Analogue Rating Scale (LARS). The 
LARS were completed at the end of each test battery, where subjects were asked how 
they felt at that time. It is possible that the act of performing the tests was in itself 
“alerting”, therefore masking any mild effects of drug, whereas the MESS was 
completed once at the end of the day, and enquired as to how subjects felt during that 
day as a whole. This pattern is similar to that observed in Experiment 4. There were 
significant effects of time in this experiment, where total reaction time was faster on 
day 8 than on day 1: this may have been a practice effect although subjects were 
trained to a performance plateau prior to the study.
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Table 4.6: Experiment 6 - The effects of citalopram (C) lOmg, citalopram (C)
20mg, citalopram (C) 40mg and dothiepin (D) 75mg on a battery of 
tests (see text for abbreviations for tests). SDs are given in 
parentheses.
Base­
line
2
hour
4
hours
5
hours
8
hours
Base­
line
2
hours
4
hours
5
hours
8
hours
CFF (Hz)
ClOmg 31.6
(2.6)
31.7
(2.3)
31.9
(2.7)
31.9
(2.8)
31.8
(2.8)
31.9
(2.6)
32.3
(2.1)
31.7
(2.3)
31.7
(2.7)
31.0
(3.1)
C20mg 31.6
(2.1)
32.2
(2.6)
32.6
(2.6)
32.6
(2.2)
31.6
(2.9)
33.0
(2.6)
31.8
(2.5)
32.2
(2.6)
31.9
(2.9)
32.0
(2.8)
C40mg 32.0
(2.8)
32.8
(2.4)
32.7
(2.3)
32.6
(2.5)
32.3
(2.6)
32.2
(3.1)
32.5
(2.3)
32.8
(2.7)
32.5
(3.3)
32.3
(2.9)
D75mg 31.6
(2.5)
30.1
(2.6)
29.9
(3.1)
29.3
(2.9)
29.9
(3.1)
31.9
(2.1)
30.0
(2.5)
30.4
(2.6)
30.2
(2.9)
30.1
(2.8)
Placebo 31.9
(2.6)
31.7
(2.6)
30.9
(2.5)
30.4
(2.8)
30.2
(2.2)
31.0
(2.0)
31.0
(2.5)
31.4
(2.2)
30.7
(2.6)
30.7
(2.6)
RRT (ms)
ClOmg 370
(70)
383
(60)
397
(110)
434
(128)
393
(150)
382
(142)
378
(79)
382
(96)
377
(56)
383
(79)
C20mg 367
(60)
372
(46)
382
(55)
366
(51)
370
(79)
348
(32)
355
(40)
367
(75)
371
(70)
372
(85)
C40mg 422
(168)
398
(118)
396
(139)
403
(113)
398
126)
360
(62)
372
(70)
387
(124)
385
(81)
377
(74)
D75mg 367
(87)
397
(137)
402
(138)
483
(357)
366
964)
348
(43)
382
(99)
391
(132)
375
(60)
353
(52)
Placebo 380
(82)
369
(59)
411
(114)
403
(107)
395
(91)
374
(64)
393
(72)
393
(71)
397
(124)
382
(54)
MRT (ms)
ClOmg 264
(70)
275
(80)
289
(87)
292
(84)
270
(69)
273
(64)
275
(59)
290
(68)
288
(54)
283
(64)
C20mg 290
(76)
286
(78)
287
(74)
292
(73)
285
(70)
287
(66)
305
(70)
310
(70)
312
(66)
300
(53)
C40mg 266
(58)
272
(72)
288
(81)
275
(64)
268
(68)
279
(69)
288
(74)
297
(77)
301
(74)
286
(67)
D75mg 267
(57)
302
(61)
294
(65)
294
(63)
278
(61)
285
(60)
296
973)
308
(94)
297
(76)
297
(62)
Placebo 272
(67)
257
(66)
276
(86)
278
(68)
275
(72)
260
(76)
276
(91)
255
(83)
268
(99)
258
(72)
TRT (ms)
ClOmg 635
(88)
645
(126)
686
(125)
726
(134)
662
(153)
655
(132)
653
(90)
672
(113)
665
(92)
666
(104)
C20mg 657
(107)
658
(99)
668
(97)
658
(96)
655
(120)
635
(86)
660
(92)
676
(115)
682
(121)
672
(108)
C40mg 688
0 7 1 )
670
(148)
684
(175)
677
(125)
666
(150)
639
(117)
660
(124)
684
(171)
638
(177)
663
(106)
D75mg 634
(116)
699
(173)
695
(188)
777
(386)
644
(106)
633
(88)
678
(148)
699
(195)
672
(112)
650
(104)
Placebo 650
(104)
628
(102)
685
(157)
680
(97)
670
(112)
635
(74)
668
(98)
649
(117)
665(15
2)
640
(95)
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Table 4.6: Experiment 6 - The effects of citalopram (C) lOmg, citalopram (C)
20mg, citalopram (C) 40mg and dothiepin (D) 75mg on a battery of 
tests (see text for abbreviations for tests). SDs are given in 
parentheses, (continued).
Base­ 2 4 5 8 Base­ 2 4 5 8
line hour hours hours hours line hours hours hours hours
SMT (ms)
ClOmg 885 908 899 912 898 855 897 895 891 882
(95) (99) (112) (130) (71) (49) (89) (71) (96) (71)
C20mg 970 899 906 925 898 885 890 889 888 887
(240) (93) (78) (104) (86) (99) (92) (91) (85) (85)
C40mg 943 929 941 954 929 913 903 913 898 912
(188) 94) (120) (162) (115) (102) (78) (98) (77) (87)
D75mg 893 935 972 988 902 907 945 961 960 887
(89) (130) (178) (155) (93) (96) (110) (174) (135) (76)
Placebo 941 937 918 885 946 894 890 918 911 883
(108) (112) (109) (81) (142) (94) (85) (115) (104) (72)
RMS (rms)
ClOmg 50.1 49.1 50.6 50.1 50.5 49.7 50.3 49.7 49.6 49.3
(3.8) (2.8) (2.6) (2.9) (2.4) (2.4) (1.7) (2.7) (1.8) (3.5)
C20mg 50.1 51.2 50.6 50.8 49.8 49.9 50.5 50.2 51.1 50.7
(5.6) (2.0) (2.6) (3.6) (2.8) (3.1) (3-9) (3.2) (3.5) (3.7)
C40mg 50.9 52.5 51.9 50.2 50.7 50.8 50.7 52.5 50.9 50.9
(4.6) (4.7) (4.2) (2.5) (3.3) (3.2) (2.2) (3.5) (2.9) (4.0)
D75mg 51.1 50.4 50.9 50.7 50.1 52.2 52.6 53.7 51.9 51.3
(3.8) (4.7) (3.4) (2.7) (2.3) (4.5) (5.0) (5.6) (3.0) (3.1)
Placebo 51.7 50.4 51.1 50.4 50.2 51.4 50.5 51.2 51.0 50.2
(4.3) (3.1) (3.4) (3.9) (2.2) (3-0) (3.1) (3.2) (3.4) (2.3)
RT (ms)
ClOmg 851 829 862 842 831 843 831 825 876 974
(116) (69) (125) (88) (81) (78) (89) (76) (156) (69)
C20mg 845 863 836 842 816 806 844 821 851 840
(101) (161) (83) (90) (71) (50) (105) (68) (116) (55)
C40mg 868 824 859 840 836 822 831 959 926 857
(225) (89) (454) (104) (81) (98) (79) (377) (334) (99)
D75mg 807 913 826 1033 822 828 849 859 853 844
(80) (337) (93) (444) (95) (95) (104) (157) (122) (106)
Placebo 845 821 837 858 844 842 832 841 866 845
(123) (86) (91) (117) (89) (97) (64) (83) (74) (85)
LARS (mm
ClOmg 50 (3) 51(3) 52(4) 51(4) 51(5) 50(2) 51(3) 52 (5) 50 (5) 52 (5)
C20mg 50 (5) 53 (5) 53 (6) 54(5) 52 (6) 51(4) 54(5) 55 (6) 57 (9) 53 (5)
C40mg 50(4) 54(6) 54
(10)
55 (7) 49 (8) 51(3) 53(4) 55(4) 55 (6) 52 (4 )
D75mg 50(3) 53 (9) 54 (6) 55 (9) 54 (6) 51(3) 55 (6) 57 (6) 57 (7) 55 (6)
Placebo 50(4) 52 (6) 54 (8) 53 (5) 52(4) 51(4) 50(2) 52(9) 51(6) 54 (8)
MESS (mm)
Day 1 Day 8
ClOmg 45 (7) 42 (13)
C20mg 42 (10) 41(13)
C40mg 43 (16) 42(11)
D75mg 33(11) 39(10)
Placebo 45(11) 39(10)
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4.7 Experiment 7: An evaluation of the pharmacodynamics of fengabine 
versus amitriptyline in healthy volunteers
4.7.1 Objective
The objective of this experiment was to compare the effects of fengabine 200mg and 
fengabine 400mg to the verum amitriptyline 25mg in healthy elderly volunteers 
following seven days administration on measures of cognition and psychomotor 
function.
4.7.2 Methods and measures
The general methods and measures are outlined in Chapter 3.
Subjects: 40 healthy male and female volunteers aged 60-78 years old (mean 68.27) 
entered the study. Three subjects from the amitriptyline group were withdrawn due to 
adverse events (sedation) and one from the placebo group due to influenza-like 
symptoms.
Design: The study was a double blind randomised parallel group comparison of four 
single and multiple dose treatments.
Drugs: The treatments were fengabine 200mg, fengabine 400mg, amitriptyline 25mg 
and placebo were taken once on day 1 then t.i.d. until day 7.
Procedure: Following consent and medical examination visits, subjects were required 
to attend the test centre on days 1, 2, 7 and 8 of the treatment period. On days 1 and 7 
tested pre-dose, then at 1, 2 and 4 hours post dose, returning the following morning 
(days 2 and 8) for a 24 hour test battery.
Test Battery: The test battery consisted of Critical Flicker Fusion (CFF), Choice 
Reaction Time (CRT), Compensatory Tracking Task (CTT), Sternberg Memory
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Scanning Task (SMT), Sternberg Word Recognition (WR) and Line Analogue Rating 
Scales for sedation (LARS). The Leeds Sleep Evaluation Questionnaire was 
completed in the mornings of days 2 and 8.
Analysis: The data from this study were analysed by an external statistician and 
neither the data nor the full statistical report were available. The results presented here 
are from a clinical study report and no significance levels were given. The method of 
analysis was by repeated measures analyses of variance (ANOVA) using differences 
from baseline scores. Post hoc testing for differences between individual means were 
carried out using Tukey’s HSD procedure and statistical significance was set at 
p<0.05.
4.7.3 Results
The mean response data are presented in Table 4.7.
CFF: Differences were apparent between the amitriptyline group and the placebo 
group at baseline, and when this taken into account, amitriptyline still impaired CFF 
compared to placebo at all other test points both on days 1 and 7 (Figure 4.24). Both 
doses of fengabine were not significantly different to placebo. However, fengabine 
400mg significantly improved CFF scores relative to baseline values.
CRT: Amitriptyline impaired recognition reaction time (RRT), significantly so at 4 
hours post dose on day 1 (Figure 4.25), whereas neither dose of fengabine had any 
effect. No differences were observed between treatments in the motor (MRT) or total 
reaction times (TRT).
CTT: Although there were no differences from placebo, amitriptyline significantly 
impaired tracking reaction time (RT) at 2 hours post dose on day 1 when compared 
too fengabine 200mg. When compared to baseline, tracking accuracy (RMS) was 
impaired with amitriptyline at 1, 2, and 4 hours post dose. Fengabine 200mg and 
400mg had no effect on this test.
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WR: There were no significant drug effects on this task following single or 
multiple dosing.
SALT: No significant differences were apparent on this task, although all treatments, 
including placebo, demonstrated a decrease in latency in the reaction times, 
suggestive of a practice effect.
LARS: No subjective differences between drugs nor test times were detected.
LSEQ: The GTS (getting to sleep), QOS (quality of sleep), AFS (ease of 
awakening from sleep) and BFW (behaviour following wakening) factors of the 
LSEQ were analysed separately. No significant differences were found in any of the 
first 3 parameters, but fengabine 200mg did impair BFW when compared to fengabine 
400mg and amitriptyline following a single dose. The difference from placebo was 
not significant.
4.7.4 Discussion
As elderly volunteers were treated in this study, the dose of the verum amitriptyline 
was lower than that given in Experiments 1 and 2 (i.e. 25mg rather than 50mg). This 
low dose of amitriptyline, however, was potent enough to decrease critical flicker 
fusion thresholds at all test points (and also when baseline differences were taken into 
account) whereas both doses of fengabine had no effect (Fairweather et al, 1993d). 
Amitriptyline also impaired recognition reaction time at one test point on day 1 but 
not on day 7. Although there was no difference to placebo, tracker accuracy became 
progressively worse with amitriptyline on day 1 compared to pre-treatment 
performance. These effects on reaction time and tracking were diminished on day 7 
and a possible explanation is that subjects had developed a tolerance to these effects. 
A more probable reason is that three of the four subjects who were withdrawn were 
from the amitriptyline group and these were the subjects most severely affected by 
sedation. Only one adverse effect was reported with fengabine, where a single dose of
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200mg impaired subjective feelings of behaviour following awakening compared to 
amitriptyline but not placebo. This may reflect the slightly impaired (but non­
significant) rating of quality of sleep with fengabine 200mg, but no impairments were 
observed following repeated dosing. This study followed a parallel groups design, and 
given the significant differences between the placebo and amitriptyline groups at 
baseline, it would be interesting to repeat this study using a cross-over design where 
each subject acted as their own control.
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Table 4.7: Experiment 7 - The effects of fengabine (F) 200mg, fengabine (F)
400mg and amitriptyline (A) 25mg on a battery of tests (see text 
for abbreviations of tests). SDs are given in parentheses.
Base­
line
1
hour
2
hours
4
hours
24
hours
Base­
line
1
hour
2
hours
4
hours
24
hours
CFF (Hz)
F200mg 25.4 25.7 25.5 25.2 26.7 27.4 28.0 25.9 25.9 26.4
(1.2) (1.4) (0.9) (1.2) (1.2) (1.5) (1.1) (1.1) (1.3) (1.2)
F400mg 25.5 25.1 26.0 25.2 26.1 26.0 26.0 25.5 25.4 27.0
(1.4) (0.9) (1.3) (1.3) (1.6) (1.3) (1.6) (1.5) (2.0) (1.5)
A25mg 25.2 24.8 23.6 23.5 24.4 23.8 24.9 23.8 23.6 24.9
(1.9) (1.7) (2.6) (2.6) (1.8) (0.7) (1.4) (1.3) (1.7) (3.4)
Placebo 27.6 28.1 28.4 27.8 28.0 28.2 27.5 27.7 28.4 28.7
(1.1) (0.7) (0.9) (1.1) (1.3) (1.6) (1.1) (1.3) (1.2) (1.4)
RRT (ms)
F200mg 492 474 508 533 431 435 497 508 464 458
(95) (94) (117) (135) (60) (30) (59) (82) (67) (61)
F400mg 457 469 484 463 410 427 443 430 432 442
(80) (74) (74) (80) (53) (86) 987) (88) (74) (HO)
A25mg 453 439 478 545 437 444 438 434 445 406
(48) (48) (63) (102) (42) (53) (43) (56) (66) (36)
Placebo 426 463 470 453 434 433 437 452 456 406
(21) (32) (32) (19) (39) (52) (24) (41) (45) (27)
MRT (ms)
F200mg 232 229 210 234 228 212 212 232 234 225
(40) (59) (73) (76) (48) (49) (45) (71) (43) (61)
F400mg 307 322 331 318 287 301 315 289 279 296
(54) (60) (80) (108) (82) (55) (75) (51) (79) (81)
A25mg 277 283 310 297 285 285 290 295 298 280
(47) (70) (83) (67) (61) (68) (75) (85) (69) (81)
Placebo 244 251 252 258 247 247 256 273 224 251
(65) (44) (71) (59) (57) (57) (54) (72) (69) (79)
*TRT (ms)
F200mg 724 703 718 996 659 646 709 740 698 683
F400mg 764 791 815 781 697 728 758 719 711 738
A25mg 730 722 788 842 722 729 728 729 743 686
Placebo 670 714 722 711 681 680 693 725 680 657
SMT (ms)
F200mg 569 537 530 506 517 542 510 534 553 512
(104) (103) (126) (115) (96) (159) (166) (141) (206) (129)
F400mg 578 533 533 561 507 520 564 511 600 456
(160) (113) (134) (148) (98) (79) (128) (39) (258) (267)
A25mg 571 619 627 611 495 574 570 510 571 533
(114) (203) (181) (148) (218) (104) (107) (74) (89) (70)
Placebo 681 684 548 668 601 581 586 570 578 637
(154) (195) (128) (218) (119) (73) (72) (77) (87) (83)
*TRT: no SDs were available in the report for this variable
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Table 4.7: Experiment 7 - The effects of fengabine (F) 200mg, fengabine (F)
400mg and amitriptyline (A) 25mg on a battery of tests (see text 
for abbreviations of tests). SDs are given in parentheses, 
(continued).
W R (ms)
F200mg 801
(181)
804
(139)
808
(76)
787
(132)
784
(140)
849
(135)
813
(129)
820
(147)
901
(367)
810
(154)
F400mg 852
(225)
937
(372)
835
(163)
805
(166)
830
(213)
764
(157)
745
(416)
759
(127)
758
(196)
898
(217)
A25mg 828
(201)
891
(253)
894
(269)
842
(209)
771
(161)
880
(257)
786
(206)
693
(269)
906
(250)
769
(177)
Placebo 841
(174)
855
(188)
884
(232)
796
(145)
800
(179)
1019
(338)
873
(183)
898
(107)
883
(108)
1006
(305)
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Table 4.7: Experiment 7 - The effects of fengabine (F) 200mg, fengabine (F)
400mg and amitriptyline (A) 25mg on a battery of tests (see text 
for abbreviations of tests). SDs are given in parentheses, 
(continued).
Base­
line
1
hour
2
hours
4
hours
24
hours
Base­
line
1
hour
2
hours
4
hours
24
hours
RMS (rms)
F200mg 21.3
(6.8)
18.4
(5.5)
16.9
(5.0)
17.6
(6.0)
16.5
(5.0)
15.6
(4.6)
15.4
(5.8)
15.1
(6.7)
15.6
(7.4)
15.1
(5.7)
F400mg 23.6
(11.9)
21.1
(8.0)
20.1
(7.9)
20.3
(8.2)
18.4
(10.4)
17.0
(9.2)
18.6
(12.0)
18.0
(11.6)
18.2
(12.1)
15.7
(8.2)
A25mg 23.2
(8.7)
26.1
(12.9)
27.7
(12.0)
27.8
(11.6)
18.9
(8.3)
18.7
(8.1)
16.7
(7.2)
15.6
(6.9)
15.7
(6.70
14.8
(6.1)
Placebo 23.2
(8.8)
22.8
(6.4)
22.0
(9.3)
27.8
(10.1)
19.0
(7.9)
18.5
(7.1)
19.2
(10.2)
18.9
(9.2)
18.7
(10.7)
18.1
(9.8)
RT (ms)
F200mg 455
(139)
405
(164)
383
(141)
408
(151)
420
(109)
393
(90)
419
(85)
436
(125)
415
(99)
379
(132)
F400mg 417
(56)
439
(49)
445
(37)
476
(65)
414
(65)
417
(56)
456
(78)
462
(55)
456
(77)
430
(69)
A25mg 482
(75)
496
(68)
529
(119)
533
(118)
466
(82)
466
(89)
456
(78)
457
(101)
480
(74)
477
(74)
Placebo 485
(92)
515
(112)
499
(81)
516
(103)
444
(68)
448
(51)
457
(114)
471
(124)
438
(147)
470
(110)
LARS (mm)
F200mg 50.4
(3.2)
48.6
(4.6)
51.4
(5.6)
51.3
(2.0)
54.1
(6.50
54.4
(12.4)
51.3
(2.1)
53.3
(8.0)
54.9
(11.7)
43.6
(4.50
F400mg 49.7
(4.3)
53.1
(5.1)
51.6
(3.8)
51.2
(4.5)
50.9
(3.4)
58.0
(13.22)
51.7
(3.8)
49.8
(4.2)
50.2
(2.7)
55.3
(15.1)
A25mg 51.1
(5.6)
48.6
(6.0)
50.0
(7.3)
48.4
(3.90
50.7
(8.1)
49.6
(2.78)
49.7
(3.5)
49.6
(2.4)
50.8
(3.2)
49.7
(4.9)
Placebo 50.7
(2.7)
48.7
(3.3)
49.9
(0.5)
49.2
(1.6)
50.5
(1.9)
49.0
(2.8)
49.1
(2.0)
50.7
(3.0)
50.5
(3.23)
50.1
(1.3)
D ayl Day 7 D ayl Day 7
GTS (mm) QOS (mm)
F200mg 42.1 (12.8) 45.2 (13.8) 49.5(10.1) 43.6(11.8)
F400mg 34.3 (9.5) 40.7 (14.4) 41.2 (9.2) 49.6 (10.8)
A25mg 38.1 (17.8) 43.9(19.1) 42.0 (10.3) 43.8 (27.8)
Placebo 41.9(19.8) 49.4 (5.0) 38.1 (17.9) 52.7(11.2)
AFS (mm) BFW (mm)
F200mg 43.3 (9.6) 44.1 (8.1) 61.1 (5.4) 47.7 (9.4)
F400mg 39.5 (10.6) 51.2 (9.4) 41.6(11.3) 46.3 (3.9)
A25mg 46.4 (5.8) 48.1 (4.9) 42.1 (15.2) 38.3 (17.2)
Placebo 52.9 (12.9) 59.3 (13.5) 51.4 (6.8) 49.7 (5.5)
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4.8 Experiment 8: The effects of fluoxetine and dothiepin on cognitive 
function and activity in depressed patients in general practice
4.8.1 Objective
In this experiment, the aim was to compare two antidepressants; fluoxetine 20mg and 
dothiepin 75mg on tests of cognitive and psychomotor performance in depressed 
outpatients being treated in general practice.
4.8.2 Methods and measures
The general methods and measures used in this experiment are outlined in Chapter 3.
Subjects:. Eighty four depressed patients (54 females, 30 males) aged between 18-70 
(mean 43.8) years were admitted to the study. All patients at entry satisfied DSMIII-R 
criteria for major depression.
Design: The study was a randomised, parallel group, double blind design six week 
study.
Drugs: Patients were randomised to receive either fluoxetine or dothiepin. Patients in 
the fluoxetine group received fluoxetine 20mg mane and placebo nocte for the 
duration of the study. Patients in the dothiepin group received placebo mane and 
dothiepin 75mg nocte for the first week, rising to 150mg for the remaining five 
weeks.
Procedure: Following consent and medical examination visits, patients were scored 
according to the Hamilton Depression Rating Scale (HAM-D). They were then 
required to attend the test centre on days 7, 14, 28 and 42 of treatment where they 
performed a series of tests and questionnaires at approximately the same time of day.
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Test Battery: The test battery consisted of a portable version of the Critical Flicker 
Fusion test (CFF), Kim’s Game (KIM), Serial Subtraction of Numbers (SSN), 
Cognitive Failures Questionnaire (CFQ), the Leeds Sleep Evaluation Questionnaire 
(LSEQ), the Milford Epworth Sleepiness Scale (MESS) and Actigraphy.
Analysis: The HAM-D scores were analysed using Wilcoxon’s matched pairs, sign- 
ranks test. The adverse event and drop-out data were analysed using Mann Whitney U 
tests. The data from the psychometric tests were analysed using independent groups 
repeated measures analyses of variance (ANOVA). Post hoc testing for differences 
between individual means were carried out using Tukey’s HSD procedure. Actigraph 
data were analysed using a two way ANOVA (drug x hour) and post hoc analysis was 
performed using Newman-Keuls test. Statistical significance was set at p<0.05.
4.8.3 Results
The mean response data are presented in Table 4.8.
Subjects: Of the 84 patients recruited to the study, 63 completed visit 5 then 9 were 
withdrawn due to protocol violations. 54 patients (26 on dothiepin, 28 on fluoxetine) 
fully completed the study.
Hamilton Depression Rating Scale Scores
Intention to Treat: On entry the mean score for the 84 patients was 21.29 (SD 5.17; 
range 10-35). Those who completed the final HAMD (n=63) scored an average of 
10.25 (SD 5.81; range 0-28). A Wilcoxon Matched Pairs Test revealed that there was 
a highly significant difference between the initial and final scores (N=63; z=6.86; 
pO.OOOOOl).
Completers: The initial mean score for those patients who completed (n=54) was 
21.13 (SD 4.50; range 10-29). The final score for this group was 10.20 (SD 5.69; 
range 0-28). Again, a highly significant difference was found between initial and final 
scores (n=54; z=6.36; pO.OOOOOl).
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Responders: Of those patients who completed the study, 36 responded to the 
medication (i.e. whose HAMD scores decreased by 50% or more).
No significant differences were found between the drugs at the initial or final 
assessments (Kolmogorov Smirnov Test) for both the intention to treat group and the 
completers. Also, there were no significant differences in initial or final HAM-D 
scores between those who completed the study and those who dropped out or were 
withdrawn.
Psychometric Test Battery 
Two sets of analyses were carried out on the psychometric data: intention to treat 
(n=84) and responders (n=36). Both sets of analyses revealed similar results.
Intention to Treat
CFF: This was performed under two conditions: with and without artificial pupils. 
Using the standard methodology (without artificial pupils) there was a significant 
main effect of time (F(4, 232) = 6.09, p<0.005) where both drugs improved 
performance over time. The drug effect only approached significance (F(l, 58) = 2.64; 
p=0.1). Post hoc analysis revealed that fluoxetine produced significantly higher 
thresholds than dothiepin on days 7 and 14 (p<0.05) (Figure 4.26). No differences 
were observed at baseline. With artificial pupils, CFF scores were again similar to 
those obtained with the standard methodology, except that there were fewer 
significant differences. The main effect of drug was not significant (F<1) but post hoc 
tests yielded a significant difference between treatments on day 14. This was due to 
higher scores with fluoxetine. A time effect was also apparent where CFF increased 
over the course of the study (F(4, 220) = 5.81; p<0.05).
SSN: In this test a main effect of time was revealed where both drugs improved 
performance over the duration of the study (F(4, 208) = 3.19; p<0.02). No significant 
differences were observed between treatments.
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KIM: Performance on Kim’s Game did not differ significantly between treatments 
although the pattern was for those patients on fluoxetine to show a greater 
improvement compared to dothiepin. Performance improved throughout the study 
with both drugs (F(4, 236) = 3.13, p<0.05).
CFQ: No significant differences were revealed between treatments, although again, 
scores improved with time (F(4, 236) = 14.05, pO.OOOOOl).
LSEQ: No differences were found in the GTS component of the LSEQ. There was 
a significant main effect of drug in quality of sleep (QOS) (F(l, 57) = 4.55; pO.05), 
where fluoxetine decreased subjective ratings on day 28. A difference between drugs 
was observed on ratings of awakening from sleep (AFS) (F(l, 55) = 5.40, pO .05) and 
post hoc analysis showed that dothiepin was worse than fluoxetine on days 7, 28 and 
42 (Figure 4.27).
MESS: No significant differences were detected in the MESS.
Responders
CFF: Using the standard methodology (without artificial pupils) there was a 
significant drug effect (F(l, 29) = 5.01; p<0.05) in patients who responded to 
treatment. Post hoc analysis revealed that fluoxetine produced significantly higher 
thresholds compared to dothiepin at all visits (Figure 4.28). As there were differences 
at the baseline assessment, an analysis of covariance (ANCOVA) was performed 
using baseline scores as the covariate. Significant differences were found (p<0.05) at 
all subsequent visits. With artificial pupils, CFF scores were again similar to those 
obtained with the standard methodology, except that there were no differences 
between treatments at baseline. CFF increased over the course of the study with (F(4, 
116) = 4.33; p<0.05) and without (F(4, 116) = 5.81; p<0.0005) artificial pupils.
SSN: In this test both drugs improved performance over the duration of the study 
(F(4, 92) = 9.43; p<0.000005). However, those patients in the dothiepin group
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consistently scored significantly lower on the 17s subtraction than the fluoxetine 
group (p<0.05) (Figure 4.29). When all of the SSN parameters were added together, 
there were no significant differences, although there was a trend for dothiepin to 
appear worse than fluoxetine, with both groups improving over time.
KIM: Performance on Kim’s Game did not significantly different between 
treatments although the pattern was for those patients on fluoxetine to have better 
scores than those on dothiepin.
CFQ: No significant differences were revealed between treatments, however there 
was an effect of time (F(4, 120) = 11.45; pO.OOOOOl) where improvements were 
noted over the duration.
LSEQ: No differences were found in the GTS component of the LSEQ. There was 
a time effect in that both drugs improved QOS over the study (F(3, 84) = 6.14; 
pO.OOl). There was a trend for fluoxetine to produce worse ratings than dothiepin but 
this did not reach significance (F(l, 28) = 3.19; p=0.8). Although there were no main 
effect, post hoc tests showed that dothiepin impaired ratings of AFS, significantly so 
on day 7 (p<0.05).
MESS: No significant differences were detected in the MESS.
Actigraphy: 14 complete actigraph data sets were available for analysis (7 from 
each treatment). The interaction between drug and time was found to be significant 
(F(23, 276) = 1.78; p<0.0169) and post hoc analysis revealed that those patients on 
dothiepin were significantly less active than the fluoxetine group at 06:00-07:00 hours 
(p< 0.05) and 07:00-08:00 hours (p<0.00005) (Figure 4.30). Mean bedtimes and 
wake-up times were similar for each group.
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4.8.4 Discussion
The results from this study show that both drugs similarly relieved the symptoms of 
depression as assessed by the HAM-D. Two analyses were performed on the 
psychometric data. The first included all patients who entered the study and the 
second included only those patients who had responded to treatment. The reason for 
this was that if patients responded to antidepressant treatment, then according to the 
argument put forward in Chapter 1, performance should improve as the depression is 
ameliorated.
Both analyses yielded similar results, where performance on the tests improved with 
time throughout the study, although the scores with fluoxetine were generally better 
than those with dothiepin. This was particularly evident in the critical flicker fusion 
task, where patients who responded to treatment performed significantly better with 
fluoxetine than dothiepin at every test point (days 7, 14, 28 and 42), whereas when all 
patients were considered irrespective of outcome, fluoxetine was superior to dothiepin 
on days 7 and 14. These patterns were also evident when subjects used artificial pupils 
(to maintain a constant pupil size), suggesting that changes produced by these 
antidepressants on critical flicker fusion thresholds were independent of pupil size. In 
patients who responded to treatment, those receiving fluoxetine had significantly 
better scores in the most challenging section of the serial subtraction of numbers tests. 
No differences between treatments were observed on short term memory, on self 
assessment of cognitive failures, or on subjective daytime sedation. Ratings of quality 
of sleep, however, were worse with fluoxetine than with dothiepin, reaching 
significance in the intention to treat analysis. Despite this, fluoxetine produced better 
feelings on awakening than dothiepin. In those patients who responded to treatment, 
the disrupting effects of fluoxetine on quality of sleep were not significant, suggesting 
that the sleep of these patients has improved as the depression is lifted.
During the first two weeks of treatment, the fluoxetine group were more active during 
the day than the dothiepin group, significantly so first thing in the morning where the 
latter were slower in getting up, or were suffering from a “hang-over” effect and early
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morning inertia. These actigraph findings correspond well with the improved 
subjective ratings of awakening from sleep and the improvements on other 
psychometric measures with fluoxetine, especially critical flicker fusion.
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Table 4.8: Experiment 8 - The effects of fluoxetine 20mg and dothiepin 75mg
on a battery of tests (see text for abbreviations of tests). SDs are 
given in parentheses.
Baseline Day 7 Day 14 Day 28 Day 42
INTENTION TO TREAT
CFF (Hz)
F20mg 29.6 (2.9) 30.2 (3.3) 30.8 (3.1) 30.4 (3.2) 30.9 (3.7)
D75mg 28.9 (3.6) 29.1 (3.4) 29.4 (3.3) 29.9 (3.2) 29.6 (3.5)
CFF + artificial pupils (Hz)
F20mg 27.2 (3.5) 28.3 (3.8) 28.7 (3.6) 28.5 (4.1) 28.9 (4.5)
D75mg 27.7 (4.0) 27.8 (3.6) 27.7 (3.7) 28.5 (3.7) 28.0 (3.3)
SSN (score)
F20mg 1.31 (0.45) 1.20 (0.42) 1.17(0.43) 1.16(0.36) 1.06 (0.33)
D75mg 1.34 (0.51) 1.24 (0.55) 1.14(0.32) 1.19(0.42) 1.12(0.42)
KIM (score)
F20mg 11.9(2.7) 11.8(2.4) 12.3 (2.4) 12.9 (2.4) 13.3 (2.3)
D75mg 11.1 (3.5) 11.6(2.8) 11.9 (3.7) 11.7 (3.9) 11.8(3.9)
CFQ (score)
F20mg 50.9(16.2) 49.6(17.1) 46.7(16.6) 44.8(14.5) 44.4 (12.6)
D75mg 52.7(17.3) 53.5 (15.0) 51.2(13.8) 48.5 (12.5) 47.2(14.9)
LSEQ - GTS (mm)
F20mg - 38.1 (15.6) 39.5 (17.4) 39.3 (17.4) 37.8 (10.9)
D75mg - 35.5 (14.4) 35.5 (14.3) 30.9(13.1) 37.2 (19.5)
LSEQ - QOS (mm)
F20mg - 47.2(16.6) 44.1 (17.1) 45.7 (20.8) 41.7(13.5)
D75mg - 38.1 (16). 38.0(18.1) 33.9(19.4) 36.1 (16.9)
LSEQ - AFS (mm)
F20mg - 50.6(12.4) 51.5 (14.9) 49.0(13.6) 45.4(13.0)
D75mg - 56.6(12.9) 54.3 (13.9) 56.3 (18.4) 54.9(16.4)
MESS (mm)
F20mg - 48.8(11.1) 47.8 (13.9) 46.9(13.2) 49.4(13.2)
D75mg - 49.3 (11.7) 46.0(11.6) 45.8 (14.6) 48.8 (15.5)
HAMD (score)
F20mg 20.88
(5.20)
" " " 10.50
(5.79)
D75mg 21.69
(5.17)
“ " “ 10.00
(5.92)
COMPLETERS WHO RESPC>NDED TO TREATMENT
CFF (Hz)
F20mg 29.8 (3.0) 30.7 (3.5) 31.6(2.8) 31.4 (3.1) 31.8 (3.8)
D75mg 28.9 (3.2) 29.3 (3.0) 29.3 (2.7) 29.8 (3.3) 29.4 (3.1)
CFF + artificial pupils (Hz)
F20mg 27.5 (3.4) 29.3 (4.0) 29.6 (3.1) 29.5 (3.8) 30.4 (4.2)
D75mg 27.5 (3.9) 28.0 (3.7) 27.7 (3.8) 28.2 (3.8) 27.6 (3.0)
SSN (score)
F20mg 1.20 (0.39) 1.03 (0.18) 1.05 (0.21) 0.93 (0.15) 0.98 (0.23)
D75mg 1.49 (0.54) 1.37 (0.56) 1.20 (0.35) 1.28 (0.45) 1.15 (0.42)
KIM (score)
F20mg 13.0 (2.0) 12.2 (2.0) 12.5 (2.6) 13.7 (3.2) 13.8 (2.0)
D75mg 11.1 (3.3) 12.0 (2.5) 11.8 (3.6) 11.7 (3.3) 12.0 (3.9)
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Table 4.8: Experiment 8 - The effects of fluoxetine 20mg and dothiepin 75mg
on a battery of tests (see text for abbreviations of tests). SDs are 
given in parentheses, (continued).
Baseline Day 7 Day 14 Day 28 Day 42
CFQ (score)
F20mg 50.9 (16.0) 48.3 (17.1) 46.9 (13.6) 41.7(11.6) 42.1 (10.6)
D75mg 55.8 (16.8) 54.3 (16.2) 50.5 (14.6) 46.8 (14.2) 47.1 (17.2)
LSEQ - GTS (mm)
F20mg - 34.2 (13.5) 34.9 (12.2) 38.0(18.4) 32.4 (10.8)
D75mg - 35.7(17.3) 34.0 (14.7) 31.6(11.9) 27.9 (13.8)
LSEQ - QOS (mm)
F20mg - 43.0 (14.8) 39.2 (10.6) 36.5 (15.9) 35.0 (9.7)
D75mg - 37.0 (17.3) 36.7(18.3) 29.8(18.5) 28.7 (12.7)
LSEQ - AFS (mm)
F20mg - 44.1 (10.7) 44.6(11.3) 41.7(10.3) 43.6 (15.0)
D75mg - 57.8 (14.9) 51.1 (14.2) 46.8 (19.0) 47.6 (16.0)
MESS (mm)
F20mg - 48.2(13.3) 45.6 (13.5) 48.2(13.8) 50.6 (13.6)
D75mg - 51.5(10.3) 47.1 (11.6) 47.6 (13.2) 50.3 (15.7)
HAMD (score)
F20mg 20.43
(4.20)
“ - 10.79
(3.14)
D75mg 21.88
(4.94)
“ - . “ 9.58
(3.56)
Sleep (Actigraphy) Bed time Wake-up time
F20mg 23:11 (00:18) 07:42 (00:44)
D75mg 23:25 (00:27) 07:56 (00:24)
Actigraphy (counts)
0000 0100 0200 0300 0400 0500 0600 0700 0800 0900 1000 1100
F20mg 133
(67)
104
(48)
105
(59)
101
(57)
102
(50)
131
(70)
243
(185)
364
(179)
440
(124)
466
(127)
485
(103)
511
(34)
D75mg 163
(63)
109
(41)
131
(26)
125
(17)
114
(35)
103
(36)
101
(43)
180
(78)
336
(78)
414
(83)
473
(50)
480
(53)
1200 1300 1400 1500 1600 1700 1800 1900 2000 2100 2200 2300
F20mg 528
(19)
517
(25)
490
(30)
482
(53)
492
(23)
484
(38)
459
(53)
424
(69)
404
(96)
379
(87)
321
(89)
241
(93)
D75mg 489
(63)
487
(59)
463
(67)
476
(66)
465
(65)
448
(61)
434
(78)
397
(91)
370
(67)
345
(86)
324
(117)
247
(118)
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4.9 Summary of experiments 1-8
Experiment 1 demonstrated that amitriptyline 25mg impaired scores on several tests 
and that moclobemide 200mg and 400mg impaired only one test at a single test point. 
Amitriptyline 50mg (alone and with alcohol) also impaired performance in all of the 
tests employed (except word recognition) in Experiment 2 and increased subjective 
ratings of sedation. Brofaromine, which had little or no effect on the test battery, 
appeared to antagonise the effects of alcohol.
In Experiment 3, paroxetine 20mg improved critical flicker fusion and choice reaction 
time tasks but impaired short term memory scanning. Furthermore, paroxetine 
reversed the disrupting effects of alcohol on critical flicker fusion. Lorazepam, with 
and without alcohol, impaired all of these tasks. Improved performance was observed 
with fluvoxamine 50mg and lOOmg (but not dothiepin) (Experiment 4), and with a 
range of doses of litoxetine (Experiment 5). Citalopram (lOmg - 40mg) increased 
critical flicker fusion thresholds where dothiepin 75mg had the opposite effect 
(Experiment 6) on this and other tests. Experiment 7 found that amitriptyline 25mg 
impaired critical flicker fusion and choice reaction time, and that fengabine (200mg 
and 400mg) had no effects. In Experiment 8, although fluoxetine 20mg and dothiepin 
75mg were equipotent in reducing Hamilton Depression Rating Scale scores, 
fluoxetine was superior to dothiepin on the battery of tests.
Overall, the vera amitriptyline, dothiepin and lorazepam either impaired performance 
or were not significantly different from placebo on the battery of objective and 
subjective tests (Table 4.10). The SSRIs paroxetine, litoxetine fluvoxamine and 
citalopram improved performance or had no detrimental effect, and only occasionally 
disrupted performance. Moclobemide, brofaromine and fengabine were virtually 
indistinguishable from placebo in the majority of tests. The results from this chapter 
are summarised in Tables 4.9 and 4.10. (No placebo condition was included in 
Experiment 8, therefore the results are omitted from Table 4.10). Table 4.10 is 
discussed in the following chapter.
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CHAPTER 5 - DISCUSSION
5.0 Chapter outline
The preceding chapter presented the results of the experimental work. The present 
chapter discusses these results in the context of the literature review (Chapter 2) and 
ranks the strength of the drug effects on central information processing. The relevance 
of these findings are then discussed in terms of the impact that they may have on the 
management of patients with major depression.
5.1 Introduction
Chapter 1 emphasised the importance of assessing the effects of antidepressants on 
performance, by firstly presenting evidence that depression is often accompanied by 
psychomotor and cognitive retardation and then discussing how an antidepressant can 
affect these processes, often to the detriment of the patient. The second generation 
antidepressants were introduced, together with information that these drugs appear to 
be as efficacious as earlier compounds in alleviating depression, but with fewer side 
effects. A review of the literature on the effects of antidepressants on performance in 
both healthy volunteer and depressed patient populations (Chapter 2) concluded that, 
despite the fact that there were many inconsistencies in the methodologies and 
assessments used, there were tests which were sensitive to the effects of 
antidepressants on human information processing when used in appropriately 
designed experiments. The outcome of the literature review was that the older TCAs 
impaired cognitive and psychomotor performance, whereas the newer antidepressants 
had little or no effect, and some studies showed that the SSRIs and RIM As improved 
performance. On the basis of these findings, the measures and methods chosen for the 
experimental work were discussed in Chapter 3. Chapter 4 described the experimental 
procedures and presented a short discussion on each of the experiments. The present 
chapter discusses the relevance and implications of the experimental results to the 
prescribing of antidepressants in general practice.
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5.2 Discussion of experimental results
Based on evidence from the literature review, amitriptyline and dothiepin were 
included as vera in the experiments described in Chapters 3 and 4. In all of the studies, 
these drugs impaired performance on tests of central and psychomotor function 
(critical flicker fusion and choice reaction time respectively) and in other tests (e.g. 
memory, sensorimotor skills), either disrupted performance or had little effect (Table 
4.10). Incidentally, these findings correspond well with reports of side effects such as 
sedation, drowsiness and fatigue in patients (Fairweather and Hindmarch, 1995b). 
These results clearly reflect the outcome of the review of the literature presented in 
Chapter 2 (Table 2.18). In the majority of cases, the SSRIs (Table 4.10) improved 
cognitive abilities in healthy volunteers, whereas the RIMAs had very little effect, and 
these results also reflected the pattern observed in previous, although limited, 
research. In addition, brofaromine and paroxetine (Experiments 2 and 3) antagonised 
the impairing effects of alcohol on critical flicker fusion threshold. This suggests that 
depressed patients taking these drugs need not refrain from alcohol as should be the 
case with the TCAs. The compounds which improve cognitive abilities may prove to 
be advantageous in the treatment of illnesses which are accompanied by cognitive 
decline, such as depression and dementia, as opposed to the TCAs which would 
inherently exacerbate these symptoms. In terms of psychomotor functioning (e.g. 
choice reaction time), very little effect occurred in that the SSRIs and RIMAs 
exhibited a similar profile to placebo. The compensatory tracking task, employed as a 
measure of sensorimotor performance in most experiments, produced equivocal 
results in that fluvoxamine and citalopram had no effect, whereas paroxetine 
improved performance, and moclobemide, and the lower doses of litoxetine (2.5mg 
and 5mg) and brofaromine (50mg) impaired performance. The evidence from the 
literature review suggests that it is unlikely for the SSRIs and RIMAs to influence 
sensorimotor skills and so further research with this test is required to clarify these 
effects. The GABA-mimetic antidepressant fengabine could not be differentiated from 
placebo at any time point on any of the test measures (Experiment 7), and this mirrors 
the conclusions of the only study encountered in the literature review (Theofilopoulos 
et al, 1989). Very few effects were observed on the remaining tests, and no
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improvement or impairment of subjective feelings were recorded with these second 
generation antidepressants.
It is interesting to note that the effects of antidepressants on cognitive and 
psychomotor function are apparent after only one dose, whereas it is known that the 
therapeutic effects appear after two to four weeks of repeated dosing. It has been 
postulated that these immediate effects may be due to acute pre-synaptic actions of 
antidepressants on neurotransmitter turnover, whereas the therapeutic response 
follows on from post-synaptic adaptive mechanisms (Leonard, 1992). Patients will 
therefore experience the changes in performance prior to the therapeutic effect, and if 
a drug exerts performance impairments during the initial phase of treatment, then it is 
likely that patient compliance will be reduced.
There have been criticisms against this type of study (Freeman and O’Hanlon, 1995a; 
1995b; O’Hanlon and Freeman, 1995) where the acute effects of antidepressants are 
assessed in healthy volunteers. These critics question the validity and inferences of 
such research in non-depressed subjects and argue that the effects of antidepressants 
on performance attenuate following chronic dosing. Despite these criticisms, 
O’Hanlon’s research group recently published a study in healthy volunteers 
(Ramaekers et al, 1995) where reductions in critical flicker fusion threshold with 
dothiepin were apparent after 22 days of treatment. The experiments reported in this 
thesis (Experiments 6 and 7) show that the effects of citalopram and amitriptyline are 
still apparent after eight and seven days dosing respectively. Furthermore, Experiment 
8 revealed that significant differences were detectable between fluoxetine and 
dothiepin in depressed patients for up to 42 days, despite the fact that both drugs were 
equipotent in alleviating depression according to clinical ratings. These findings were 
similar to those observed in a previous study comparing fluoxetine and amitriptyline 
(Fairweather et al, 1993b) in elderly depressed patients. In addition, Hale and Pinninti 
(1995) revealed that there were significant differences between TCAs and SSRIs in 
depressed patients even after a minimum of three months of dosing. The results in 
these and other patient studies generally parallel those observed in healthy volunteers.
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In their critique, Freeman and O’Hanlon (1995a) also point out that many healthy 
volunteer studies employ antidepressant at doses which are below those prescribed to 
patients. This is in fact correct and justifiable. For example, in the experiments 
performed for this thesis, the doses of amitriptyline (25mg - 50mg) and dothiepin 
(75mg) were lower than those recommended for the treatment of depression (125mg - 
150mg daily) (Paykel and Priest, 1992; British Association for Psychopharmacology 
(BAP), 1993), but even at these sub-therapeutic doses, impairments in performance 
were evident. It follows that patients who are prescribed these low doses of 
antidepressants may be suffering adverse effects without the benefit of therapeutic 
efficacy. Recently published data shows that as many as 88% of prescriptions for 
TCAs are below the recommended dose (Donoghue and Tylee, 1996) and that the 
main reason given by prescribers for this practice is to avoid side effects which are 
likely to result in reduced patient compliance (Beaumont et al, 1996). It is therefore 
essential to establish the effects of the whole dose range of doses (including very low 
doses) of putative antidepressants on tests of performance.
5.2.1 Comparison of drug effects on critical flicker fusion
Measurement of critical flicker fusion threshold was the most widely used technique 
cited in the experiments reviewed in Chapter 2, and despite the differences in 
methodologies, this test proved to be sensitive to the effects of antidepressants. The 
criticahflicker fusion test was also successful in discriminating between the second 
generation antidepressants and TCAs studied in this thesis. Experiments 1-6 inclusive 
1 employed identical tests and followed similar designs (i.e. double blind, placebo 
controlled, cross-over), thereby allowing quantitative comparisons across studies to be 
made. (As experiments 7 and 8 used parallel groups, the latter in patients, these were 
excluded from this comparison). Table 5.1 shows the results of a comparison of the 
strength of drug effects compared to placebo, which were calculated using a meta- 
analytic technique (Glass and Kliegal, 1983) where effect sizes (Cohen’s d  scores) 
were derived from the maximum drug-placebo differences (Cohen, 1976). This mode 
of comparison between studies has been used previously at the Human 
Psychopharmacology Research Unit (Sherwood and Hindmarch, 1993) to rank the
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effects of drugs relative to placebo (these rankings are intended to be descriptive 
only).
Table 5.1 Ranked magnitudes of the effects of antidepressants on critical 
flicker fusion (d CFF). (The drugs grouped with placebo are not 
significantly different to placebo; those grouped to the left are better 
than placebo*, and the group to the right are worse than placebo1-, 
p<0.05)
Drug d  CFF Drug d  CFF Drug d  CFF
citalopram 20mg 0.866* fluvoxamine 50mg 0.521 dothiepin 75mg 0.690*
citalopram 40mg 0.810* litoxetine 2.5mg 0.199 amitriptyline 50mg 0.822*
fluvoxamine lOOmg 0.806* brofaromine 75mg 0.099
litoxetine 25mg 0.776* placebo 0.000
litoxetine lOmg 0.732* brofaromine 50mg 0.026
citalopram lOmg 0.659* moclobemide 200mg 0.153
litoxetine 5mg 0.604* moclobemide 400mg 0.267
paroxetine 20mg 0.597*
These rankings of strengths of effects show that the TCAs dothiepin and amitriptyline 
(at the doses investigated) have a strong negative effect on this measure of central 
information processing, whereas the SSRIs citalopram (lOmg, 20mg, 40mg), 
fluvoxamine (lOOmg), litoxetine (5mg, lOmg, 25mg) and paroxetine (20mg) all 
improve this function. Lower doses of fluvoxamine and litoxetine have weaker 
effects, and the RIMAs brofaromine and moclobemide are neutral with respect to this 
test. These findings correspond well with the conclusions from the literature review 
(Table 2.18, Chapter 2) where the trend for the TCAs was to impair performance, for 
the SSRIs to improve performance, and for the RIMAs to have little or no effect.
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The method of categorising antidepressants according to their strength of effects on 
tests of information processing also appears to parallel the biochemical classification 
presented by Leonard (1994) (see Chapter 1), however more research is required on 
the remaining categories of these drugs and of the emerging third generation 
antidepressants in order to substantiate these claims.
5.3 Relevance of findings to the prescribing of antidepressants
It is generally accepted that there is little to choose between antidepressants in terms 
of efficacy. The evidence gathered in the literature review and the experimental data 
presented in this thesis suggest that there are differences in the extent to which these 
drugs influence performance. The BAP guidelines (1993) for the treatment of 
depression recommend that, following efficacy, the side effect profile of an 
antidepressant drug should be the second most important aspect to be considered. 
However, as an extensive literature shows that antidepressants are clinically 
equipotent in alleviating depression (e.g. Lund Laursen et al, 1985; Amore et al, 1989; 
Guillibert et al, 1989; Cohn et al, 1990; March et al, 1990; Bech and Cialdella, 1992; 
Kasper et al, 1992; Mendlewicz, 1992; Song et al, 1993; Wilde et al, 1993; Anderson 
and Tomenson, 1994; Montgomery et al, 1994a), then differentiating them with 
respect to behavioural toxicity and cognitive and psychomotor side effects could be 
regarded as a principal factor.
5.3.1 The “cost” of treating depression
The Department of Health (DOH) guidelines are encouraging physicians to consider 
their budgets when choosing a prescription. Initially, the TCAs appear to be the 
cheaper option, however, when other costs are taken into account the practice of 
prescribing (at first sight) cheaper drugs is a “false economy” (Fairweather and 
Hindmarch, 1995a). This was illustrated by Jonsson and Bebbington (1993) who 
compared the costs of treating depression with a TCA (imipramine) and an SSRI 
(paroxetine). The daily treatment costs were 20p for imipramine and £1.13 for 
paroxetine. However, when success of treatment was considered, paroxetine was 
reported to be more cost effective at £785 per patient per year than imipramine at
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£1024. The results of this study reflect the consensus of opinion that the newer drugs 
may be more expensive to prescribe initially, but are actually more cost effective 
when all other factors are taken into account. Song et al (1993) however, state that the 
SSRIs have no significant advantage over the TCAs, and that as a first line treatment 
for depression, the increased cost would be offset by “only questionable benefit”.
In addition to direct costs of treatment, other indirect costs should be considered in 
cost-benefit analyses (Currie et al, 1993; Fairweather et al, 1995a). These have been 
estimated to be greater than the direct costs and have been defined as those that arise 
from the fact that sufferers are unable to maintain their economic roles (Jonsson and 
Bebbington, 1993). Other indirect costs arise from the workplace, i.e. reduced 
productivity and increased absenteeism. Intangible social and family costs are also 
high, where the depressed individual loses interest and is unable to interact socially, 
and where role changes occur in the home causing stress and anxiety for the family. 
Inability to cope with work may lead to unemployment and financial hardship. 
Although these problems may already be apparent in some depressed patients, they 
may also be affected by the treatment of the illness. If an antidepressant has been 
shown to be behaviourally toxic, then it has the potential to exacerbate these problems 
thereby increasing the indirect costs.
Another indirect cost which may arise as a consequence of antidepressants is that of 
accidents. The risk of being involved in an accident is greater in depressed patients, 
and this risk is potentiated if the patient is prescribed a drug which is behaviourally 
toxic. Research has shown that drugs which impair performance on laboratory tests 
(i.e. TCAs) increase the risk of being involved in accidents on the road (Ray et al,
1992; Currie et al, 1995), at work, and during domestic or leisure pursuits (Currie et 
al, 1995). In studies performed at the Human Psychopharmacology Research Unit, 
sub-therapeutic doses of amitriptyline and dothiepin have been^tonnpair reaction time /  
to a greater extent thah80mg/100ml alcohol, which is the legal limit for driving in the ^  v \ 
U.K. (Hindmarch, 1987; Hindmarch et al, 1983; Hindmarch et al, 1988, Dal Pozzo et 
al, 1996; K erretal, 1996).
235
Non-compliance with drug therapy is a problem encountered with poorly tolerated 
drugs which can lead to relapse or intensification of symptoms. In addition to physical 
side effects, patients will be less c&Mjkamt if they perceive that the drug they are 
prescribed causes behavioural and performance impairments. Johnson (1983) reporte 
that only 46% of non-hospitalised patients undergoing treatment with TCAs were 
compliant, compared to 71% being treated with newer non-tricyclic drugs. The main 
reasons for discontinuation of treatment included poorly tolerated side effects, 
particularly sedation.
Taking all of this into account, the antidepressants which have been shown to impair 
performance in this thesis, are therefore likely to be more expensive overall than the 
second generation antidepressants which appear to be less detrimental. If physicians 
are forced to consider the costs of the drugs they prescribe, then indirect costs such as 
those outlined above must also be taken into account, and not just the initial price of 
the prescription. More information and education on the potential impairing effects of 
drugs must be made available to physicians, especially considering the results of an 
anonymous survey which revealed that the majority of general practitioners have had 
little or no post-graduate training in psychiatry, and that 26% of responders confessed 
an inability to make an informed choice of antidepressant, with 14% prescribing the 
same drug for each patient without evaluating individual patient requirements 
(Matthews et al, 1993). It is interesting to note, that despite the fact that amitriptyline 
has the strongest effect on cognitive function, this survey also found that this TCA is 
the most frequently prescribed antidepressant.
5.4 Conclusions and recommendations for future research
The conclusions to be drawn from this thesis are that the SSRIs and RIMAs do not 
appear to impair cognitive or psychomotor function, whereas the most frequently 
prescribed antidepressants in the U.K., amitriptyline and dothiepin, consistently 
produce performance decrements, in both healthy volunteer and patient populations. 
These findings have implications in the treatment of depression in ambulant patients, 
and highlight the need for training of general practitioners in this area. As there is
debate over attenuation of such effects following repeated dosing, it would be 
beneficial to increase the treatment period in healthy subjects to such a length that 
unequivocal findings concerning tolerance are obtained. It would also seem 
appropriate that future studies in depressed patients should be of longer duration than 
those reported in the literature to date, especially since current guidelines suggest that 
depression should be treated for at least four to six months (Paykel and Priest, 1992; 
Cowen, 1996). Such studies would enable the assessment of the long term effects of 
antidepressants on cognitive and psychomotor performance. -Also? rf=eeent 
eognitive^nd^isyjchojiLotQiLperformanee. In addition to increasing the duration of such 
studies, research would benefit from studies which were designed to detect the early 
onset of efficacy (i.e. days rather than weeks) with putative third generation compounds.
Actigraphy appears to be a useful tool in the measurement of drug action, and so future 
experiments should utilise this in order to obtain continuous records of subjects’ activity 
to complement the results of psychometric test batteries performed at discrete test 
points. Recent developments in actigraphic techniques now permit continuous 
measurement of patients’ activities for periods of up to one year, and so it would be o f 
interest to monitor the time course of depression and its treatment in the long term. Such 
a technique will allow the researcher to obtain information on patients in real life 
situations, and to confirm the relevance of the findings of controlled laboratory studies.
As depression is often accompanied by sleep disturbance it is important to have an 
understanding of the effects of antidepressants on sleep. Also, as hypnotics, including 
over-the-counter products, are increasingly being co-administered with novel 
antidepressants, research into interactions with such compounds must also be 
considered. Interactions into the effects of “social substances” such as alcohol, nicotine 
and caffeine with antidepressants should also be investigated.
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Females are more likely to suffer from depression than males, and so a re-analysis of the 
data from the experimental chapters, using sex as a factor, would identify whether there 
were any differences in how drugs affected cognitive function in males and females. 
Research into the effects that ethnic differences may have on the cognitive profile of 
drugs is also of interest. It is likely that age will affect these drug-induced responses, 
and so this too must be investigated further.
In addition to measuring drug effects, it is possible that the tests employed in this thesis 
can be used to categorise the type and extent of cognitive and psychomotor retardation 
in depressed patients. Drugs can then be prescribed with this in mind, e.g. if  the patient 
is suffering from memory problems, then an antidepressant which improves memory 
would be more beneficial than an antidepressant which does not affect memory or is 
known to induce memory deficits. The fact that some of the second generation 
antidepressants improve cognitive function implies that these drugs may be beneficial in 
the treatment of illnesses where cognitive impairment is debilitating (e.g. dementia) and 
may be of use in age-related cognitive decline. Further research is required to clarify 
these effects.
If future research into the effects of antidepressants follows standardised designs and 
procedures, and adopts an accepted battery of measurements such as those outlined in 
this thesis, it would be possible to perform multi-national meta analyses of the effects of 
antidepressants on behaviour, thereby creating internationally accepted indices of 
behavioural toxicity which could be displayed on drug packaging. These factors should 
then be included in education programmes for physicians and other health care 
providers.
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